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 After an increase in the total number of live born infants from 181,294 infants 
born in 1980 to 202,603 infants in 2001, the total number of live born infants 
in the Netherlands is decreasing again to 187,910 infants in 2005 (www.CBS.
nl). From all registered infants in 2003, 7.9% were born preterm (20 – 37 weeks) 
and 1.6% very preterm (20 – 32 weeks).1 So every year, about 3000 very preterm 
infants are admitted to a Neonatal Intensive Care Unit, unless they are non-
viable in case of extremely low gestational age.
New interventions in relation to survival and outcome  
 During the last decades the survival of very preterm infants has improved 
due to the introduction of antenatal steroids, the use of surfactant replacement 
therapy and postnatal steroids. New ventilation strategies (like High Frequency 
Oscillation Ventilation [HFOV]) did possibly also contribute to the improved 
survival of these infants. Everybody hoped that these new drugs and techniques 
would decrease the number of infants with bronchopulmonary dysplasia (BPD) 
and intracerebral abnormalities, which are the major morbidities of these infants 
responsible for later developmental problems.
 Surfactant therapy did increase the likelihood of survival, even in infants 
between 23 and 26 weeks: survival increased from 56% in untreated infants to 
75% in treated infants.2 Vohr et al.3 studied the neurodevelopmental outcome of 
ELBW-infants from 1993 and 1998 and found that administration of antenatal 
steroids was the only intervention associated with improved neurodevelopmental 
outcome at 18-22 months corrected age. HFOV was in their study associated 
with a lower Mental Developmental Index (MDI) on the Bayley Scales of Infant 
Development. Marlow et al. however found no difference in outcome at the 
corrected age of 2 years in extremely preterm infants who received HFOV 
compared to conventional ventilation.4 In the late 1990s the first publications 
about the adverse effect of postnatal corticosteroids (especially dexamethasone) on 
neurodevelopmental outcome were reported by Yeh5, O’Shea6 and Shinwell.7 In 
the study of Vohr et al., postnatal steroids were associated with a higher incidence 
of cerebral palsy (CP), a lower Mental Developmental Index (MDI) and a lower 
Psychomotor Developmental Index (PDI). 
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Increased survival, but what about long term outcome in the 
post-surfactant area?
 This higher survival rate has led to an increased interest in the long-term 
neurodevelopmental outcome of the preterm infants. Some studies described an 
increase in percentage of severe disabilities8 while others found a similar handicap 
rate.9-13 An increase in CP among very preterm infants was found by Vincer et al.14 
and de Kleine et al.15  Vohr et al., on behalf of the NIHCD Neonatal Research 
Network3 showed that from 1993 till 1998 neurodevelopmental outcome of 
extremely low birth weight (ELBW)-infants was stable in case of CP (18-20% 
in infants 22-26 weeks, 11-12% in infants born between 27-32 weeks GA) and 
hearing disorders (2-3%). Outcome improved for blindness (from 6.5% in 1993 
to 2.6% in 1998 in infants 22-26 weeks GA, from 3.5% in 1993 to 1.2% in 1998 
in infants 27-32 weeks GA). Outcome also improved for Bayley Scales of Infant 
Development (BSID)-scores: at 18-22 months’ corrected age the percentage of 
infants with a MDI < 70 decreased from 41.8% in 1993 to 37.2% in 1998 in 
infants 22-26 weeks GA, and from 29.9% in 1993 to 22.8% in 1998 in infants 
27-32 weeks GA. Furthermore 31.6% of the infants with GA 22-26 weeks had 
a PDI < 70 in 1993 compared to 26% in 1998 and numbers for the infants with 
GA 27-32 weeks were 23.4% in 1993 and 16.9% in 1998 (all changes reached 
statistical significance). According to Cooke et al.16 the percentage of infants 
with major neurological disabilities has declined; Foulder-Hughes and Cooke17 
mentioned that above all minor motor disabilities persist in survivors of preterm 
birth, despite improvements in care and that these disabilities were not confined 
to the smallest or most preterm infants. 
 Outcome studies are increasingly restricted to the extremely preterm 
infants with GA < 28 weeks (or < 26 weeks) or to the extremely low birth 
weight infants (ELBW) with birth weight < 1000 grams18, probably because 
these infants did not survive in the past and there has been a growing interest 
in the outcome of these extremely preterm infants. Only a few studies have 
focussed on neurodevelopmental outcome of low risk preterm infants (GA > 
28 weeks and birth weight > 1000 or 1500 grams). Pasman et al.19 showed in a 
prospective study of 44 low risk preterm infants (i.e. infants with a neonatal risk 
score indicating a favourable outcome, GA 25–34 weeks) that an unfavourable 
neurodevelopmental outcome of low risk preterm infants is due to moderate 
to severe impairment in a few low risk infants, rather than slight impairment in 
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the majority. Pietz et al.18 studied 70 low risk preterm (i.e. infants born between 
28-37 weeks GA, birth weight between 1000-2500 grams and without severe 
intraventricular haemorrhage, sepsis or prolonged ventilation) and compared 
them with a matched control group born at term. They found a normal Mean 
Griffiths Developmental Quotient (102 ± 8) at 20 months in the preterm group. 
At 7 years of age, reduced mean test results in the range of -0.5 SDS were 
observed for language and visual-motor abilities in the preterm group. The 
frequency of children with suboptimal growth at the age of 7 years was increased 
in the preterm infants (14% < P3). In general, growth lags behind in preterm and 
very low birth weight infants although different percentages of catch-up growth 
have been described.20-24
Leiden Follow-Up Project on Prematurity (LFUPP)
 The Leiden Follow-Up Project on Prematurity (LFUPP), a regionally defined, 
prospective study, included all live born infants with a gestational age less than 32 
weeks, born 1996/1997 in three health regions: Leiden, The Hague and Delft. 
The purpose of the study was to assess mortality and neonatal morbidity of 
the very preterm infants and especially of the extremely preterm infants (GA 
below 27 weeks). We were curious to know if new interventions like antenatal 
steroids and surfactant replacement therapy had resulted in a higher survival rate 
and moreover in a higher handicap- and disability-free survival. In the nineteen 
nineties the Neonatal Intensive Care Unit (NICU) of the Leiden University 
Medical Center (LUMC) initiated active treatment in infants with a GA of 24 
weeks and onwards; most other NICUs in the Netherlands generally started 
active resuscitation from 25 or 26 weeks GA. To evaluate this limit of viability of 
24 weeks, we studied the outcome of the extremely preterm infants (< 27 weeks 
GA) and compared it with preterm infants born between 27–32 weeks GA and 
with data from literature.  
 Antenatal and perinatal data were collected including diseases of the mother, 
socio-economic status, diseases and medication like antenatal steroids during 
pregnancy, gestational age, birth weight, Apgar score and data about perinatal 
morbidity and medication. Severity of respiratory distress syndrome (RDS), 
incidence of patent ductus arteriosus (PDA), use of surfactant and the number of 
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days on the ventilator were registered. Bronchopulmonary dysplasia (BPD) was 
defined as need of oxygen at 36 weeks postmenstrual age (PMA), but need of 
oxygen at 28 days was also noted. Dexamethasone was given in 1996/1997 in an 
initial dose of 0.5 mg/kg/day, tapered over 42 days to 0.1 mg/kg/day. Some infants 
who remained ventilator-dependent received a non-standardised second course 
of dexamethasone. Ultrasound abnormalities like intraventricular haemorrhage 
(IVH) and periventricular leucomalacia (PVL) were noted. An ophthalmologist 
assessed the infants at several times for retinopathy of prematurity (ROP). The 
condition at discharge from the hospital was considered to be normal when there 
was no neurological disorder (on clinical examination), no pulmonary problems 
(need of oxygen and/or diuretics), no cardiac disorder, no feeding problems (tube 
feeding or regurgitation) and no visual, hearing or psychosocial difficulties. 
 At term age and at the corrected age of 1 and 2 years paediatricians 
experienced in neurodevelopmental examination assessed the infants. A complete 
physical examination was performed and data about length, weight and head 
circumference were collected. Length was measured in supine position with 
straight back and knee on a standardised infantometer. Infants were weighed 
undressed on a calibrated infant balance scale. Head circumference was measured 
with a standard measuring non-stretch tape taking the largest measurement 
across the occipito-frontal line. At term age the infants were neurologically 
examined according to Prechtl25: infants were classified as definitely abnormal 
(DA), which meant the presence of a full-blown neurological syndrome like 
asymmetry, general hyper/hypotonia, hyper/hypokinesia or hyperirritability/
apathy; mildly abnormal (MA) when only part of such a syndrome was present; 
or normal (N). At one year of age infants were assessed according to Touwen26 
and Hadders-Algra27 and classified as DA in case of a cerebral palsy; as having a 
minor neurological dysfunction (MND I in case of an abnormality in one of 
the four neurodevelopmental clusters (tone/reflexes, gross motor function, fine 
motor function or cranial nerve function, MND II in case of at least two of 
these clusters); or normal (N). At 2 years a neurological examination according 
to Hempel28 was performed, focused on major as well as minor neurological 
dysfunctions. The children were considered DA in case of definite neurological 
dysfunction; MA in the presence of mild deviations in muscle tone regulation, 
reflexes, fine or gross motor performance; or normal (N). Furthermore, at the 
corrected ages of 18 and 24 months a Mental Developmental Index (MDI) and 
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a Psychomotor Developmental Index (PDI) according to the Bayley Scales of 
Infant Development I29;30 were determined. During the study period the BSID 
II was not yet validated for the Dutch population. The BSID I have a mean value 
of 100 and a standard deviation of 16. A Mental Developmental Index (MDI) 
or Psychomotor Developmental Index (PDI) ≥ 84 (≥ -1 SDS) was considered 
normal (N), MDI or PDI between 68 and 84 was considered as moderate delay 
(MD) and < 68 (< -2 SDS) as severe delay (SD). At two years of age behaviour was 
assessed using Achenbach’s Child Behavior Checklist for 2-3 year old children, 
completed by the parents. According to this list, behaviour could be assessed by 
using a total problem score: a score above the 90th percentile was defined as 
clinically abnormal; a score between the 85th and 90th percentile as borderline 
clinical; below the 85th percentile as normal.31-33 
 Another purpose of the study was to compare mortality and perinatal 
morbidity of very preterm infants born in the nineteen nineties (LFUPP) with 
results from the Project on Preterm and Small for gestational age infants (POPS), 
a cohort from the nineteen eighties. In the POPS, all live born infants born in 
1983 with a gestational age < 32 weeks and/or a birth weight <1500 grams 
were included. The total cohort existed of 1338 infants; in-hospital mortality was 
25.4%. Gestational age was a better predictor of neonatal mortality than birth 
weight.34 In-hospital mortality in infants < 27 weeks of gestation was 76%; total 
handicap rate in the surviving children at two years of age was 21% (9% major 
handicap, defined as presence of retardation (DQ < 80) and/or at least one of 
the following: a severe neurological disorder, sever visual or hearing defects or 
serious psychosocial problems). In contrast to mortality, handicap was apparently 
unrelated to gestational age or birth weight.35;36 Compared with the handicap 
rate of the same cohort at 2 years of age, a more favourable outcome at 5 years 
was seen in 10% and a less favourable outcome in 7% of the children.37
Children from this cohort are assessed at later ages; the 19-year follow-up program 
is still ongoing and incorporated in a large collaborative study in the Netherlands. 
Various investigators are looking at the long-term effect of prematurity and 
being small for gestational age on various medical, psychological and social 
parameters.38;39 
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Outline of the thesis
This thesis describes the results of the Leiden Follow-Up Project on Prematurity. 
The first part of the thesis is focussed on extremely preterm infants (gestational 
age < 27 weeks), the second part on very preterm infants (gestational age < 32 
weeks).
 In chapter 2 the mortality and neurological, mental and psychomotor 
development at 2 years of age of the infants born with a gestational age below 
27 weeks are analysed and compared with the results of the infants born with a 
gestational age between 27 – 32 weeks. Ethical considerations about maintaining 
these extremely preterm infants are described in chapter 3, where an overview 
is presented of the results and opinions of the limits of viability in most European 
countries along with some examples from the United States of America and 
Australia. 
 In chapter 4 growth of the preterm born infants until the corrected age of 
2 years is presented: length, weight, weight for length and head circumference 
measurements were expressed as standard deviation scores (SDS) compared 
to Dutch references. The association between perinatal risk factors (especially 
dexamethasone) and growth was also analysed. Chapter 5 was designed to study 
the effect on later growth and development of intra-uterine growth restriction 
in comparison to extra-uterine growth restriction in preterm infants. Preterm 
growth restraint, which means extra-uterine growth restriction, was defined as 
length or weight at term age < -1.3 SD.
 Chapter 6 describes major risk factors in preterm infants for neurological 
morbidity at term age, especially hypotension, next to bronchopulmonary 
dysplasia and cystic periventricular leucomalacia. Because bronchopulmonary 
dysplasia is an important complication of prematurity despite new interventions, 
the aim of chapter 7 was to analyse the respiratory and neurodevelopmental 
outcome at 2 years of age, in children born with bronchopulmonary dysplasia 
(BPD). BPD was defined as need of supplemental oxygen at 36 weeks post 
menstrual age. In chapter 8 the developmental outcomes of the study group 
(according to the BSID I) at 18 and 24 months corrected age are presented. 
Both Mental and Psychomotor Developmental Indices of the children were 
assessed. Risk factors for delayed development at 18 or 24 months were also 
determined. The aim of chapter 9 was to compare the results of two cohorts of 
very preterm infants born in the Netherlands: the POPS-infants, born in 1983 
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and the LFUPP-infants, born in 1996-1997. For this purpose, only infants from 
the POPS-cohort with a gestational age < 32 weeks and from the same health 
regions (selection by postal code) as the infants from the LFUPP-cohort were 
included in the analyses. 
 In chapter 10 the main findings of the thesis are discussed, together with 
some perspectives in relation to ongoing changes in neonatology. A summary is 
presented in chapter 11 (in Dutch in chapter 12).
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Abstract
Objective: To determine the outcome of infants with a gestational age (GA) 
<27 weeks, born in the mid-1990s.
Design: Regional, prospective study; part of the Leiden Follow-Up Project on 
Prematurity (LFUPP).
Setting: Three health regions in the Netherlands.
Patients: A total of 266 live born infants (1996/1997) with GA <32 weeks; 46 
infants were <27 weeks. 
Main outcome measures: Neurologic examination (according to Hempel) 
and assessment of mental and psychomotor development using the Bayley-Scales 
of Infant Development I, at the corrected age of 2 years.
Results: Mortality was 35% (16 of 46) <27 weeks, compared with 6% (14 of 
220) in infants with GA 27 to 32 weeks; withdrawal of treatment in 60% and 
43%, respectively. Below 27 weeks mortality was higher after extra-uterine trans-
port and pregnancy induction. Neonatal morbidity was higher in infants <27 
weeks compared with infants 27 to 32 weeks. Below 27 weeks postnatal use of 
dexamethasone and being hospitalized at term were associated with abnormal 
neurologic outcome; there was a higher incidence in (mild) mental developmen-
tal delay compared with the older infants (p=0.048). Adverse outcome (dead or 
abnormal neurologic, psychomotor or mental development) in infants 23 to 24, 
25, 26, and 27 to 32 weeks GA was, respectively, 92% (11 of 12), 64% (7 of 11), 
35% (8 of 23) and 18% (40 of 220). 
Conclusion: Mortality and neonatal morbidity were higher in infants with GA 
<27 weeks compared with infants born between 27 and 32 weeks. The high 
adverse outcome of infants <25 weeks suggests that one should carefully weigh 
whether or not to aggressively resuscitate and treat these extremely premature 
infants.
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Introduction
 In the 1990s, new techniques have been introduced to increase viability of 
very premature infants. The use of surfactant, antenatal steroids and better ven-
tilation strategies have resulted in an increased survival of infants of extremely 
low gestational age (GA) or low birth weight. Some studies report an increase 
in percentage of severe disabilities1 with this better survival while others have 
reported that the handicap-rate has remained the same.2-5  Finally, with a decreas-
ing mortality and therefore more survivors, the absolute number of infants with 
handicap has increased.
 Worldwide, there is a difference in opinion about the limit of viability: at what 
GA should one start to resuscitate? Studies from the United States report that 
resuscitation is indicated from 23 or 24 weeks of gestation, although the chances 
of intact survival are poor6-8; McElrath et al. 9 found no survivors, born at 23 
weeks’ gestation, free from substantial morbidity. Studies from Japan report 18% 
survival in infants born at 22 to 23 weeks; these survivors, however, have high 
rates of neurologic sequelae.10 In Europe (Sweden11, United Kingdom12-14) high 
mortality rates (>70%) at 23 and 24 weeks were found. Unfortunately, articles 
about GA and outcome are relatively scarce. In the past, Verloove et al. 15 showed 
that GA is a more important indicator of maturation than is birth weight. 
 The aim of this study, which is part of the Leiden Follow-Up Project on 
Prematurity (LFUPP), was to compare mortality, neonatal morbidity and out-
come (neurologic, psychomotor, mental and behavioral) at the corrected age of 
two years, of infants born with a gestational age of <27 weeks to infants born 
between 27 and 32 weeks GA. In addition, we looked for intra-group differ-
ences among the infants <27 weeks GA. Furthermore, predictors of abnormal 




 The LFUPP, a Dutch regional prospective study, included 92% of eligible live 
born infants of <32 weeks of gestation, born in 1996/1997 in the health regions 
The Hague, Leiden and Delft (n=266).
 A total of 122 infants (46%) were born in the Leiden University Medical Cen-
ter (LUMC), 45 (17%) were born in another university hospital with a NICU, 64 
(24%) in a regional hospital in The Hague and transported to the NICU of the 
Juliana Children’s Hospital (JCH); another 35 infants (13%) were born in another 
regional hospital. Infants admitted to one of the hospitals mentioned above but 
coming from another geographical area were not included in this study. The 
hospitals contributing to this study had the same clinical protocol for resuscita-
tion, with the exception that other hospitals with a NICU did not resuscitate 
infants born <25 weeks, in contrast to the LUMC. Seventy percent of the infants 
were admitted to the LUMC or JCH, 2 hospitals which have the same clinical 
neonatal care.
 Forty-six infants were born < 27 weeks GA. Of these infants, 25 (55%) were 
born in the NICU of the LUMC, 8 (17%) in another NICU, and 13 (28%) in a 
regional hospital and immediately after birth transported to a NICU.
Although in the 3 mentioned health regions treatment (full resuscitation in the 
delivery room without restrictions) was started when an infant had a gestational 
age of at least 24+0 weeks, two infants with a GA of 23 weeks were included 
because the precise GA was uncertain at the time of birth. In general the GA is 
very well known in the Netherlands because of good antenatal care and early 
ultrasound assessments. When a GA of 24 weeks is mentioned, a GA of 24+0 to 
24+6   weeks is meant.
Data collection
 Antenatal and perinatal data were collected including health status and diseases 
of the mother, socio-economic status (SES), pregnancy induction, reliability of 
gestational age, diseases and medication during pregnancy, gestational age, birth 
weight, Apgar score and data about perinatal morbidity and medication. SES 
was determined by the level of education of each parent individually. A score of 
1 was given if the parent’s education was low, a score of 2 for an average educa-
tional level and a score of 3 for higher levels of education. SES-scores of both 
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parents were then combined and divided by 2 (range 1-3). Dexamethasone was 
given in 1996/1997 in an initial dose of 0.5 mg/kg, tapered over 42 days to 0.1 
mg/kg. Some infants who remained ventilator-dependent got a second course 
of dexamethasone but this was not given in a standardized way. The condition at 
discharge from the hospital was noted and was considered to be normal when 
there was no neurologic disorder (on clinical examination), no pulmonary prob-
lems (need of oxygen and/or diuretics), no cardiac disorder, no feeding problems 
(tube feeding or regurgitation) and no visual, hearing or psychosocial difficul-
ties. The cause of death was noted and also whether they died naturally or after 
withdrawal of treatment.
 The Medical Ethics Committee of the LUMC approved the study and 
informed consent of the parents was obtained.
Follow-up
 Children were assessed at 2 years of age (corrected for prematurity) by 4 neo-
natologists experienced in developmental assessment. The examination included 
a general examination and a neurologic examination according to Hempel16, 
focused on major as well as minor neurologic dysfunctions. The children were 
considered definitely abnormal (DA) when muscle tone and reflexes were both 
abnormal (which meant the presence of a cerebral palsy), mildly abnormal (MA) 
when only part of the reflexes or muscle tone were abnormal, or normal (N). 
 Mental and psychomotor development were assessed by a developmental psy-
chologist using the Dutch version of the Bayley-Scales of Infant Development I 
(BSID I).17,18 During the study period the BSID II was not yet validated for the 
Dutch population. The BSID I have a mean value of 100 and a standard deviation 
of 16. A Mental Developmental Index (MDI) or Psychomotor Developmental 
Index (PDI) ≥ 84 (≥ -1 SDS) was considered normal (N), MDI or PDI between 
68 and 84 was considered as moderate delay (MD) and < 68 (< -2 SDS) as severe 
delay (SD).
 To attain a single outcome measure, neurologic outcome, PDI and MDI were 
combined. When at least one of these three outcome-measures was DA, children 
were considered DA and when at least one outcome was MA, children were 
considered MA.
 At 2 years of age behavior was assessed using Achenbach’s Child Behavior 
Checklist19,20 for 2- to 3-year-old children, completed by the parents. Accord-
ing to this list, behavior could be assessed by using a total problem score: a score 
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above the 90th percentile was defined as clinical (abnormal), a score from the 
85th through 90th percentile as borderline clinical; below the 85th  percentile 
as normal.
Statistical analyses
 SPSS10 for Windows was used for statistical analyses. Fischer’s Exact test was 
used to evaluate associations in a 2x2 table/X2–test. A test on linear association was 
used in a 2x3 table. Correction for confounding variables was done with binary 
logistic regression for mortality and the Hempel examination with GA and BPD 
as confounders. Differences were considered significant with P values < .05.
Results
Mortality
 Fifteen (33%) of the 46 extremely premature infants (<27 weeks) died in the 
neonatal period, one girl died at the corrected age of six months, increasing the 
overall mortality to 16 (35%). In the infants born between 27 – 32 weeks GA 
(n=220), in hospital mortality was 6% (14 infants), which is significantly lower than 
in the infants of <27 weeks GA (p < .001). Mortality decreased with increasing 
GA. 
Infants born <27 weeks GA
 Seventy percent of the infants born <27 weeks had a birth weight <1000 grams. 
Mortality was 50% when birth weight was <750 grams. Mortality decreased with 
increasing birth weight. 
 Neonatal mortality was higher in infants born in peripheral hospitals and then 
immediately afterwards transported to a NICU, compared with infants born in a 
hospital with a NICU: 10 of 13 (77%) versus 6 of 33 (18%); odds ratio (OR) 15 
(95% confidence interval [CI]: 3.1 – 71.7), p < .001. After correction for GA the 
OR remained about the same: 13.4 (95% CI: 2.4 – 75.1; p = .003). Mortality was 
higher when pregnancy was induced: 5/7 (71%) in IVF (4) /ICSI (1) compared 
with 11/39 (28%) in spontaneous pregnancies (OR 6.4, 95% CI: 1.1 – 37.8; p 
= .04). After correction for GA the OR remained at the same level of 6.1 (95% 
CI: 0.8 – 45.0; p = .08), hence little confounding in the data. Although multiple 
birth occurred more often in case of pregnancy induction (p = .001), multiple 
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birth itself was not associated with higher mortality: 25% in multiple pregnancy 
compared with 37% in singleton pregnancy, this was not statistically significant. 
Withdrawal of treatment (when further treatment was considered futile) occurred 
in 60% of cases (n=9). Two infants died the first day; 8 infants (53%) died in the 
first week, mainly because of pulmonary or intracerebral problems; withdrawal 
of treatment occurred in 63% of them. Another 7 infants died before the fourth 
week because of various problems. One infant died at the age of six months 
secondary to BPD.21 In the 14 infants born between 27-32 weeks gestation that 
died, treatment was withdrawn in 43%.
 For a more detailed study of the extremely premature infants we divided the 
group into infants with a gestational age of 23–25 weeks (n=23) and of 26 weeks 
(n=23). In the first group 12 infants died (52%), in the second group 4 infants 
(17%): OR 5.1, 95% CI: 1.3-20.1; p = .03.
Perinatal morbidity
Comparison of infants <27 weeks GA to infants of 27 to 32 weeks GA
 The mean GA in the group <27 weeks GA was 25.7 weeks, compared with 
30.0 weeks in the group 27 to 32 weeks GA; mean birth weight was 843 grams 
and 1335 grams, respectively. The incidence of perinatal problems in infants with 
a GA <27 weeks was compared with the incidence in infants born between 
27 and 32 weeks. The incidence of pregnancy-induction, male gender, percent-
age of twin or triplet, use of antenatal steroids, and the number of infants with 
intrauterine growth failure did not vary between the 2 groups; the percentage of 
delivery by Cesarian section was higher (p < .001) in the infants born between 
27 and 32 weeks of gestation (Table 1). Neonatal morbidity was much higher in 
the more premature group (Table 2).
 The condition at discharge is summarized in Table 3: the extremely premature 
infants were more frequently considered abnormal at discharge and more fre-
quently discharged with oxygen or a home monitor.
Comparison of infants born at 23 to 25 weeks GA to infants born at 26 weeks GA
 No differences existed between the groups in the incidence of pregnancy-
induction, gender, singleton versus twin/triplet and antenatal use of glucocor-
ticosteroids. The mean birth weight in the group 23 to 25 weeks GA was lower 
than in infants born at 26 weeks of gestation (739 grams compared with 948 
grams, p<.001). The incidence of respiratory distress syndrome22,  hypotension, 
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patent ductus arteriosus, need for oxygen at 28 days, BPD, necrotizing enteroco-
litis (NEC), retinopathy of prematurity (ROP)23, intra-ventricular hemorrhage 
(IVH), or cystic periventricular leucomalacia (PVL) was the same in the 2 groups. 
The younger group tended to be more frequently treated with diuretics (92% 
versus 56%, p = .05) and with dexamethasone postnatally (83% versus 50%, p = 
.06) than the older group. Condition at discharge was abnormal in 91% of the 
infants born at 23 to 25 weeks gestation compared with 61% in infants born at 
26 weeks gestation (Table 3). 
Table 1. Prenatal factors in infants < 27 weeks versus 27 to 32 weeks GA
Gestational age
< 27 weeks 
N (%)















Gender: male 25/46 (54) 122/220 (56)
Multiple birth


























Intra uterine growth retardation (<P
10
) 2/46 (4) 31/219 (14)
Cesarean section 6/46 (6) 40/160 (25)
SES (mean, range 1-3) 2.10 1.93
IVF indicates in vitro fertilization; ICSI, intracytoplasmatic sperm injection. Antenatal steroids: 6 mg 
Bethamethasone, second gift after 24 hours. 
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Neurologic outcome at 2 years
 At 2 years, 23 of the 30 survivors (87%) with GA <27 weeks were exam-
ined according to Hempel; 1 child was examined by another pediatrician and 
considered normal, 2 children were considered completely normal according to 
another pediatrician at the age of 18 months corrected age and they were not 
followed any further because they were doing so well. The results of these 26 
children are shown in Figure 1. 
 Infants with a GA <27 weeks were more often classified as DA than infants 







27 – 32 wks 
 N (%)* 
p-
value†
No RDS     
   RDS grade I/II 














Use of surfactant 14/23 (61) 14/22 (64) 28/45 (62) 84/220 (38) .004
Hypotension 19/22 (86) 16/23 (70) 35/45 (78) 55/215 (25) <.001
PDA 15/23 (65) 17/23 (74) 32/46 (69) 38/219 (18) <.001
NEC 4/23 (17) 3/23 (13) 7/46 (15) 18/219 (8) .003
No IVH 
   IVH Grade I / II














Cystic PVL 2/23 (9) 3/23 (13) 5/46 (11) 8/212 (4) .06
No ROP 
   mild ROP (grade 1/2)














No dexamethasone postnat. 
    one course dexameth.














Oxygen for 28 d 12/23 (52) 18/23 (78) 30/46 (65) 36/214 (17) <.001
BPD  (Oxygen at 36 wk) 8/23 (35) 15/23 (65) 23/46 (50) 26/216 (12) <.001
* % of liveborn ; † p-value GA < 27 wks versus 27 to 32 wks. RDS indicates respiratory distress syn-

















Figure 1. Neurologic outcome at 2 years corrected age
Percentage of children with 
definitely abnormal outcome 
(black), mildly abnormal 
outcome (gray) and normal 
outcome (white), according 
to GA; missings (striped) 
included.
Table 3. Condition at discharge according to GA 




27 – 32  wks
N (%)
p-value
Condition abnormal: 10/11 (91) 11/18 (61) 67/218 (31) <.001
  - neurologic disorder 4/11 (36) 2/18 (11) 17/217 (8) .007
  - respiratory disorder 9/11 (82) 7/18 (39) 23/217 (11) <.001
  - feeding problems 6/11 (55) 4/18 (22) 13/217 (6) <.001
  - ROP (any grade) 5/11 (46) 3/17 (18) 4/205 (2) <.001
Home monitor 6/11 (55) 4/19 (21) 10/217 (5) <.001
Supplemental O
2
4/11 (36) 3/19 (16) 3/218 (1) <.001
Still admitted at term 7/11 (64) 4/18 (22) 39/213 (18)  .003
born between 27-32 weeks GA (35% compared with 9%; p < .001); in the older 
group, 73% had a normal neurologic examination compared with 42% in the 
youngest group. Because of small numbers, infants with a normal outcome were 
compared with infants with a MA or DA outcome. In the infants born <27 weeks 
none of the antenatal or neonatal factors was associated with an abnormal neu-
rologic outcome, neither was gender, GA or SES. Still hospitalized at term was 
associated with an abnormal neurologic outcome: OR 20, 95% CI: 2.0-203.3; 
p = .004 (from the 11 infants still admitted, 10 had an abnormal neurologic out-
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come compared with 5 infants of the 14 discharged infants). After correction for 
GA this difference remained significant: OR 17 (95% CI: 1.5 – 194.4; p = .02). 
With respect to the use of postnatal steroids, 67% (6 of 9) of the infants who were 
not treated with postnatal steroids were classified as normal, compared with 25% 
(4 of 16) of the infants who did receive postnatal steroids (OR 6.0, 95% CI: 1.0 
– 35.9; p = .05). After correction for GA the OR was 4.8, after correction for just 
BPD the OR remained 6.0. After correction for GA and BPD the OR was 4.1 
(95% CI: 0.5 – 33.4; p = .2), so there was some confounding by GA but there still 
remains an association between the postnatal use of dexamethasone and abnor-
mal outcome. A normal condition at discharge from the hospital was associated 
with a normal neurologic examination at 2 years (OR 11.7, 95% CI: 1.1 – 122.4; 
p = .03): 5 of 6 infants who were normal at discharge had a normal neurologic 
examination at 2 years, compared with 6 of 20 infants who were not normal at 
discharge. Especially infants with pulmonary problems at discharge were more 
frequently neurologically abnormal: 12 infants were abnormal of the 16 infants 
with lung problems compared with 3 of 10 infants who had no lung problems at 
discharge (OR 7.0, 95% CI: 1.2 – 40.8; p = .03). No association existed between 
feeding difficulties or neurologic problems at discharge and abnormal outcome 
at 2 years.
 Although 27% of the infants born between 23 and 25 weeks GA had a normal 
neurologic examination at 2 years, compared with 53% of the infants born at 26 
weeks GA, this difference did not reach significance (p = .4).
Bayley-scales at 2 years
 The developmental psychologist tested two-third of the survivors born <27 
weeks: in 21 children a MDI was measured, in 22 children a PDI. Children were 
lost because of different reasons: in 1 case removal to another country, 1 child was 
blind, 1 was in the hospital for a long time for pulmonary problems, 2 were seen 
by another pediatrician, 1 couple of parents did not want any contact with the 
hospital anymore and 2 children were tested by the Stutsman Intelligence Test 
instead of the BSID I. The lost group did not differ from the tested group in GA, 
gender, neonatal morbidity or SES.
 In the immature group (<27 weeks) more (mild) mental delay occurred com-
pared with the older premature infants (27 to 32 weeks; p = .048);  psychomotor 
delay occurred also more frequently (45% compared with 30%) but this differ-
ence did not reach significance (Fig 2). No association was found between any 
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of the perinatal factors (SES, RDS, hypotension, patent ductus arteriosus, NEC, 
PVL, IVH etc, as summarized in Table 2) and the developmental delay.
Behavior at 2 years
 Parents of 23 children (23 of 30 = 77%) returned the Child Behavior Check-
list: 20 children (87%) had normal behavior and 3 children (13%) abnormal 
(clinical) behavior (2 born at 25 weeks, 1 born at 26 weeks). These percentages 
did not differ from the infants born between 27 and 32 weeks GA. Two of these 
3 children with abnormal behavior had a complete normal neurologic examina-
tion and normal Bayley-scores, 1 child was classified as MA according to Hempel 
and the Bayley-scores.
Combining neurologic development, MDI and PDI at 2 years in a total 
outcome score
 Twenty-six of the 30 survivors were neurologically examined. Of the 4 chil-
dren without a neurologic examination, in 2 cases an intelligence test according 
to Stutsman was done: one child had a normal IQ, the other a mildly abnormal 
IQ. For the total-score (neurologic, psychomotor and mental development) these 
2 children were included. So finally the loss in the immature group was 2 of 30 
(7%) for this total outcome score.
 Thirty-six percent (10 of 28) of the assessed survivors born <27 weeks had 
a DA outcome compared with 16% (26 of 167) of the assessed survivors born 
between 27 and 32 weeks GA (OR 3.0, 95% CI: 1.3 – 7.3; p = .02). Infants born 
at 23 to 25 weeks were classified as DA in 55% (6 of 11), infants born at 26 weeks 
GA in 21% (4 of 17); this difference did not reach significance.
 When we add behavior to this total outcome-score, 46% (13 of 28) of the 
assessed survivors born <27 weeks had a DA outcome (compared with 21% of 
the infants born between 27 and 32 weeks, p < .001). 
One of the infants born <27 weeks was blind, and 2 infants were deaf at the age 
of 2 years (all 3 neurologically abnormal).
 Neurologic examination as well as both the Bayley tests and the Child Behav-
ior Checklist, were available from 21 of the 30 survivors born <27 weeks gesta-
tion; of these 21 children only 3 had a normal outcome at all tests (2 born at 25 
weeks, 1 born at 26 weeks).
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Adverse outcome
 Overall, adverse outcome (defined as dead or at least 1 conclusion DA in 
neurologic, mental or psychomotor development) was 57% in infants born <27 
weeks gestation compared with 18% in infants born between 27 and 32 weeks. 
Adverse outcome in infants born at 23 to 24, 25, and 26 weeks gestation was, 
respectively, 92%, 64%, and 35% (Fig 3).  
Figure 2. MDI and PDI of infants < 27 wks GA and of infants 27 – 32 weeks 
GA at two years corrected age
Percentage of children with 
severe delay (black), moderate 
delay (gray) and no delay 


































Percentage of children who 
died (black) or who survived 
with definitely abnormal 
outcome (gray), with mildly 
abnormal outcome (spotted) or 
with normal outcome (white), 





 Reports about an increase in survival come from all over the world (United 
States, Canada, Australia and Japan), but, as already noticed by Hack and Fan-
aroff 24, there are very few reports from Europe: only a few from the United 
Kingdom (12-14), Sweden11 and Finland.25 It is difficult to compare survival rates 
in different studies because of several reasons: some groups present survival rates 
according toGA, but most of them to birth weight which is not always a reliable 
marker for maturation. Furthermore, the definition of survival often differs: some 
report survival from the resuscitation room, some from the NICU or in-hospital 
period and some report about the survival at 1 year. 
 In the health regions in the Netherlands in which this study was performed, 
treatment was started at 24+0 weeks. In-hospital survival in infants with a GA of 
24 weeks was 40%, at the age of two years survival was 30% which is comparable 
with studies from the United Kingdom12, 13, 26, Sweden11 and Canada.27,28 Most 
studies from the United States found higher survival rates: survival at discharge 
and in the first year 48-62%.6-8, 24, 26 Survival in the infants born at 25 weeks 
GA was 64% in our study, comparable to various results from Sweden11 and 
Canada27,28; somewhat higher than in the United Kingdom12-14,29 but lower than 
in the United States.3,7,8,24,26,30-32 Survival in infants of 26 weeks GA was 83%, 
rather high compared with literature.8,13,28,31,32 Jacobs et al.33 found exactly the 
same mortality-rate (35%) as we did in infants born between 23-26 weeks, born 
between 1990-1994. Because mortality was higher in the group infants trans-
ported postnatally compared with infants born in a center with a NICU (77% 
vs. 18%, independent of GA), we expect that mortality would be lower when 
all infants would have been born in a neonatal center. It is also concerning that 
mortality was higher in infants born after pregnancy induction, irrespective of 
multiple pregnancy.
Neonatal morbidity
 With respect to literature, we found a comparable incidence of grade III / IV 
IVH (18%) and cystic PVL (11%) in infants <27 weeks GA. Gibson34 reported 
incidences of 25-32% for the combination of serious IVH and PVL; Hack and 
Fanaroff 24 in a recent review found a range of 10-83% for infants born at 23 to 
24 weeks GA and of 10-22% for infants born at 25 weeks GA for severe cranial 
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ultrasound-abnormalities. The incidence of NEC (15%) was comparable with 
literature, the incidence of severe retinopathy of prematurity (2%) somewhat 
lower. Gibson34 reports that the need of oxygen at the age of 28 days is almost 
universal, like in this study (97%). We found a rather high percentage of infants 
with BPD (50%) compared with for example Kilpatrick (15%)7, but Hack and 
Fanaroff 24 report a wide range in BPD: 57-70%, 23-89% and 16-71% for infants 
born at respectively, 23, 24, and 25 weeks of gestation. The reason could be a dif-
ference in oxygen saturation monitoring practices with varying criteria for the 
administration and weaning of oxygen.24
Outcome at 2 years
 Perhaps even more important than survival itself is intact survival. Hack and 
Fanaroff 24 report that there is a wide variety in outcome among survivors of 
extremely premature infants: they found severe disabilities in 30%, 17-45% and 
12-35% for infants of 23, 24, and 25 weeks of GA, respectively. There are many 
explanations for these wide ranges but the most important ones are differences 
in definition of disabilities and handicaps and in the length of follow-up. For 
example, Holtrop35 found a good short-term outcome in 90% of the survivors 
of 23-25 weeks GA, this just being defined as the absence of PVL or IVH, while 
Piecuch36 demonstrated that in extremely premature infants PVL and IVH do 
not account for all of the neurologic abnormalities. However, in our study an 
IVH grade III or IV or cystic PVL were not associated with abnormal neurologic 
outcome at the age of two years, maybe because of small numbers. In general, 
Cooke29 found in a 10-year cohort of premature infants with a GA <26 weeks 
74% free of serious handicaps; Tin14 also reported 75% of the survivors with a GA 
<26 weeks free from a severe disability. In our study 55% of the survivors born 
<26 weeks had a normal or MA outcome at the age of 2 years.
 At 2 years, the percentage of children with a completely normal neurologic 
examination remained about the same as at term age (48% at term – data not 
shown – and 42% at 2 years), but the percentage of children with a MA exami-
nation decreased (from 33% to 19%) at the cost of an increase in the number of 
children with a DA neurologic examination (16% to 39%). We know that a lot 
of problems concerning speech and language development, concentration, and 
behavior appear later and are not noticed yet at the age of 2 years.37 It is alarm-
ing that 36% (10/28) of the assessed survivors born <27 weeks gestation had a 
DA total outcome score at this age; 46% (13/28) when behavior was added to 
this score.  
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Starting active treatment
 Worldwide, people do not agree about the limit of viability: Kramer8 from the 
USA suggests an active approach from 24 completed weeks, Kilpatrick7 advises 
not to resuscitate infants born at 23 and 24 weeks GA (only if the parents insist) 
and to resuscitate infants from 25 weeks GA only when birth weight is >600 
gram; Sanders (USA)38 and Battin (Canada)2 agree that 22 weeks is not accept-
able, 23 to 24 weeks a sort of limit with high morbidity and they suggest starting 
at 25 weeks. Piecuch36 remarks that in infants born at 24 and 25 weeks the high 
rate of cognitive problems is concerning. Recently, Wood39 from the EPICure 
Study Group showed that severe disability is common among children born 
<26 weeks GA (half of the infants had any disability; 23% a severe disability) and 
remains a major challenge in this group of infants. The question remains if one 
should start to resuscitate these infants when there is 25, 50 or 75% chance on 
intact survival? There will always be differences in opinion on what is ethical. 
Maybe one can start resuscitation (at 24 or 25 weeks) but after having started one 
should not be negative towards withdrawal of treatment in cases of very poor 
prognosis. However, not starting treatment always seems easier than withdrawing 
treatment.40 Recently Lorenz et al. 41 reported about the differences in manage-
ment strategies for extreme prematurity in the United States and some countries 
in Europe like the Netherlands. They explain that in the United States (offering 
intensive care to all infants), there will be more survivors at the cost of a higher 
percentage of disabling cerebral palsy, while in the Netherlands (more selective 
treatment) some infants will die who might have survived without disability. This 
is a moral dilemma without a definitive answer, depending on the personal view 
of parents and doctors.
 It would be helpful if there were some risk factors associated with adverse 
outcome. In this study, the postnatal use of dexamethasone and still being admit-
ted at term seem to be associated with an abnormal neurologic outcome. Both 
factors could be taken into consideration in the communication with the parents. 
An explanation for the lack of association between other perinatal factors and 
outcome could be the small numbers in this study.
 The set up of our study was prospective and regional. Not only a standardized 
neurologic examination was performed, but also mental and psychomotor devel-
opment and behavior were assessed. In the Netherlands, the GA is in general pre-
cisely known in pregnant women, so this makes it possible to associate outcome 
with gestational age instead of birth weight. The endpoint was the corrected 
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age of 2 years, which is not so frequently described in a cohort infants born in 
the 1990s. The flaws of this study are the small numbers and the rather high loss 
(about 30%) in the BSID, but the parameters of the lost group and the assessed 
group did not differ and the conclusions point in the same direction as found 
in literature: higher mortality and morbidity with decreasing GA. We also found 
higher mortality in extremely premature infants born after pregnancy induc-
tion (p = .04) and when transported extra-uterinely (p < .001); the association 
between abnormal neurologic outcome and the postnatal use of dexamethasone 
is compatible with literature. The high percentage (74%) of adverse outcome in 
infants born <26 weeks’ gestation is reason for concern and needs to be kept 
in mind when counseling the parents. The even higher percentage of adverse 
outcome in infants < 25 weeks (92%) suggests that one should carefully weigh 
whether or not to aggressively resuscitate and treat these extremely premature 
infants.
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Summary
 Advances in pharmacology and technology have pushed back the limits of 
viability to 23-24 weeks of gestation at the expense of an increasing number of 
survivors with disabilities. Treatment of these extremely preterm infants should 
be based on a thorough determination of diagnosis and prognosis, followed by 
decision-making on the basis of futility of treatment or quality-of-life issues and 
counseling of parents. This paper reviews survival rates and outcome of infants 
under 26 weeks of gestation born in Europe and the rest of the world and dis-
cusses the role of parents and the influence of condition at birth, gender, and 
birth weight in ethical decision-making on behalf of these infants. Dutch guide-
lines on treatment of extremely preterm infants at birth are presented to assist the 
clinician in facing the challenging ethical, moral, legal, and emotional dilemmas 
that surround this hot topic in perinatology. 
Practice points
• Survival at 22 weeks of gestation has not improved over the past three decades
• Higher survival in pro-active treatment versus a more selective approach
• Surviving infants born at 23-24 weeks of gestation show high rates of disabili-
ties
• Condition at birth is only partially related to survival and later outcome
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Introduction
 Over the past ten years the ethics of maintaining extremely preterm infants 
has become a hot topic at medical conferences and is discussed frequently in the 
medical press. Newer ventilation techniques and medication (antenatal steroids 
and surfactant) have dramatically improved survival of these tiny infants, but at 
the expense of worries about their neurodevelopment, growth and later aca-
demic achievement. More and more controversy has evolved over whether we 
are doing the right thing in neonatology.1 We continue to search for the limits of 
viability and place it somewhere between 23 and 25 weeks of gestation. Below 23 
weeks, it is biologically almost impossible to ventilate a preterm infant because of 
the immature structure and physiology of the foetal human lung. Inconsistency 
of pregnancy data or biological variations may account for the occasional survi-
vors who are reported at this gestational age.2 Since the mid-1980s a gestation of 
23 weeks has been an insurmountable  biological barrier and neither surfactant, 
steroids nor new ventilation modalities have been able to change this.2 
 In an ideal world, guidelines about the limits of viability should be readily 
available. To develop these, one needs recent data about survival and later out-
come. Data on survival of infants born at the margins of viability are difficult 
to compare because survival rates are dependent on the denominator used to 
calculate them, i.e. on the number of all births (including stillbirths), all live born 
infants or all infants admitted to the Neonatal Intensive Care Unit (NICU). 
Survival rates for unborn infants are lower than survival rates reported for infants 
admitted to the NICU.3 This should be kept in mind when counselling parents 
before threatening or imminent preterm delivery. Survival will be higher in a 
neonatal unit which only admits inborn infants than in a regional referral unit 
admitting outborn infants. Different attitudes from obstetricians and neonatolo-
gists towards resuscitation will also influence survival numbers: a pro-active man-
agement results in higher survival rates.4;5 However, the ultimate goal reaches 
beyond mere survival and should be to survive without major disabilities. Despite 
an increase in survival rates of extremely preterm infants during the last decade, 
this has not been associated with a reduction in disabilities. Most studies report a 
steady prevalence of disabilities, i.e. an identical increase in the absolute numbers 
of survivors with and without disabilities, or an increase in the percentage of 
infants with disabilities.6
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In this paper we present an overview of survival rates and later outcome of 
extremely preterm infants born in Europe and the rest of the world and discuss 
the factors which play an important role in decision-making on behalf of them.
Outcome
Survival
 Table 1 shows survival of extremely preterm infants, according to gestational 
age, in various European countries. The reported percentages are the percentages 
of live born infants who survived until discharge. Survival is relatively high in 
Norway, Sweden, Germany and Austria. Markestad et al.7 from Norway contrib-
ute their good outcome to a high percentage (95%) of inborn infants, good peri-
natal care and instillation of surfactant in the delivery room in two-thirds of the 
infants. Serenius et al.8 report a survival rate similar to their countryman Hakan-
son4 in the Northern part of Sweden. The higher survival rate and pro-active 
attitude is in sharp contrast with the lower survival rate in the Southern part of 
Sweden, where a more selective approach is used. Herber-Jonat et al.5 state that 
the relatively high survival in Germany is also the result of pro-active treatment. 
Weber et al. who report the results of 16 NICU’s in Austria found their data to be 
comparable with the rest of Europe, although at the upper range.9 In Denmark, 
where continuous positive airway pressure (CPAP) is the ventilatory support of 
choice, survival data are higher when calculated as a percentage of actively treated 
infants compared to a percentage of the total number of live born infants.3
 Table 2 gives some examples of survival of extremely preterm infants born 
outside Europe, with relatively high survival rates in cases of extremely short 
gestation (23 weeks).
Neurodevelopmental and cognitive outcome
 The problem of predicting outcome of these very preterm infants is perfectly 
described by Jobe in an editorial in which he asks the ultimate question ”Is any 
very preterm infant normal?”.10 Predictors of early outcome do not predict later 
outcome very well. Levene, after reviewing the most recent best available data, is 
uncertain about whether it is right to provide intensive care for all babies referred 
to their service: only less than 25% of babies born alive ≤ 24 weeks survive with-
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out major disability.11 MacDonald et al.12 describe that 30-50% of the survivors 
among live born infants <25 weeks have moderate or severe disability. Hintz et 
al.13 found that in a cohort from the National Institute of Child Health Develop-
ment [NICHD] Neonatal Research Network, born between 1996-1999 with 
gestational age <25 weeks and birth weight > 500 grams, 47% had a Mental 
Developmental Index <70 (-2 SD) and 31% had a Psychomotor Developmental 
Index <70 at 18-22 months; only 21% was unimpaired. McElrath et al. found a 
33% survival rate among live born 23-wekers and none were free from substan-
tial morbidity.14 In a Canadian study of infants admitted to the NICU, only 11% 
born at 23 weeks of gestation survived without major neonatal morbidity, 21% 
at 24 weeks and 29% at 25 weeks.15 Yu found a comparable 33% severe disability 
rate in survivors born at 23 and 24 weeks.16
 In many European studies neonatal morbidity (Table 1) is used as a measure for 
short-term outcome, but, as mentioned before, early outcome does not predict 
later outcome very well. Hakanson et al.4 from Sweden found that 43% of infants 
born at or below 25 weeks who were actively treated, survived without broncho-
pulmonary dysplasia (BPD), severe retinopathy (ROP) or severe intraventricular 
haemorrhage (IVH), compared to 28% of the infants who were more selectively 
treated. Another Swedish study with an active treatment approach reported that 
81% of the survivors went home without severe ROP/IVH or periventricular 
leucomalacia and 36% with BPD.17 Markestad et al. from Norway described that 
44%, 49% and 67% of infants born at respectively 23, 24 and 25 weeks survived 
“without severe illness”.7 In a Finnish study 100% of the infants born at 22-23 
weeks and 62% of the infants born at 24-25 weeks had at least one morbidity, 
defined as severe ROP/BPD/abnormal neurological examination at 36 weeks.18 
In the EPIBel-study (gestational age <26 weeks) the chance to survive free from 
serious neonatal morbidity was less than 15%.19 In the EPICure-study 49% of 
survivors were disabled at 30 months (23% were severe disabled).20 At 6 years of 
age cognitive impairment (<-2 SD) was present in 21%, but this value rose to 
41% when the results were compared with those for their classmates.21 These 
high rates of disabilities remain a major challenge.
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Decision-making
Role of the parents
 Codes of medical ethics require doctors to give absolute priority to their 
patient’s welfare and have advocated that a physician has no duty to treat, espe-
cially when the treatment is futile (no chance, no purpose, unbearable) and that 
in this event the physician, and not the parents, has the authority to decide.22 
Involvement of the parents in the decision-making process implies that they 
have a correct insight as to whether care is ethically justified, optional or still the 
subject of investigations.22
 In 2000 the results of a large European study were published in which a 
hypothetical case of extreme prematurity was presented to physicians and nurses 
(EURONIC group).23 In Great Britain and the Netherlands, parental wishes 
appeared to exert influence on the treatment decision. In many countries resus-
citation guidelines mention an individual approach at a gestational age less than 
24 weeks, with the goal of a parental consult. Recently Peerzada et al. published 
a survey in which they reported that 93% of the neonatologists in Sweden would 
resuscitate a very preterm infant if they considered treatment clearly beneficial, 
despite parental requests to withhold treatment. When the respondents consid-
ered treatment to be of uncertain benefit, only 25% would honour parental 
requests to withhold treatment. Thus in general the respondents envisioned a 
very limited parental role in delivery room decision-making for extremely pre-
term infants.24 This same survey was done earlier in the USA, also by Peerzada, 
and here 76% of the respondents would honour parental requests to withhold 
treatment when it was considered to be of uncertain benefit.25 Fear of litigation 
however, especially in the USA, might increase resuscitation of infants born near 
the limits of viability: Ballard et al. showed that there was a strong disposition 
among neonatologists towards respecting parental wishes in a hypothetical case 
of a 23-weker and that this disposition was stronger when neonatologists were 
given additional reasons to be concerned about litigation.26 
Influence of condition at birth
 There is much controversy about whether cardiopulmonary resuscitation in 
the delivery room always indicates a uniformly bad prognosis. However, the char-
acteristics of the resuscitation may predict outcome. The question is if there is 
any ethically relevant information that can be obtained by examining an infant 
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of 23 or 24 weeks’ gestation immediately after birth and whether this informa-
tion is critical in making a decision to resuscitate or not. Nevertheless, 75% of 
the Swedish physicians in the earlier mentioned study of Peerzada24 found the 
condition of the infants at delivery to be (very) important in delivery room deci-
sion-making. Shankaran studied 1,016 infants born with a gestational age ≤24 
weeks, birth weight ≤750 grams and a 1-minute Apgar score ≤3. She found 60% 
to have a severe neurological impairment at 18-22 months.27 Janvier and Bar-
rington suggest that extensive resuscitation can be followed by intact survival if 
the resuscitation required is brief. After 3 minutes of active resuscitation and a 
continuous heart rate <100 beats/minute, short-term outcome is very poor.28 
Often the decision to continue intensive care is based on the efficacy of positive 
pressure ventilation in the delivery room, but this is not really evidence-based as 
nearly all publications on the efficacy of neonatal resuscitation define “resuscita-
tion” as external cardiac massage, epinephrine administration or both.29
Influence of gender and birth weight
 Males tend to be at a disadvantage: most studies show significant better survival 
in preterm infants of female gender8;30-35 and a greater risk for impaired outcome 
in males.13;20 Morse36 described the best survival in black females and the worst 
survival in white males. Because of this male disadvantage, some authors advise to 
start active treatment in males one gestational age-week later than in females.37
 The question remains whether survival without severe disabilities is possible 
when birth weight is below 500 grams. Lucey et al.38 described an overall survival 
rate of 17% in a large cohort of infants who weighed 401-500 grams at birth. The 
survivors experienced a high rate of serious morbidities in the neonatal period. 
Because there is very little information about long-term outcomes of these foetal 
infants, Professor Jerold Lucey concluded we are all engaged in a large uncon-
trolled experiment.38  
Conclusion
 There is widespread agreement that the aim of neonatal resuscitation should 
be a qualitatively acceptable survival of the child. In the USA guidelines state 
that it is inappropriate to resuscitate infants <400 grams or <23 weeks.12 Most 
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European and Canadian guidelines propose an active approach at 25 and 26 
weeks, and a flexible approach at 23 and 24 weeks, depending on the opinion of 
the parents and the condition of the infant at birth. Nevertheless, more and more 
infants born at 23 and 24 weeks are resuscitated, especially in Sweden, Norway 
and Germany. In future studies the qualities of life of these infants, their neuro-
developmental outcome and later academic achievements have to be shown.
In the Netherlands, extremely preterm infants are not routinely resuscitated and 
intensive care will be withdrawn if treatment is clearly futile. This policy is based 
on reports from the Dutch Medical Association and the Dutch Paediatric Asso-
ciation, which argue that withholding or withdrawing life-sustaining treatment 
in newborn infants with extremely poor prognoses is justifiable medical practice 
and that decisions should be taken by the medical and nursing team, together 
with well-informed parents.39 In Table 3 the Dutch guidelines are illustrated.
Table 3. Consensus on treatment of extremely premature infants at birth in the 
Netherlands (Dutch Paediatric Association, November 2005).
Gestational 
age in weeks 
& days
Intrauterine 







treatment in the 
delivery room











comfort care, unless 
an active approach 
seems justified
25+0 – 25+6 Indicated Yes Rarely on foetal 
indication
Active approach, 
unless comfort care 
seems more justified
> 26+0 Indicated Yes Yes, unless an 
active approach 
does not seem 
justified
Active approach, 
unless comfort care 
seems more justified
If a child weighs less than 500 grams at birth, neonatal treatment will be withheld, except for 
family-centred comfort care.
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Lorentz reminds us how difficult it is to decide before delivery, so an option 
could be to start intensive care to extremely preterm infants, then reconsider 
and eventually withdraw treatment. There are little data to support the predic-
tive value of the condition at birth for survival.29 Levene warns us to keep in 
mind that treatment of extremely preterm infants (23 and 24 weeks of gesta-
tion) should be viewed as an experimental therapy with properly informed con-
sent rather than the automatic process that it often becomes.11 Because of the 
often poor long-term neurological and mental outcome of these very immature 
infants, decisions about justified care should include the alternative of no life-
supporting treatment.40
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Abstract
Objective: To describe growth in infants < 32 weeks GA. To assess the relation-
ship between growth and perinatal factors (like intrauterine growth retardation 
and the postnatal use of dexamethasone) and neurodevelopmental outcome.
Design: Regional, prospective study in two health regions in the Netherlands. 
Part of the Leiden Follow-Up Project on Prematurity (LFUPP).
Patients: 196 live born infants with GA < 32 weeks.
Methods: At two years corrected age length, weight and head circumference of 
160 of 196 surviving infants (82%) were evaluated. Standard Deviation Scores 
were calculated and means were compared to Dutch growth references. Mean 
SDS for length was corrected for the mean SDS for target-height. Birth weight 
(BW)-SDS for gestational age (GA) was calculated according to Swedish refer-
ences.
Results: Length, weight and weight-for-length were equally impaired in both 
sexes at two years in premature infants compared to Dutch growth charts. Catch-
up in length and weight occurred mostly in the first year of life. Intrauterine 
growth retardation was associated with impairment of all growth parameters. The 
use of postnatal dexamethasone was associated with shorter length, lower weight, 
lower weight for length and smaller head circumference; this effect remained after 
correction for GA, BW and BW-SDS. Growth retardation (length and weight) 
was associated with an abnormal neurologic examination; smaller head circum-
ference also with mental and psychomotor delay. 
Conclusion: Growth at two years corrected age in children born < 32 weeks is 
impaired. Postnatal dexamethasone is associated with impairment of all growth 
parameters including head circumference, which may be a significant contribut-
ing factor for abnormal neurodevelopmental outcome. 
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Introduction
 In the last decades an increase in survival of very premature infants is described, 
but concern remains about their neurodevelopmental outcome and catch-up 
growth. Most studies describe growth (length and weight) to lag behind in very 
low birth weight infants, although different percentages of catch-up growth are 
reported.1-5 Authors usually agree that most catch-up growth occurs in the first 
year of life and that later catch-up is disappointing. Because postnatal growth 
seems to be related to neurodevelopmental outcome5;6, paediatricians usually aim 
for rapid catch-up growth in the first years in these preterm infants. 
 Different causes for poor growth are reported, like intrauterine growth retarda-
tion4;7 and the presence of risk factors like chronic lung disease.8;9 Data about the 
use of postnatal dexamethasone and growth are conflicting. Romagnoli reported 
no differences at the corrected age of 3 years in premature infants with or with-
out dexamethasone10;11; Yeh et al.12 found impaired growth (length and head cir-
cumference) at two and eight years of age after the use of dexamethasone. 
The purpose of this prospective study was to describe length, weight, weight-
for-length and head circumference of premature infants at the corrected age of 
two years, compared to the Dutch growth references.13 Furthermore we assessed 
the relationship between growth and perinatal parameters like body size at birth, 
bronchopulmonary dysplasia and use of postnatal dexamethasone. The possible 
relationship between growth and the neurologic examination and the mental 
and psychomotor development at two years was also analysed.
Patients and methods
 The data of all live born infants with a gestational age of  < 32 weeks, born in 
1996/1997, in the regions The Hague and Leiden were studied. At the corrected 
age of two years, 196 of the 225 infants (87%) were alive. Data were taken from 
the The Leiden Follow-Up Project on Prematurity, a Dutch regional prospec-
tive study, which included live born infants of < 32 weeks of gestation, born in 
1996/1997 in the health regions The Hague, Leiden and Delft (n=266).14 The 
infants from the health region of  Delft were excluded because of the high per-
centage of missing growth data (59%).
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Antenatal and perinatal data were collected including health status and diseases 
of the mother, socio-economic status, diseases and medication during pregnancy, 
gestational age, birth weight and data about perinatal morbidity and medica-
tion. Twenty-three infants were considered small for gestational age (SGA) with 
birth weight < P
10 
 (-1.3 standard deviation (SD) according to the charts of 
Niklasson15); for infants born between 24 – 28.5 weeks the reference-data were 
extrapolated. 
 Twenty-nine infants received dexamethasone. In 1996/1997 dexamethasone 
was given in an initial dose of 0.5 mg/kg, tapered over 42 days to 0.1 mg/kg. It 
was started at a mean postnatal age of 17.5 days (range 5 – 42 days) and given for 
an average of 38 days (range 5 – 60 days with one infant receiving dexametha-
sone for 143 days). The cumulative dose ranged between 2.0 and 14.3 mg/kg. It 
was not possible to distinguish the influence of prenatal or postnatal steroids: 25 
of the 115 infants who received antenatal steroids were also treated with dexa-
methasone postnatally; only 4 infants received dexamethasone without antenatal 
steroids.
 The Medical Ethics Committee of the LUMC approved the study and 
informed consent of the parents was obtained.
Follow-up
 At term age and at the corrected age of one and two years a neonatolo-
gist experienced in developmental examination assessed the infants. A complete 
physical examination was performed and data about length, weight and head cir-
cumference were collected. Length was measured in supine position with straight 
back and knee on a standardized infantometer. Infants were weighed undressed 
on a calibrated infant balance scale. Head circumference was measured with a 
standard measuring tape taking the largest measurement across the occipito-fron-
tal line. Length (L), Weight (W) and head circumference (HC) were expressed as 
standard deviation scores (SDS) according to the Dutch growth charts13 at the 
ages of one and two years. To correct for genetic growth potential, at the age of 





length is corrected for the target height (TH). The formula used was TH boys = 
(height father + height mother + 13)/2 + 4.5 cm.; TH girls = (height father + 
height mother – 13)/2 + 4.5 cm. Parental heights were obtained by self-report. 
SDS for the TH were calculated: based on the mean ± SD adult height for males 
(184 ± 7.1 cm) and females (170.6 ± 6.5 cm). Infants born from non-Caucasian 
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parents were also plotted on the Dutch growth charts because at the age of two 
years the influence of ethnic origin is negligible.16;17
 At term age special growth curves were developed because the growth charts 
according to Niklasson15 can be used until the postmenstrual age of 40 weeks 
and the growth charts according to Fredriks13 from 42 weeks onwards. So for the 
children examined between 40 – 42 weeks postmenstrual age the two reference-
curves were interpolated. 
 None of the included infants had a post-hemorrhagic hydrocephalus for which 
a ventriculoperitoneal shunt was needed. In 3 patients a single lumbar puncture 
was performed with good result; the head circumference of all these infants were 
within the normal range at two years.
 At the corrected age of two years infants were neurologically examined 
according to Hempel18 focused on major as well as minor neurologic dysfunc-
tions. The children were considered definitely abnormal (DA) when muscle tone 
and reflexes were both abnormal (which meant the presence of a cerebral palsy), 
mildly abnormal (MA) when mild deviations in muscle tone regulation, reflexes, 
fine or gross motor performance were present, or normal (N). 
 Mental and psychomotor development was assessed by a developmental psy-
chologist using the Dutch version of the Bayley-Scales of Infant Development I 
(BSID I).19;20 During the study period the BSID II were not validated yet for the 
Dutch population. The BSID I have a mean value of 100 and a standard deviation 
of 16. A Mental Developmental Index (MDI) or Psychomotor Developmental 
Index (PDI) ≥ 84 (≥ -1 SDS) was considered normal (N), MDI or PDI between 
68 and 84 was considered as moderate delay (MD) and < 68 (< -2 SDS) as severe 
delay (SD).
Statistical analyses
SPSS 11 for Windows was used for statistical analyses. Fischer’s Exact test and 
X2–test were used to evaluate associations in a 2x2 table. The two-sample t test 
was used for comparison of continuous variables. The one-sample t test was used 
to compare means with Dutch growth charts. Correction for possible confound-
ing variables was done with linear regression with GA, BW and SDS
BW
 as con-
founders. Differences were considered significant when p < 0.05.
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Results
 At two years the length and weight of 160 children were obtained (82% of 
196), 66 females and 94 males. Data of 36 children remained unknown, mainly 
because of departure to other countries (5 children) or to untraceable places. 
There were no differences between the lost-to-follow-up group and the study 
group in perinatal parameters, but the parents of the lost-to-follow-up group 
had lower socio-economic status (SES) and were more often non-Caucasian 
(Table 1). Head circumference at two years was measured in 142 children (72%), 
59 girls and 83 boys.
 Twenty-three (14 %) infants (12 females, 11 males) were born small for gesta-
tional age (SGA, < P
10
). Three infants had birth weights > 2 SDS.
Table 1. Characteristics of the infants from the health regions Leiden/The Hague
Growth known:
number of infants  (%)
(total n = 160)
Growth unknown:
number of infants (%)
(total n = 36)
Male gender 94 (59) 21 (58)
Multiple birth 49 (31) 12 (33)
Non-Caucasian * 37 (23) 14 (47)
SES*   low ( < 2)





Antenatal steroids 115 (74) 22 (76)
Postnatal steroids 29 (18) 5 (14)
RDS      none
              grade 1-2









 – 28 days 46 (29) 9 (27)
BPD – 36 wks 35 (22) 7 (20)
PDA 35 (22) 9 (26)
NEC 14 (9) 4 (12)
Cystic PVL  7 (4) 0 (0)
IVH       none
              grade 1-2







Gestational age (mean, range) 29.5 wks (23.7 – 31.9) 29.0 wks (25.6 – 31.9)
Infants with GA < 28 wks 39 (24) 10 (28)
Birth weight (mean, range) 1292 grams (530 – 2382) 1208 grams (830 – 1800)
Infants with BW < 1000 grams 39 (24) 9 (25)
SES = socioeconomic status; RDS = respiratory distress syndrome; BPD = bronchopulmonary 
disease; PDA = patent ductus arteriosus; NEC = necrotising enterocolitis; PVL = periventricular 
leucomalacia; IVH = intraventricular haemorrhage.
* significant difference between the two groups
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Length 
 Mean SDS for length (SDS
L
) at two years was lower in the preterm group 
(-0.25) compared with the reference group (p = 0.008). When length was cor-
rected for target height, it was even more abnormal in preterm infants (-0.46; 
p < 0.001) (Table 2).
 Mean SDS
Lcorr
 at two years in relation to gender, perinatal factors (like SGA, 
BPD, cystic PVL and the postnatal use of dexamethasone) and the neurological 
and developmental examination at two years, are shown in Table 3. The mean 
SDS
Lcorr
 was significantly lower compared to the Dutch reference group, in all 
subgroups. 
 In Table 4 the regression coefficients of the linear regressions are given. SDS
L
 
at two years was positively associated with GA, BW and SDS
BW
. The mean SDS
L
 
in infants with BPD was 1.00 SD lower compared to infants without BPD; in 
infants who received dexamethasone postnatally, the mean SDS
L
 was also 1.00 
SD lower compared to infants without dexamethasone. After correction for GA, 
BW and SDS
BW
, this difference still was 0.77 SD. For length corrected for target 
height numbers are about the same (data not shown). 
Table 2. Mean SDS for length, weight, weight for length, BMI and head circumference at 
term, 1 and 2 years of age in infants born < 32 weeks compared to the reference group
term age 1 year 2 years
Mean-SDS 
(95% CI)
% < -2 SD
Mean-SDS
(95% CI)
% < -2 SD
Mean-SDS
(95% CI)

















































Lcorr  = length corrected for target height, W/L = weight for length, BMI = body mass index, 
HC = head circumference; SDS = standard deviation score 
*significantly different compared to the reference group (Dutch growth charts)
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Table 3. Growth parameters (mean-SDS and 95% CI) at 2 years in infants born < 32 weeks





















































































































SGA = small for gestational age; 
 
BPD = bronchopulmonary dysplasia; PVL = cystic periventricular 
leucomalacia; dexa = postnatal dexamethasone; Neur. = neurologic examination according to Hempel; 
N = normal; MA = mildly abnormal; DA = definitely abnormal; MDI = mental developmental index; 
MD = mild delay; SD = severe delay; PDI =psychomotor developmental index; Lcorr = length 
corrected for target height; SDS = standard deviation score.
* significant difference compared to the reference group (Dutch growth charts)
Weight
 Mean SDS for weight (SDS
W
) at two years was lower in the preterm born 
children (-0.58) compared to the reference group (p < 0.001; Table 2). For all 
factors listed in Table 3 weight was smaller at two years in the preterm born 
children compared to the Dutch reference group. SDS
W
 was positively associ-
ated with GA, BW and SDS
BW
  (Table 5). SDS
W
 of infants with BPD was1.04 
SD lower compared to infants without BPD; the difference was 1.82 SD for 
infants with or without cystic PVL and 1.20 SD for infants who received dexa-
methasone compared to infants who did not. After correction for confounders 
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(GA, BW and SDS
BW
) these differences remained highly significant (resp. 0.60, 
1.47 and 0.89 SD for BPD, PVL and use of dexamethasone). The mean SDS
W
 
of infants having a mildly abnormal neurologic examination was 0.81 SD lower 
than in neurologically normal infants; SDS
W
 was 1.06 SD lower in definitely 
abnormal infants. 
Weight-for-length
 Mean SDS for weight-for-length (SDS
W/L
) at two years was lower (-0.62) in 
the preterm group compared with normal Dutch children (p < 0.001; Table 2). 
The results for SDS
W/L




: a smaller weight-
for-length in the premature infants compared to the reference group for all peri-
natal and postnatal factors listed in Table 3.
 SDS
W/L
 was associated with GA, BW and SDS
BW
, but also with BPD, cystic 
PVL, the postnatal use of dexamethasone and the neurologic examination and 
the PDI (Table 5). After correction for confounding factors like GA, BW and 
SDS
BW
, all parameters except BPD and PDI were still associated with weight-
for-length. The use of postnatal dexamethasone for example remained associated 
with lower weight-for-length (difference 0.58 SD, p = 0.040), also after correc-
tion for BPD (difference 0.65 SD, p = 0.042). 
Head circumference  
 Head circumference (HC) was not different at two years in the premature 
born infants compared to the Dutch references, although the head circumference 
of the premature males tended to be bigger than in the reference group (Table 
3). Perinatal factors like SGA and BPD did not result in smaller HC, but use 
of postnatal dexamethasone, an abnormal neurological examination or a severe 
delay in MDI or PDI were associated with smaller HC compared to the refer-
ence group (Table 3). 
 Table 4 shows the positive association of GA, BW and SDS
BW 
and head circum-
ference. Infants with cystic PVL had a lower mean SDS
HC
 (difference 1.15 SD, 
after correction for confounders 0.97 SD). The SDS
HC
 of infants who received 
dexamethasone was 0.87 SD lower (after correction for confounders still 0.78 SD 
lower) compared to the infants who did not receive dexamethasone. There was 
also a relationship between smaller HC and an abnormal neurologic examina-
tion according to Hempel (difference 1.04 SD for definitely abnormal vs. normal 
infants) and between smaller HC and abnormal mental and psychomotor devel-
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opmental index (resp. 0.95 and 0.97 SD smaller head circumference for severe 
delayed infants compared to normal infants). After correction for confounders 
these associations remained significant. 
 No significant association between growth and other perinatal factors like 
for example intraventricular haemorrhage, patent ductus arteriosus, necrotising 
enterocolitis or rethinopathy of prematurity was found. 
 Although there was a negative influence of the postnatal use of dexamethasone 
on all growth parameters, no association was found between the cumulative dose 
of  dexamethasone and growth, nor between the duration of the dexamethasone-
course or the date of starting dexamethasone.
 Not all infants who received dexamethasone developed BPD (defined as need 
of oxygen at the postmenstrual age of 36 weeks); likewise not all infants who 




 at 2 years in infants 




 at 2 years SDS
HC













GA (wks)  0.13 (0.04;2.11)*  0.10 (0.01;0.19)*      
BW (kg)  1.07 (0.65;1.49)*  0.84 (0.39;1.28)*
SDS
BW
  0.26 (0.10;0.43)*  0.24 (0.06;0.42)*
BPD (+ vs. -) -1.00 (-1.38;-0.61)* -0.80 (-1.25;-0.36)* -0.27 (-0.70;0.16)  0.09 (-0.40;0.58)
PVL (+ vs. -) -1.22 (-2.05;-0.38)* -0.97 (-1.76;-0.17)* -1.15 (-1.95;-0.34)* -0.97 (-1.77;-0.16)*
Dexa (+ vs. -) -1.00 (-1.43;-0.58)* -0.77 (-1.25;-0.28)* -0.87 (-1.31;-0.42)* -0.78 (-1.30;-0.26)*
Neur.  MA vs N









MDI MD vs N









PDI MD vs N









GA = gestational age; BW = birth weight; BPD = bronchopulmonary dysplasia; PVL = cystic 
periventricular leucomalacia; dexa = postnatal dexamethasone; Neur. = neurologic examination 
according to Hempel; N = normal; MA = mildly abnormal; DA = definitely abnormal; MDI = 
mental developmental index; MD = mild delay; SD = severe delay; PDI = psychomotor develomental 
index; HC = head circumference; SDS = standard deviation score.; * =  significant; † = corrected 
for GA and BW-SDS.
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 at 2 years in 




 at 2 years SDS
W/L













GA (wks)  0.16 (0.06;0.26)*  0.13 (0.03;0.23)*
BW (kg)  1.53 (1.07;1.98)*  1.34 (0.87;1.81)*
SDS
BW
  0.45 (0.26;0.64)*  0.43 (0.24;0.62)*
BPD (+ vs.-) -1.04 (-1.49;-0.59)* -0.60 (-1.09;-0.11)* -0.70 (-1.17;-0.22)* -0.21 (-0.73;0.31)
PVL (+ vs.-) -1.82 (-2.75;-0.90)* -1.47 (-2.31;-0.63)* -1.68 (-2.61;-0.74)* -1.37 (-2.24;-0.50)*
Dexa (+ vs.-) -1.20 (-1.68;-0.72)* -0.89 (-1.42;-0.38)* -0.92 (-1.42;-0.42)* -0.58 (-1.10;-0.26)*
Neur. MA vs N









MDI MD vs N









PDI MD vs N









GA = gestational age; BW = birth weight; BPD = bronchopulmonary dysplasia; PVL = cystic 
periventricular leucomalacia; dexa = postnatal dexamethasone; Neur. = neurologic examination 
according to Hempel; N = normal; MA = mildly abnormal; DA = definitely abnormal;  MDI = 
mental developmental index; MD = mild delay; SD = severe delay; PDI = psychomotor developmental 
index; SDS = standard deviation score; 
* = significant; † = corrected for GA, BW and BW-SDS
Table 6. Mean SDS for growth at 2 years in infants with Bronchopulmonary Dysplasia 
and/or Dexamethasone  
BPD + /Dex +  
(n = 21)
mean SDS (95% CI)
BPD + /Dex – 
(n = 14)
mean SDS (95% CI)
BPD – /Dex + 
(n=7)
mean SDS (95% CI)
Length-corr -1.29 (-1.76;-0.82) -0.97 (-1.48;-0.45) -1.22 (-2.89;0.45)
Length -1.21 (-1.66;-0.75) -0.69 (-1.11;-0.26) -0.44 (-1.87;0.99)
Weight -1.69 (-2.14;-1.24) -0.90 (-1.54;-0.26)* -1.15 (-2.79;0.48)
Weight-for-length -1.44 (-1.85;-1.03) -0.75 (-1.46;-0.03) -1.30 (-2.66;0.05)
Head circumference -0.59 (-1.09;-0.08)  0.61 (-0.06;1.28)* -0.72 (-2.21;0.77)
BPD = bronchopulmonary dysplasia; Dex = dexamethasone;* significant difference to BPD +/Dex +
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developed BPD received dexamethasone, so the numbers of infants with BPD 
and dexamethasone are not the same. Table 6 shows that from all infants with 
BPD, the ones who received dexamethasone have lower weight (p = 0.035) and 
smaller head circumference (p = 0.004) compared with the infants with BPD 
who did not receive dexamethasone. In this table is also illustrated that among all 
infants who received dexamethasone, there is no difference in growth between 
the infants with or without BPD.
Catch-up growth
 In 40% of the infants at term age SDS
W
 was below –1.3 and in 50% SDS
L
 below 
–1.3, while in only 11% the SDS
HC











 below -2 SDS at different times (term 
age, the corrected age of one and two years) are listed in Table 2. Between term 
age and the age of 1 year the percentage of children with very low length or 
weight decreased fast, but between the ages of one and two years the numbers 
remained about the same, suggesting that catch-up growth occurred mostly in 
the first year of life. In this cohort there were a limited number of infants with 
very small head circumference and this number remained equal over time.
 Catch-up growth was worse in the SGA-infants (n = 23): at two years 17 % had 
L and Lcorr < -2 SDS, 26 % had W and W/L < -2 SDS and 14 % HC < -2 SDS. 
Discussion
Comparison to Dutch growth charts
 We found shorter length, lower weight and lower weight-for-length at two 
years in very preterm infants compared with the Dutch growth charts. Smaller 
length and weight at this age were also described by Ford et al.3 when they com-
pared very low-birth-weight children (< 1500 grams) with normal birth weight 
children (> 2500 g). As shown in Table 2 a number of children at two years had 
growth parameters < –2 SDS. Hack4 found 15.5% subnormal length (< P
3
) at 20 
months corrected age in a cohort of infants born < 1500 g compared to 5% in 
our cohort with L-SDS < -2 SD (= P
2
); when we use length corrected for target 
height we found about the same percentage as in the American study (12%). 
 Head circumference at two years was comparable with the Dutch growth 
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charts, in contrast with Daily et al.2 who showed that 45% of infants born < 800 
g at 3 years still had a head circumference < P
5
. Maybe this percentage is so much 
higher because of the extremely low birth weight of the infants included in their 
study: in our study only 15 infants (9%) had a birth weight < 800 grams. Casey 
et al.1 divided a large cohort of preterm infants in three birth weight groups 
(≤ 1250 grams, 1250 – 2000 grams and 2000 – 2500 grams), in which they found 
significant differences between the 3 subgroups in length, weight and head cir-







 at two years were remarkably similar for males and 
females. In literature the influence of gender on growth is often not analysed and 
if so, results are not correspondent. Casey et al.1 also found almost similar growth 
patterns for both sexes (and larger head circumference in the heaviest preterm 
group compared to their reference group). Others, however, have reported better 
growth in males.9;21
Small for gestational age
 We found significant differences in weight (0.76 SD) and weight-for-length 
(0.82 SD) at two years in infants born SGA compared to infants born non-SGA, 
but unlike others4;5;7;22 we only found small differences in length and head circum-
ference in these infants. However, when we used SDS
BW
 as a continuous variable, 
we found significantly lower length, smaller weight and weight-for-length and 
smaller head circumference at two years in infants with lower SDS
BW
. 
 In the literature different definitions have been used for SGA. We plotted the 
LFUPP-infants in the reference curves according to Niklasson15, Marsal23 and 
Usher & McLean24: mean SDS
BW
 was -0.16, -1.24 and 0.13 respectively and the 
number of infants with SDS
BW
 < P10 (-1.3 SD) was 14, 45 and 22% respectively. 
We concluded that our infants resembled most the group of infants described by 
Niklasson et al. and decided to use their reference curves. 
Influence of postnatal dexamethasone
 In this study a negative influence of the postnatal use of dexamethasone on 
length, weight, weight-for-length and head circumference was found, which 
remained after correction for confounders. There was no association between 
the cumulative dose of  dexamethasone and growth parameters. An explanation 
for the absence of this association could be that the cumulative dose was high 
in all children (2 – 14.3 mg/kg), in comparison with the cumulative dosage in 
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presently used short courses (2.3 mg/kg dexamethasone), and that above a cer-
tain threshold of dexamethasone the dose-response relationship becomes less 
prominent. An additional explanation may be that the study group receiving 
dexamethasone was too small to detect subtle dose-effect relationships.
 Many studies have concentrated on short-term influences of dexamethasone 
and data about later catch-up growth show conflicting results. The group of 
O’Shea25 found in 2 cohorts with or without dexamethasone, similar propor-
tions of infants with head circumference, length or weight below the 10th per-
centile at 1 year of age. Yeh et al.12 studied infants who received an early course of 
dexamethasone to prevent chronic lung disease compared with a control group; 
they found a shorter height and smaller head circumference at school age in the 
infants who received dexamethasone. 
 Murphy et al.26 showed on MRI at term age 35% reduction of cortical grey 
matter in infants who received dexamethasone compared to infants who did not. 
This is consistent with the increase of abnormal neurologic findings in newborns 
that received postnatal dexamethasone in recent literature. We also found an asso-
ciation between smaller head circumference and abnormal neurologic examina-
tion and also between smaller head circumference and severe delay in psycho-
motor and mental developmental index. Infants who received dexamethasone 
more often had smaller head circumference and more developmental delay. It is 
difficult to distinguish if this delay and abnormal neurologic findings are a conse-
quence of the use of dexamethasone or of the smaller head circumference.
 In general, head circumference is known to be related to mental and motor 
development.5;27-30 Forslund et al.31 found a neurologic optimality score to be 
related to head circumference but not to length or weight. In this study we found 
a relationship also between lower weight and weight-for-length at two years and 
abnormal neurologic development. There are not many studies concentrating on 
the association of later growth with neurodevelopmental outcome, but recently 
Latal-Hajnal et al.6 reported that impaired postnatal growth (weight for length < 
P
10
 at two years) rather than being SGA was associated with abnormal neurode-
velopmental outcome at that age. 
Other perinatal factors
 BPD was related to smaller length, weight and weight-for-length, which could 
be explained by the higher energy expenditure in the infants with chronic lung 
disease. Daily et al.2 found no relation between BPD and growth at 3 years of age 
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in a cohort of infants < 800 grams; Dusick et al.5 found BPD not to be related to 
poor growth at two years. Other studies8;9;32 however do report impaired growth 
in infants with higher medical risk like BPD, severe IVH or PVL. In our study 
cystic PVL was also associated with all growth parameters except weight-for-
length.
 Our study was not designed as a randomized controlled trial to assess the effect 
of postnatal dexamethasone on growth and the number of infants who received 
dexamethasone might be too small. Still, the differences in mean growth param-
eters including head circumference at two years in infants who did or did not 
receive dexamethasone, are significant in this prospective regional study. The dif-
ferences in weight and head circumference at two years in infants who received 
dexamethasone within the group infants with BPD, illustrate the additional neg-
ative effect of dexamethasone on top of the BPD. We realize that in the years 
1996/1997 we gave higher doses and longer courses of dexamethasone than is 
recommended today, however, the question remains if one should give dexa-
methasone at all or prefer other glucocorticosteroids. Shinwell et al.33 described a 
decline in the use of dexamethasone by neonatologists in Israel (22% in the years 
1993/1994 down to 6% in 2001). Jobe reported figures of 23% (Vermont Oxford 
Network) and 19% (Neonatal Research Network) of infants with birth weight 
of 501 – 1000 g still receiving postnatal corticosteroids.34
 In this study not only length and weight but also weight-for-length ratio 
is analysed, which is necessary to get an impression of the body composition. 
Because of the influence of the parental height at two years, it is also important 
to relate the length of the children to target height, which was done in this study. 
In addition, the reference for SDS
BW
 (as a measure of being small for gestational 
age)15 was carefully chosen after a study of mostly used definitions for SGA.
 In conclusion, we found significantly shorter length, smaller weight and smaller 
weight-for-length at two years corrected age in these preterm born children 
compared to the Dutch growth charts. Head circumference was comparable with 
the reference group. The number of children with length, weight and weight-for-
length < –2 SD at two years was about 12%; 4% had a head circumference < -2 
SD. Infants with BPD and cystic PVL showed reduced growth. Postnatal use of 
dexamethasone was negatively associated with all growth parameters, especially 
head circumference. SDS
BW
 was also associated with impaired growth. Part of the 
growth retardation may be explained as a result of intrauterine growth retarda-
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tion, but also by the use of postnatal dexamethasone in case of BPD. Catch-up 
growth in weight and length occurred mostly in the first year of life. Children 
with impaired growth (length, weight, weight-for-length and head circumfer-
ence) had an abnormal neurologic examination and in case of smaller head cir-
cumference also more psychomotor and mental delay.
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Similar growth in preterm infants with
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Objective: To analyse the influence of preterm growth restraint (PGR) in pre-
term infants born appropriate-for-gestational-age (AGA) on growth achieve-
ment at 2 years of age and to compare their growth with preterm small-for-ges-
tational-age (SGA) infants. 
Design: Regional, prospective study of infants born < 32 weeks gestational age 
(GA). Length, weight and head circumference were measured at term, 1 and 2 
years of age and expressed as Standard Deviation Scores (SDS). PGR was defined 
as length and/or weight at term age < -1.3 SD.
Results: Of the 158 infants, 23 (14%) infants were SGA, 61 (39%) were AGA-
PGR and 74 (47%) AGA-nonPGR. At all ages the SGA-infants had the lowest 
length, weight and head size. At 2 years of age AGA-PGR-infants had a similar 
mean length as SGA-infants (-0.68 vs. -0.80 SDS), a lightly bigger head cir-
cumference (-0.09 vs. -0.40 SDS) and a higher weight (-0.93 vs. -1.50 SDS) 
and weight-for-length (-0.79 vs. -1.51 SDS). The AGA-nonPGR-infants dis-
played growth parameters comparable to the Dutch reference group, except for a 
relatively large head circumference (0.38 SDS). After correction for confounders 
PGR remained the most important predictor for sub-optimal growth at 2 years 
in the AGA-infants.
Conclusion: Preterm infants, who experience preterm growth restraint, are 
at increased risk for sub-optimal growth at the corrected age of 2 years. Their 
growth is similar to that of SGA-infants concerning length and head circumfer-
ence.
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Introduction
 Advances in neonatal care have resulted in an improvement of survival of pre-
mature infants, but survivors have remained at an increased risk of neurological 
sequelae and sub-optimal growth. Sub-optimal growth may be the result of a com-
plex interaction of perinatal factors including inadequate nutrition and is com-
mon in extremely preterm children, particularly when the infants are born small-
for-gestational-age (SGA)1, when they have bronchopulmonary disease (BPD)2 or 
when prolonged courses of systemic steroids have been given for BPD.3-5 Most cli-
nicians strive at a normal growth pattern of preterm infants, as a sign of sufficient 
nutrient intake, which is believed to be crucial for early brain development.6
 We have recently postulated that the extra-uterine growth restriction of AGA 
born preterm infants who suffer from medical complications in the neonatal 
period may have a similar effect on later growth as intrauterine growth restric-
tion leading to SGA at term. Thus, “preterm growth restraint” (PGR) may be 
the relevant issue, more than the environment where it is experienced (in utero 
or ex utero).7 Indeed, in a nationwide cohort of very preterm infants born in 
the nineteen-eighties, infants who experienced PGR displayed a growth pattern 
similar to that of preterm SGA-infants.8 An association between the incidence 
of in-hospital growth failure in extremely low birth weight infants and growth 
failure at 2 years of age was described earlier by Dusick et al.9
 In a previous study in a regional cohort of very preterm infants from the 
nineteen-nineties, we found impaired growth at 2 years of age and postnatal 
dexamethasone to be related to sub-optimal growth.10 In the present study we 
compared various growth parameters until the corrected age of 2 years of three 
subgroups (SGA, AGA-PGR and AGA-nonPGR) in the same cohort. 
Methods
Data were taken from the Leiden Follow-Up Project on Prematurity (LFUPP), a 
Dutch regional prospective study, which included live born infants < 32 weeks of 
gestation, born in 1996/1997 in the health regions The Hague, Leiden and Delft 
(n=266).11 The infants from the health region Delft were excluded because of a 
high percentage of missing growth data (59%). At the corrected age of 2 years, 
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196 of the 225 infants (87%) born in the regions The Hague and Leiden were 
alive. From 160 survivors (82% of 196) length and weight were measured at the 
corrected age of 2 years. From 36 children no data could be obtained. No differ-
ences were observed between the lost-to-follow-up group and the study group 
in perinatal parameters, but the parents of the lost-to-follow-up group had lower 
socio-economic status and were more often non-Caucasian. Head circumference 
at 2 years was measured in 142 children (72%). 
 For this analysis small-for-gestational-age was defined as birth weight <-1.3 
SD (P
10
) according to Niklasson.12 All other infants were considered appropriate-
for-gestational-age (AGA), including three infants with birth weights >2 SD. In 
the AGA-infants preterm growth restraint (PGR) was defined as length and/or 
weight at term age less than -1.3 SD. When the postmenstrual age (PMA) was 
<40 weeks (29 infants, 18%) growth parameters were compared to Niklasson12; 
when PMA was >42 weeks (45 infants, 29%) the Dutch nation-wide growth 
reference was used13; and for the children examined between 40 – 42 weeks 
PMA (84 infants, 53%) the two reference-curves were interpolated. In 2 infants 
data concerning length and weight at term age were missing, so the final cohort 
consisted of 158 infants. Seven infants were examined not precisely at term age 
(resp. at 46, 48, 49, 51 and 58 weeks PMA); when we excluded these infants and 
analysed the data, results remained the same (data not shown). 
 Antenatal and perinatal data were collected including health status and diseases 
of the mother, socio-economic status, diseases and medication during pregnancy, 
gestational age, birth weight and data about perinatal morbidity and medication. 
In 28 cases dexamethasone was administered. In 1996/1997 dexamethasone was 
given in an initial dose of 0.5 mg/kg/day, tapered over 42 days to 0.1 mg/kg/
day. 
 The Medical Ethics Committee of the LUMC approved the study and 
informed consent of the parents was obtained.
Follow-up
 At term age and at the corrected age of 1 and 2 years four neonatologists expe-
rienced in developmental examination assessed the infants. A complete physical 
examination was performed and data about length, weight and head circumfer-
ence were collected. Length was measured in supine position with straight back 
and knee on a standardised infantometer. Infants were weighed undressed on a 
calibrated infant balance scale. Head circumference was measured with a standard 
Similar growth in preterm infants with intra- or extrauterine growth restriction 77
measuring tape taking the largest measurement across the occipito-frontal line. 
Length (L), weight (W) and head circumference (HC) were expressed as stan-
dard deviation scores (SDS) according to the Dutch growth charts at the ages 
of 1 and 2 years.13 Because of differences in length due to differences in genetic 
growth potential, at the age of 2 years another outcome measure for length was 
added: Lcorr-SDS. In Lcorr-SDS, length was corrected for target height (TH). 
Target height was calculated as [mean parental height + or – 13 cm]/2 + 4.5 
cm, in which 4.5 cm represents the secular trend per generation of 30 years.13 
Height of both parents was obtained in 93% of the infants. At 2 years of age a 
mental developmental index (MDI) and a psychomotor developmental index 
(PDI) were assessed by a developmental psychologist using the Dutch version of 
the Bayley-Scales of Infant Development I (BSID I). During the study period 
the BSID II were not validated yet for the Dutch population. The BSID I have a 
mean value of 100 and a standard deviation of 16. 
Statistical analyses
 SPSS 11 for Windows was used for statistical analyses. Fischer’s Exact test and 
X2–test were used to evaluate associations in a 2x2 table. The two-sample t test 
was used for comparison of continuous variables. The one-sample t test was used 
to compare means with Dutch growth charts. A multiple regression analyses was 
conducted with growth parameters at 2 years as dependent variables and GA, 
BW-SDS, PVL, BPD, dexamethasone and PGR as independent variables. Differ-
ences were considered significant when p < 0.05.
Results
 Twenty-three (14.6%) of the 158 children analysed at 2 years could be classi-
fied as SGA, 61 (38.6%) as AGA-PGR and 74 (46.8%) as AGA-nonPGR. Char-
acteristics of the 3 groups including mean gestational age (GA) and mean birth 
weight (BW) are listed in Table 1. Mean BW, multiple birth, patent ductus arte-
riosus (PDA), use of surfactant, need of oxygen at 28 days, bronchopulmonary 
dysplasia (BPD), use of postnatal dexamethasone, still being admitted at term 
and the MDI and PDI were significantly different in the 3 groups. Among the 
AGA-infants GA, BW, female gender, respiratory distress syndrome (RDS), use 
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of surfactant, patent ductus arteriosus (PDA), need of oxygen at 28 days, BPD, 
postnatal dexamethasone, abnormal neurological examination at 2 years and both 
lower PDI and MDI were associated with PGR. Multiple birth, race, necrotising 
enterocolitis, periventricular leucomalacia (PVL) and intraventricular haemor-
rhage were not associated with PGR. For all growth parameters, PGR was an 
important predictor for sub-optimal growth at 2 years in the AGA-infants. Mean 
differences were 0.97 SD for length, 0.60 SD for length corrected for target 
height, 0.93 SD for weight, 0.57 SD for weight-for-length and 0.47 SD for head 
circumference. For length, PGR remained a significant predictor after correction 
for confounding factors like GA, BW-SDS, PVL, BPD and use of dexamethasone 
(mean SDS was 0.88 lower in AGA-PGR-infants compared to AGA-nonPGR-
infants). 







Total infants (n = 23) (n = 61) (n = 74)
GA (wks, mean+range) 30.4 (26.1-31.9) 28.4 (23.7-31.9) 30.1 (25.9-31.9)
BW (grams, mean+range)* 943 (530-1210) 1118 (550-1928) 1540 (900-2382)
Male gender 11 (48) 31 (51) 50 (68)
Multiple birth* 2  (9) 20 (33) 27 (37)
PDA* 4 (17) 21 (34) 9 (12)
surfactant* 5 (22) 37 (61) 24 (32)
O2-28 days* 6 (26) 34 (56) 5  (7)
BPD 36 wks* 5 (22) 27 (44) 3  (4)
NEC 3 (13) 7 (12) 3  (4)
Cystic PVL 2  (9) 2  (3) 3  (4)
IVH grade 3/4 - 4  (6) 3  (4)
Dexamethasone* 4 (17) 23 (38) 1  (1)
Still admitted at term* 8 (35) 22 (37) 8 (11)
Normal neurol. exam. at term 6 (26) 31 (51) 41 (55)
Normal neurol. exam. at 2 yrs 15 (65) 36 (59) 59 (80)
BSID   MDI – mean (SD)*







GA = gestational age; BW = birth weight; PDA = patent ductus arteriosus; BPD = bronchopulmo-
nary dysplasia; NEC = necrotising enterocolitis: PVL = periventricular leucomalacia; IVH = intra-
ventricular haemorrhage; MDI = mental developmental index; PDI = psychomotor developmental 
index; SGA = small-for-gestational age; AGA = appropriate-for-gestational age; PGR = preterm 
growth restraint. *Significant difference between the 3 groups.
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 Growth parameters for the 3 groups (SGA, AGA-PGR and AGA-nonPGR) at 
term age and at 1 and 2 years corrected age are shown in Table 2. Compared to 
Dutch nation-wide reference diagrams, mean SDS for L, Lcorr, W and W/L were 
significantly lower in the SGA- and AGA-PGR-infants at all ages. Head circum-
ference was only smaller in the SGA-infants at term age and at 1 year of age; at 
2 years of age HC was similar to the reference group. Growth of the infants in 
the AGA-nonPGR-group was similar to the reference group, except for mean 
L-SDS at 1 and 2 years of age and the mean HC-SDS at all ages, which were 
larger than in the reference group. After correction for the target height, length 
at 2 years was close to the mean of the reference group.
 Growth was significantly different in the 3 groups: p <0.001 for L and W, p = 
0.002 for Lcorr, p = 0.003 for W/L and 0.005 for HC. In the AGA-group the 
infants with PGR grew significantly worse than the infants without PGR. The 
SGA-infants had the lowest mean SDS for length, weight and head circumfer-






Mean-SDS   (95% CI)
AGA-PGR 
(n = 61)
Mean-SDS  (95% CI)
AGA-nonPGR 
(n = 74)











  0.37 (0.16;0.59)†
  0.29 (0.07;0.51)†













  0.34 (0.18;0.50)†
  0.02 (-0.15;0.19)


























  0.28 (0.05;0.51)†
  1.03 (0.82;1.24)†
  0.50 (0.25;0.75)†
  0.38 (0.13;0.64)†
* significantly smaller than the reference group; † significantly larger than the reference group
SGA = small-for-gestational-age; AGA = appropriate-for-gestational-age; PGR = preterm growth 
restraint
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ence at all ages. At 2 years the mean SDS for length (L), length corrected for 
target height (Lcorr) and head circumference (HC) were similar in SGA- and 
AGA-PGR-infants; W-SDS and W/L-SDS were significantly lower in the SGA-
infants compared to the AGA PGR-infants, 0.57 and 0.72 SD respectively. 
 Figure 1 shows the percentages of the 2 year old children in the three groups, 
who had a growth parameter of less than -1.3 SD. Significant differences were 
observed for length, weight and weight-for-length. 
Lcorr = length corrected for target height; W/L = weight-for-length; HC = head circumference; SGA = 
small-for-gestational age; AGA = appropriate-for-gestational age; PGR = preterm growth restraint. 
Figure 1. Comparison of percentage of infants with growth-SDS < -1.3 (P
10
) at the cor-
rected age of 2 years, between SGA-infants, AGA-PGR-infants and AGA-nonPGR-infants
(Chapt r 5 - Fi ure 1 
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Discussion
 In this prospective regional study of very preterm infants, 45% of the infants 
born AGA experienced extra-uterine growth restriction (preterm growth 
restraint). After 2 years, their mean length was similar to SGA born children, 
and significantly lower than AGA-nonPGR children and population references. 
Weight for age and for length of AGA-PGR children were also significantly 
lower than population references, but higher than of SGA born children. Head 
circumference was within the normal range for each group at 2 years. Growth in 
AGA-nonPGR children was normal for the population and for target height. 
 These findings support our hypothesis that preterm growth is an important 
predictor for growth later in childhood, and are in agreement with the similar 
growth patterns over a period of 19 years of preterm born children either born 
SGA or AGA with PGR. In that cohort a more strict definition was used of 
SGA and PGR (-2 SDS instead of –1.3 SDS).8 We chose -1.3 SD because if we 
had used -2 SDS in our study only 5 infants (0.6%) would have been classified 
as SGA; 35 infants (26% of the non-SGA-infants) had a weight or length < -2 
SD at term age. Our results are also compatible with those of Jordan et al.2, who 
described significant catch-up between birth and 36 months which was greater 
for SGA- than for AGA-infants; in their group AGA-infants with serious neo-
natal pathology had lower length at term age compared to AGA-infants without 
serious pathology, but weight and head circumference did not differ. Recently 
Casey et al.14 published a study in which very-low-birth-weight infants who 
developed postnatal growth problems demonstrated lower physical size at 8 years 
of age compared to infants with adequate postnatal growth.
 Suboptimal growth of preterm babies is observed in multiple studies. Clark 
et al. described the incidence of extra-uterine growth retardation (defined as 
growth < P10 at the moment of discharge from the hospital) in a large cohort 
infants born between 23 and 34 weeks’ gestation to be 28%, 34% and 16% for 
weight, length and head circumference, respectively.15 In our study these numbers 
were 23%, 12% and 10% for the whole group but 31%, 18% and 17% for the 
AGA-PGR-group. Recently the National Institute of Child and Human Devel-
opment (NICHD) Neonatal Research Network reported that 97% of infants 
with a birth weight < 1500 grams at 36 weeks post conceptional age had weights 
less than the 10th percentile and they conclude that optimising nutritional sup-
port of these very preterm infants remains a challenge.16 Clark et al. found male 
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gender, need for respiratory support and exposure to steroids to be associated 
with extra-uterine growth retardation.15  We also found RDS and use of postna-
tal dexamethasone to be associated with PGR, but in our study female gender 
was associated with PGR. 
 The decrease in L-SDS, W-SDS and HC-SDS between birth and term age 
in the AGA-PGR-infants is probably mainly due to significant morbidity in 
the neonatal period. Indeed, RDS, PDA and BPD occurred more often in the 
AGA-PGR-group; furthermore these infants received more often postnatal 
dexamethasone which is also described to have a negative influence on growth.17 
Nowadays however this drug is used much less in neonates.18 Ehrenkranz et 
al.19 also reported that preterm infants who survived without developing BPD, 
severe intraventricular haemorrhage or necrotising enterocolitis, gained weight 
faster than comparable infants with those morbidities. In our study, it is not clear 
whether the differences in neurological performance, MDI and PDI at 2 years 
between the AGA-PGR- and AGA-nonPGR-children, are the result of more 
significant neonatal morbidities or poorer catch-up growth in the AGA-PGR-
children.
 In this study data on growth were missing from 36 infants (18%). However, the 
study group and the lost-to-follow-up group did only differ in socio-economic 
status and race, and because we found no association between growth and these 
two parameters, it is not likely that including these infants would have made the 
results different.
 We have now shown evidence, that a proper early postnatal growth is also a 
good predictor of normal growth in early childhood. However, it was recently 
suggested that rapid catch-up growth of preterm infants may also have long-
term effects that may be harmful, such as the development of insulin resistance20, 
particularly if body mass index SDS increases during childhood and adolescence. 
However, the respective roles of environmental and genetic factors in the devel-
opment of insulin resistance is still unknown.21;22    
In conclusion, preterm infants born AGA who grow poorly up to term age, 
show sub-optimal growth at 2 years of age, similarly to preterm infants born 
SGA. After correction for confounders the effect of sub-optimal early growth 
remains. Weight of AGA-PGR infants at 2 years is also low, but not as low as of 
SGA-infants.
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“What is already known on this topic”
• Growth in preterm infants is usually impaired 
• Several risk factors can be pointed out for this impaired growth, like broncho-
pulmonary dysplasia and use of postnatal corticosteroids 
“What this study adds”
• Preterm infants who suffer from preterm growth restraint (extra-uterine 
growth retardation), display similar growth as preterm infants who experience 
intra-uterine growth retardation
• Preterm growth restraint is an important predictor for sub-optimal growth at 2 
years of  age
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Abstract
Objective: To investigate the influence of perinatal risk factors, especially hypo-
tension, on neuromotor status at term in surviving preterm infants born before 
32 weeks of gestation.
Methods: This study is part of the Leiden Follow-Up Project on Prematurity: 
a prospective, regional study of 266 live born infants with a gestational age < 
32 weeks born in 1996 – 1997. Twenty-eight infants died before term age. Two 
hundred and eleven infants were examined neurologically at term according to 
Prechtl. The findings were classified as normal (N), mildly abnormal (MA) or 
definitely abnormal (DA). Hypotension was defined as a mean arterial blood 
pressure < 30 mmHg on at least two occasions. 
Results: One hundred and six (50%) infants were classified as neurologically 
N, 92 (44%) infants were classified as MA and 13 (6%) infants as DA. Hypoten-
sion, bronchopulmonary dysplasia, flaring and cystic periventricular leucomalacia 
were risk factors for neurological morbidity. Of the 68 infants with hypotension 
33 (49%) were classified as MA and 7 (10%) as DA. Of the 141 infants without 
hypotension 58 (41%) were MA, and 5 (4%) were DA. The odds ratio of hypo-
tension for neurological morbidity was 1.9 (95% CI 1.06 - 3.40), adjusted for 
gestational age, birth weight, small for gestational age and gender it was 1.96 
(95% CI 1.02 - 3.77). The adjusted odds ratio of PVL was 18.6 (4.4 - 78.5), of 
flaring was 2.37 (1.18 - 4.74) and of BPD was 2.44 (1.08 - 5.5).
Conclusions: Apart from gestational age, periventricular leucomalacia, and 
bronchopulmonary dysplasia, hypotension in preterm infants is a major risk fac-
tor for neurological morbidity at term. 
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Introduction
 Preterm birth is associated with an increased risk of neurological disorders1;2, 
including cerebral palsy3 and mental retardation4;5, learning difficulties6-8 and 
behavioural problems.9 Due to major recent advances in neonatal intensive care, 
approximately 85% of preterm infants < 31 weeks gestational age (GA) now 
survives.10 The purpose of the present study is to investigate the influence of 
perinatal risk factors on neurological condition at term.
 Hypoxic-ischemic brain events and intracranial haemorrhages in the perinatal 
period are common complications associated with the development of cerebral 
palsy in preterm infants.11 Disturbances of blood pressure play an important role 
in the pathogenesis of these intracranial lesions.12-14 Previous studies in preterm 
infants < 31 weeks have shown a significant association between a mean arterial 
blood pressure (MABP) < 30 mmHg and severe cerebral haemorrhage or isch-
emia or death within 48 hours.15;16
 This study addressed the question if hypotension, defined as a MABP < 30 
mmHg irrespective of GA, affects neurological morbidity at term age in very 
preterm infants. Neurological morbidity at term was chosen as an outcome 
parameter because (a) it evaluates the functional status of the nervous system, 
(b) it is known to be a significant predictor of major and minor neurological 
dysfunction at school-age17, and (c) in contrast to functional evaluations at older 
age, it has the advantage of the absence of interference with environmental fac-
tors and later occurring illnesses. Additional questions were: (a) does hypotension 
have a greater impact on immature infants (GA < 27 wks) than on more mature 
(GA ≥ 27 wks) ones, because of the higher vulnerability to cerebral haemor-
rhage and ischemia of more immature infants and (b) can other adverse neonatal 
events, possibly leading to hypotension, predict adverse neurological outcome 





 The present study is part of the Leiden Follow-Up Project on Prematurity 
(LFUPP), which is a geographically defined collaborative follow-up study of 
preterm infants in the Dutch health regions The Hague, Leiden and Delft. Two 
hundred and sixty-six live born infants born between January 1996 and Janu-
ary 1998 with a GA < 32 weeks were included. The mean age at birth was 29.2 
weeks (range of 23.4 – 31.6 wks), the mean BW was 1250 gram (SD 383 g). 
One hundred and sixty-three (61%) infants were born in a university centre 
and immediately admitted to a neonatal intensive care unit (NICU), 103 (39%) 
infants were delivered in centres without a NICU. These neonates were either 
transported to a NICU or stayed in a regional hospital, depending on whether or 
not they needed intensive care. The in-hospital mortality rate was 11% (29 of the 
266 children died; 28 before term age, one after term age). From the remaining 
237 children 211 were included in this analysis. These infants all had a detailed 
and age-specific neurological examination according to Prechtl.21 Twenty-six 
infants were not examined according to Prechtl. They were excluded from the 
present analysis because we were of the opinion that a standard clinical neuro-
logical examination would overlook mild neurological findings. These 26 infants 
as a group did not differ in mean GA, mean BW, gender, PVL, BPD and SGA 
from the 211 infants included into the analysis. There was, however a significant 
difference in the percentage who suffered from hypotension; 33 % in the study 
group versus 12 % in the group of the 26 excluded infants (Chi-Square Test, 
p < 0.035). A detailed dataset of antenatal and perinatal factors was collected 
including mother‘s health, socio-economic status, pregnancy induction, disease 
and medication during pregnancy, reliability of GA, birth weight (BW), Apgar 
scores, cardiovascular and respiratory complications, neurological abnormalities 
and cerebral ultrasound findings.
Definitions
 Cerebral ultrasound scans were performed as part of the clinical work-up. For 
study purposes an ultrasound scan was made in all infants at term. The ultrasound 
scans were performed through the anterior fontanel using an Ultramark 4-sector 
scanner with multifrequency head (5 or 7.5 MHz). Haemorrhages were graded 
according to Papile et al.22 Flaring was defined as areas of increased echogenicity 
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in the periventricular region distinct from the ventricles. Periventricular leu-
comalacia (PVL) was defined as parenchymal lesions of increased echogenicity 
in the periventricular region distinct from the ventricles, which were replaced 
by cystic areas. Hypotension: MABP < 30 mmHg on at least two occasions, 
measured intra-arterially (umbilical) in 43% of the infants and/or with the oscil-
lometric technique (Dinamap monitor, Critikon, Inc., Tampa, Fla.). Small for 
gestational age (SGA): birth weight < P10.23 Patent ductus arteriosus: a clinical 
diagnosis confirmed by cardiac ultrasonography. Bronchopulmonary dysplasia 
(BPD): oxygen need at 36 weeks postconceptional age.24 Sepsis: a clinical diag-
nosis confirmed by positive blood cultures.
Neurological examination
 The remaining 211 infants were examined according to Prechtl by specially 
trained paediatricians. These infants were the subjects of the present paper. The 
neurological findings were classified as normal (N), mildly abnormal (MA), or 
definitely abnormal (DA). Definitely abnormal means the presence of a full-blown 
neonatal neurological syndrome, such as apathy or hyperexcitability, hypotonia or 
hypertonia, hypokinesia or hyperkinesia, or a hemi syndrome. Mildly abnormal 
denotes the presence of only part of such a syndrome. Examples of minor neuro-
logical signs are an abnormal posture, abnormal head control, frequently occur-
ring tremors or startles and absent or abnormal responses or reflexes.25
 The study was approved by the Medical Ethics Committee of the Leiden Uni-
versity Medical Center. Parental informed consent was obtained.
Statistical analysis
 The X2 – test and the Student’s t - test were used for univariate analyses, Fish-
er’s exact test was used where appropriate. Correction for confounding variables 
was done with ordinal logistic regression analysis contrasting normal with mildly 
and definitely abnormal infants, using GA, BW, gender, SGA, BPD and PVL as 
confounders. P-values < 0.05 were considered significant.
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Results
 At term 106 (50%) of the 211 infants were classified as neurologically N, 92 
(44%) infants as MA and 13 (6%) as DA. The risk factors for neurological mor-
bidity at term age are summarised in Table 1. Infants born before 27 weeks of 
gestation showed more a DA outcome than infants born after 27 weeks of gesta-
tion (15% versus 5%) although the difference did not reach statistical significance 
(p = 0.133). Infants below 1250 grams at birth were more often categorised as 
neurologically MA and DA infants (p = 0.02). Also infants born SGA (n = 28) 
had a higher risk for neurological morbidity than the 182 AGA infants. Addi-
tional factors associated with neonatal neurological morbidity were flaring, PVL, 
BPD, diuretics, dexamethasone postnatal given and hypotension in the neonatal 
period. For example, of the 68 infants with hypotension 33 (49%) were classified 
as MA and 7 (10%) as DA, whereas in the group of 141 infants without hypoten-
sion 58 (41%) were MA and 5 (4%) were DA (Table 1, Fig. 1). Of two children 
the blood pressure variables were not available. 
 Gender, prolonged rupture of membranes, sepsis, meningitis, respiratory dis-



























Figure 1. Distribution of neurological morbidity at term in infants with and without 
hypotension
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GA = gestational age; BW = birth weight; SGA = small for gestational age; IVH = intraventricular 
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**Diuretics, Dexamethasone were given postnatal.
* P-value of one-way ANOVA, or Fisher’s exact test, where appropriate.
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lation, surfactant therapy, patent ductus arteriosus, necrotising enterocolitis, intra-
ventricular haemorrhage (IVH) and post haemorrhagic ventricular dilatation 
were not related to the neurological condition at term.
 Table 2 summarises the raw odd ratios of the risk factors mentioned above and 
the odd ratio’s adjusted for GA, BW, SGA and gender. After correction for the 
latter confounders, hypotension, PVL, flaring and BPD remained associated with 
neurological dysfunction at term. PVL was the most important factor. Adjusted 
for PVL, the odds ratio of hypotension was slightly smaller (OR = 1.87, 95% CI 
0.94 -3.71, p = 0.07).
 To increase our understanding of the role of hypotension, the characteris-
tics of infants (and their mothers) with or without hypotension were compared 
(Table 3).  This table presents available data of all the surviving infants. There 
were no significant differences between the two groups with respect to mater-
Table 2. Raw and adjusted Odds ratio’s of risk factors for neurological morbidity at term age
Adjusted for GA, BW, Gender, SGA















 need at 28 days 1.70 (0.92-3.15) 1.49 (0.67-3.33)
BPD 2.60 (1.30-5.03) 2.44 (1.08-5.51)
IVH grade 3 and 4 13.87 (4.15-46.43) 1.53 (0.44-5.28)
PVL 20.1 (5.03-80.24)  18.60 (4.40-78.50)
Flaring 2.20 (1.13-4.32) 2.37 (1.18-4.74)
Hypotension 1.90 (1.06-3.40) 1.96 (1.02-3.77)
Diuretics 2.20 (1.10-4.20) 2.00 (0.93-4.31)
Dexamethasone* 2.37 (1.13-4.96) 2.36 (0.98-5.67)
Bilirubine 1.00 (0.99-1.00) 1.00 (0.99-1.01)
OR = odds ratio; GA = gestational age; SGA = small for gestational age;  BPD = bronchopulmonary 
dysplasia; IVH = intra ventricular haemorrhage; PVL = cystic periventricular leucomalacia, 
*Dexamethasone postnatal given.
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nal and obstetrical complications like pre-eclampsia and intra-uterine growth 
retardation. Moreover, the use of anti-hypertensive medication in the mother 
was not associated with hypotension in the newborn. Substantial differences in 
neonatal morbidity were found. Infants with hypotension were of lower GA and 
BW than those without hypotension. In addition, the presence of hypotension 
was associated with RDS, oxygen need at 28 days, BPD, PVL, PDA, diuretics 
and postnatal treatment with dexamethasone and lower Apgar scores at both 5 
and 10 minutes. Infants with hypotension did not have more IVH (p = 0.13). 
Infants with hypotension were more often of a multiple pregnancy, they were less 
often transported postnatal, they were less often born by caesarean section and 
the mothers of hypotensive infants were more often treated with Indomethacine 
medication before delivery. Except for postnatal transport, which is known to 
have a negative influence on outcome26, none of these factors was significantly 
related to neurological morbidity at term. 
 Finally, we saw no difference in neurological outcome at term between the 
infants born with a GA < 27 weeks (MA + DA = 14 (61%)) having hypotension 
and the infants with hypotension and born with a GA ≥ 27 wks (MA + DA = 26 
(58%)). This suggests that the more immature infants were not more susceptible 
to the adverse effect of hypotension.
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Gestational Age <27 weeks 8 (5) 22 (31) <0.001
Male Gender 96 (59) 37 (53) 0.47
Birth weight <1250 gr 66 (41) 47 (67) <0.001
SGA 22 (14) 9 (13) 0.99
Apgar-score:    5 min.







IVH 4 (3) 5 (8) 0.13
PVL 1 (1) 6 (9) 0.004
Flaring 31 (19) 21 (30) 0.09
RDS 79 (50) 52 (74) <0.001
O
2
 need at 28 days 27 (17) 37 (54) <0.001
BPD 21 (13) 26 (38) <0.001
Diuretics 21 (13) 25 (36) <0.001
Postnatal Dexamethasone 13 (8) 22 (31) <0.001
Patent ductus arteriosus 31 (19) 27 (39) 0.002
Meningitis 4 (3) 2 (3) 0.99
NEC 13 (8) 7 (10) 0.80
Sepsis (clin symptoms or positive
          blood culture)
131 (78) 54 (89) 0.06
Inotropics 3  (2) 49 (70) <0.001
MOTHeR:
Pre-eclampsia 19 (12) 3  (4) 0.07
Indocid treatment 16 (10) 23 (33) <0.001
Anti-hypertensive treatment 32 (21) 8 (12) 0.7
Antenatal Glucocorticosteroids 114 (74) 52 (80) 0.4
PROM 48 (30) 17 (25) 0.52
Caesarean Section 75 (46) 21 (30) 0.03
Multiple birth 46 (28) 29 (41) 0.07
Transport 64 (40) 13 (9) 0.002
SES 3.6 (1.3) 4.4 (1.3) <0.001
Age 30.3 (4.7) 31.1 (4.6) 0.22
Smoking during pregnancy 18 (13) 12 (18) 0.41
* P-value of Student’s t-test, or Fisher’s exact test, where appropriate.
SGA = small for gestational age; IVH = intraventricular haemorrhage; PVL = cystic periventricular 
leucomalacia; BPD = bronchopulmonary dysplasia; RDS = respiratory distress syndrome; NEC = 
necrotising enterocolitis; PROM = prolonged rupture of membranes; SES = socio-economic status.
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Discussion
 Our primary goal was to analyse the influence of perinatal risk factors on 
neurological morbidity at term. We found that infants who had a mean arterial 
blood pressure of < 30 mmHg more often showed neurological dysfunction at 
term than infants without hypotension. After adjustment for gestational age, birth 
weight, gender and SGA this association remained significant. We chose a MABP 
of less than 30 mmHg as definition of hypotension in line with other authors 
who pointed out the relevance of this cut-off point in premature infants < 31 
weeks of GA.15
 Several explanations for the association between hypotension and neurological 
morbidity can be delineated. 
 First, fluctuating patterns of cerebral blood flow (CBF) velocity can induce 
intraventricular haemorrhage.14;27;28 In addition, sustained hypotension plays an 
important role in the pathogenesis of intracranial lesions.15 In our study group, 
hypotension was clearly related to neurological morbidity at term. This neuro-
logical morbidity could not be attributed to IVH caused by hypotension, since 
IVH was not related to hypotension (Table 3). The relation between hypotension 
and PVL could explain only part of neonatal neurological morbidity. This implies 
that another part of neurological morbidity related to hypotension escapes the 
ultrasonic eye.29
 Second, increased neurological morbidity in the hypotensive infants might 
have been due to disorders causing the hypotension. No association was found 
between hypotension and sepsis or prolonged rupture of membranes. However, 
the infants with hypotension had a lower GA and birth weight and more respi-
ratory problems. Theoretically, changes in intrathoracic pressure associated with 
removal of spontaneous breathing effort may decrease venous return and cardiac 
output; these in turn may lead to hypotension if ventilator settings are not appro-
priately adjusted, particularly in the presence of hypovolemia.30 These findings 
reinforce the concept that the overall condition of the infant and particularly 
RDS is an important determinant of cerebral pathology.16 Furthermore, infants 
who developed hypotension had lower Apgar scores than those without hypo-
tension. This illustrates the entanglement of risk factors, and reminds us of the 
danger of pinpointing only one factor as the major risk factor. 
 Third, the association between hypotension and neonatal neurological morbid-
ity may have been induced by the treatment of the hypotension. The majority of 
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infants were treated with dopamine, some were treated with volume expansion 
only. Various studies have suggested that dopamine treatment may put preterm 
infants at risk for IVH and/or PVL, since they may have an increased responsive-
ness to the hemodynamic actions of dopamine and an inadequate auto regulation 
of CBF.31-33
 This study showed no difference in neurological outcome at term comparing 
the more immature infants (GA < 27 wks) with the more mature ones. Espe-
cially, the younger infants were not more often categorised as MA than the older 
ones. Nevertheless they were somewhat more often classified as DA (15% versus 
5%). Summarising, we found that hypotension in very preterm infants is associ-
ated with an increased neurological morbidity at term. At this point of time it is 
not clear whether this association persists with advancing age. We do know how-
ever, that neurological morbidity at term is a substantial risk factor for neurologi-
cal dysfunction, behavioural and learning problems at school age.17;34 Long-term 
follow-up is planned to study this correlation at school age.
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 The objective of this study was to describe the incidence of bronchopulmonary 
dysplasia (BPD) in a regional, prospective study of live born infants < 32 weeks 
gestational age (GA), born in 1996/1997 in the Netherlands. Furthermore we 
wanted to analyse associations between BPD and respiratory but also neurode-
velopmental outcome at 2 years of age. BPD was defined as supplemental oxygen 
at 36 weeks postmenstrual age (PMA). At 2 years of age, a neurodevelopmental 
examination and a psychological examination (Bayley Scales of Infant Develop-
ment) was performed. At 36 weeks PMA, 49 infants (21% of the survivors at 
that time, 18.5% of all live born infants) had BPD. Respiratory problems were 
the cause of death in 50%. Infants with BPD had lower GA and birth weight 
compared to infants without BPD (27.5 vs. 30 weeks, 948 vs. 1378 grams). At 2 
years of age BPD-children had more respiratory problems and used more lung 
medication than children without BPD. The mean MDI and PDI were lower in 
BPD-children compared to children without BPD (88 and 87 compared to 101 
and 99). Eighty percent of the children without BPD had a normal neurological 
examination compared to 38% of the children with BPD. Results remained the 
same when infants with severe cerebral problems were excluded. 
Conclusion: About 20% of very preterm infants < 32 weeks suffered from BPD. 
Preterm infants with BPD had more pulmonary problems and showed more 
abnormal neurodevelopmental outcome at 2 years of age compared to preterm 
infants without BPD. 
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Introduction
 Bronchopulmonary dysplasia (BPD) was originally described by Northway1 
in 1967 and was defined in preterm infants as chronic respiratory failure in com-
bination with characteristic pulmonary radiographic changes after prolonged 
mechanical ventilation. In 1979 Bancalari defined BPD as a continued oxygen 
dependency during the first 28 days plus compatible clinical and radiographic 
changes.2 In 1988 it has been proposed to use the need for supplemental oxygen 
at 36 weeks postmenstrual age (PMA) as a better criterion for BPD.3 The latest 
definition dates from 2000, when the National Institute of Health in the USA 
organised a workshop to come up with a definition of BPD based on severity.4;5 
These changes in definitions originate from a transforming pattern (clinically as 
well as radiologically) of presentation of BPD. In the past, severe BPD (“classic 
BPD”) was seen in premature infants who received aggressive ventilation and 
had a prolonged exposure to high inspired oxygen concentrations. Atelectasis and 
fibrosis were seen as a result from mechanical injury. The “new” BPD is thought 
to be a result of an arrest in lung development for which various factors might be 
responsible: exposure of the immature lung to gas breathing, volutrauma, oxygen 
toxicity, inflammatory processes due to ante- or postnatal infections, exposure of 
immature pulmonary vasculature to increased flow through a persistent ductus 
arteriosus (PDA) and other hormonal and nutritional factors.2
 Another reason for refining the definition of BPD was to be able to improve 
the prediction for long-term outcome in premature infants. Although analyses of 
associations between outcome and BPD is complicated by coexisting morbidi-
ties, most authors find more developmental problems at later ages in infants with 
BPD compared to infants without BPD.6;7 Ehrenkranz et al. found an increase 
in adverse neurodevelopmental outcome as the severity of BPD, identified by 
the latest NIH consensus, worsened.8 More hospitalisation and more pulmonary 
problems at later ages are also described.5;9 
 The purpose of the present prospective regional study was to analyse associa-
tions between BPD and perinatal risk factors like respiratory distress syndrome 
(RDS), PDA and duration of mechanical ventilation. At the corrected age of 2 
years respiratory problems and neurodevelopmental outcome were analysed and 
related to BPD. 
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Patients and methods
 The Leiden Follow-Up Project on Prematurity, a Dutch regional prospec-
tive study, included 92% of eligible live born infants of < 32 weeks of gestation, 
born in 1996/1997 in the health regions The Hague, Leiden and Delft (n=266). 
Details about the LFUPP-cohort are described previously.10
Data collection
 Antenatal and perinatal data were collected including diseases of the mother, 
socio-economic status (SES), diseases and medication like antenatal steroids dur-
ing pregnancy, gestational age, birth weight, Apgar score and data about perina-
tal morbidity and medication. Severity of respiratory distress syndrome (RDS), 
incidence of patent ductus arteriosus (PDA) and use of surfactant were regis-
trated. Bronchopulmonary dysplasia (BPD) was defined as need of oxygen at 36 
weeks postmenstrual age (PMA), but need of oxygen at 28 days was also noted. 
Dexamethasone was given in 1996/1997 in an initial dose of 0.5 mg/kg/day, 
tapered over 42 days to 0.1 mg/kg/day. Some infants who remained ventila-
tor-dependent got a second course of dexamethasone but this was not given in 
a standardized way. The condition at discharge from the hospital was considered 
to be normal when there was no neurological disorder (on clinical examination), 
no pulmonary problems (need of oxygen and/or diuretics), no cardiac disorder, 
no feeding problems (tube feeding or regurgitation) and no visual, hearing or 
psychosocial difficulties. The Medical Ethics Committee of the LUMC approved 
the study and informed consent of the parents was obtained.
Follow-up
 Children were assessed at two years of age (corrected for prematurity) by 
4 neonatologists experienced in developmental assessment. The examination 
included a general examination and a neurological examination according to 
Hempel, focused on major as well as minor neurological dysfunctions.11 The 
children were considered definitely abnormal (DA) in case of definite neuro-
logical dysfunction, mildly abnormal (MA) in the presence of mild deviations 
in muscle tone regulation, reflexes, fine or gross motor performance, or normal 
(N). Parents were asked if their children suffered from pulmonary problems and 
if so, if they used inhaled or systemic medication. For this purpose, a recom-
mend selection of questions according to de Boer et al. was used, adapted from 
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two childhood respiratory symptom questionnaires, developed by the American 
Thoracic Society and the World Health Organisation.12;13
 Mental and psychomotor development was assessed by a developmental psy-
chologist using the Dutch version of the Bayley-Scales of Infant Development 
I (BSID I). During the study period the BSID II was not yet validated for the 
Dutch population. The BSID I have a mean value of 100 and a standard deviation 
of 16. A Mental Developmental Index (MDI) or Psychomotor Developmental 
Index (PDI) ≥ 84 (≥ -1 SDS) was considered normal (N), MDI or PDI between 
68 and 84 was considered as moderate delay (MD) and < 68 (< -2 SDS) as severe 
delay (SD).
 At two years of age behaviour was assessed using Achenbach’s Child Behavior 
Checklist for 2-3 year old children, completed by the parents. According to this 
list, behaviour could be assessed by using a total problem score: a score above the 
90th centile was defined as clinically abnormal, a score from the 85th through the 
90th percentile as borderline clinical; below the 85th percentile as normal.
Statistics
 SPSS 11 for Windows was used for statistical analyses. Fischer’s Exact test and 
X2–test were used to evaluate associations in a 2x2 table. The two-sample t test 
was used for comparison of continuous variables. The independent samples t test 
was used to compare means between the infants with or without BPD. We calcu-
lated the correlations between outcome at 2 years and BPD with dexamethasone 




 At 36 weeks PMA (postmenstrual age), 238 (89.5%) of the 266 live born 
infants of the LFUPP were still alive. One infant was excluded because of Down’s 
syndrome. In 4 infants it was not known if they had BPD. Forty-nine infants 
(49/233 = 21% of the survivors, 49/266 = 18.5% of all live born infants) could 
be classified as having BPD, defined as need of oxygen at 36 weeks PMA. Four-
teen (50%) of the 28 infants who did not survive until 36 weeks PMA, died 
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Total number of infants: 184 49
GA (mean + range), weeks 30.0 (24.7 – 31.9) 27.5 (23.7 – 31.7)
BW (mean + range), grams 1378 (703 – 2382) 948 (530 – 1635)
Male gender 105/184 (57.1) 28/49 (57.1)
Antenatal steroids (betamethason)
    None
    Incomplete course (1 gift)








   None
   Grade 1-2







Surfactant 60/184 (32.6) 32/48 (66.7)
Days on IPPV (mean+range)   3.7 (0 – 37) 17.7 (2 – 44)
Days on CPAP (mean+range)   6.6 (0 – 35) 20.3 (0 – 63)
O2-28 days 18/184 (9.9) 46/47 (97.9)
PDA 31/184 (16.8) 27/49 (55.1)
IVH 
    None
    Grade 1 – 2







Cystic PVL 3/180 (1.7) 5/49 (10.2)
ROP
    None
    Grade 1 – 2







Dexamethasone 8/183 (4.4) 28/48 (58.3)
Courses of antibiotics
     0 – 1
     2 – 3







Still admitted at term 22/177 (12.4) 28/46 (58.3)
O
2
 at home 0 11/49 (22.4)
Condition normal at discharge 134/183 (73.2) 9/48 (18.8)
Bold = p < 0.05
BPD = bronchopulmonary dysplasia; GA = gestational age; BW = birth weight; RDS = respiratory 
distress syndrome; IPPV = intermittent positive pressure ventilation; CPAP = continuous positive 
airway pressure; PDA = patent ductus arteriosus; IVH = intraventricular haemorrhage; PVL = peri-
ventricular leucomalacia; ROP = retinopathy of prematurity.
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because of pulmonary problems: 9 infants because of solitary pulmonary prob-
lems and another 5 infants because of respiratory difficulties combined with 
other serious neonatal morbidities. Characteristics of the 49 infants with BPD 
are compared with the 184 infants without BPD (Table 1). Infants with BPD had 
lower gestational age and lower mean birth weight compared to infants without 
BPD. There was no difference in gender. Infants with BPD had more severe RDS 
and were more frequently treated with surfactant. Infants with BPD were signifi-
cantly longer on the ventilator. Almost all infants with BPD at 36 weeks received 
supplemental oxygen at 28 days, while only 10% of the infants without BPD 
received oxygen at that time. Percentages of infants with BPD according to ges-
tational age and birth weight are shown in Figure 1 and 2. Thirty-three percent 
of the females (32/98) needed supplemental oxygen at 28 days compared to 26% 
of the males (34/134). If an infant needed oxygen at day 28 (O
2
-28), male gender 
was a risk factor for developing BPD: 28 out of 33 (85%) male infants developed 
BPD, compared to 19 out of 32 (59%) female infants (p = 0.02). Infants with 
BPD had more often PDA, cystic PVL, severe ROP and they received more 
courses of antibiotics.
At 2 years of age
 From all survivors at 36 weeks PMA, another two infants died during the first 
year, both of them because of severe BPD. The incidence of pulmonary problems 
at the corrected age of 2 years in the remaining 231 infants is described in Table 
2. Infants with BPD had more periods of coughing, wheezing and shortness of 
breath and used more pulmonary medication than infants without BPD. 
 The mental and psychomotor development according to the BSID at the cor-
rected age of 2 years could be assessed in 148 infants (64% of surviving infants 
with known BPD-status). Parents of the children in the lost to follow-up group 
were of lower socio-economic status and more frequently of non-Dutch origin. 
The mean MDI and PDI were significantly lower (p = 0.006 resp. 0.003) in 
infants with BPD compared to infants without BPD (Table 3). When the infants 
were classified in 3 subgroups (normal, moderate or severe delay), differences 
between the infants with or without BPD were only significant for the MDI. A 
neurological examination was performed in 189 infants (81% of the survivors): 
80% of the infants without BPD had a normal neurological examination com-
pared to 38% of the infants with BPD (Table 3). Physiotherapy was prescribed 
in 64% of the infants with BPD compared to only 14% of the infants without 
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Figure 1. Percentage of infants with BPD according to gestational age
BPD = bronchopulmonary dysplasia; PMA = postmenstrual age; wks = weeks
Figure 2. Percentage of infants with BPD according to birth weight
BPD = bronchopulmonary dysplasia; PMA = postmenstrual age
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Coughing (irrespective of a common 
cold) during the last 12 months
    Never
    < 1x / month







Shortness of breath + wheezing 
during the last 12 months
    never
    sometimes







Parental smoking behaviour 35/131 (26.7)  6/36 (16.7)
Lung medication 25/133 (18.8) 14/37 (37.8)
Betamimethics (inhaled) 17/127 (13.4) 11/36 (30.6)
Steroids (inhaled) 14/126 (11.1)  6/36 (16.7)
Bold = p < 0.05; BPD = bronchopulmonary dysplasia
Table 3. Mental, psychomotor and neurological outcome at 2 years of age, in infants with-





MDI at 2 years
    Normal
    Mild delay
    Severe delay




  101 (24)
20/38 (52.6)
10/38 (26.3)
  8/38 (21.1)
  88 (25)
PDI at 2 years
    Normal
    Mild delay
    Severe delay










    Normal
    Mild abnormal







Physiotherapy  19/133 (14.3) 18/28 (64.3)
Bold = p < 0.05; BPD = bronchopulmonary dysplasia; MDI = mental developmental index; 
PDI = psychomotor developmental index; SD = standard deviation
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BPD (p < 0.001). After correction for dexamethasone as the most important 
confounder, no differences were found in MDI and PDI between the infants 
with or without BPD. More infants with BPD had an abnormal neurological 
examination compared to the infants without BPD even after correction for the 
use of dexamethasone (p = 0.031). When infants with a serious IVH (grade 3 or 
4) or a cystic PVL were excluded there was still an association between BPD and 
more delay in MDI and PDI and abnormal neurological examination.
 Seven (18%) out of 39 infants with BPD had a clinically abnormal behaviour 
compared to 9/119 (8%) infants without BPD, which was almost significant (p = 
0.064). In infants without severe IVH or PVL the numbers were 5/33 (15%) for 
BPD-children compared to 8/110 (7%) for children without PBD.
Discussion
 In this prospective study of very premature infants born in the nineteen-nine-
ties, 21% of the infants alive at 36 weeks PMA, suffered from bronchopulmonary 
dysplasia, defined as need of supplemental oxygen at 36 weeks. In the infants 
with birth weight < 1000 grams, 54% (31/57) had BPD, in infants < 1500 grams 
29% (46/156). In the non-survivors, pulmonary problems were the cause of 
death in 50%. Studies in infants born with birth weight < 1000 grams mention 
40 – 45% BPD.7;14 Ehrenkranz et al.8 mention 30% moderate and 16% severe 
BPD in infants with GA < 32 weeks and birth weight < 1000 grams, alive at 36 
weeks PMA. In 3 large neonatal networks (the National Institute of Child Health 
and Development Neonatal Research Network, the Vermont Oxford Network 
and the Canadian Neonatal Network) incidences of 27%, 29% and 24% BPD in 
infants with birth weights between 500 and 1499 grams are recently described.15 
Because of differences in definitions of the cohorts and time periods and differ-
ences in clinical definitions of BPD like accepting different oxygen saturations, 
numbers are difficult to compare. As expected, infants with BPD were of lower 
gestational age16 and of lower birth weight. Half of them were born with RDS 
grade 3 or 4, compared to 21% of the infants without BPD. They received more 
surfactant and remained longer on the ventilator compared to the infants without 
BPD (mean 18 versus 4 days). Other possible explanations for the development 
of BPD like a persistent ductus arteriosus and multiple courses of antibiotics16 
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occurred more frequently in the infants with BPD. Gender was not associated 
with the incidence of BPD, although more males than females with supplemental 
oxygen at 28 days developed bronchopulmonary dysplasia at 36 weeks. A com-
plete course of antenatal steroids was given in an equal percentage of the infants 
with and without BPD. 
 Infants with BPD are at risk for having pulmonary sequelae and rehospitalisa-
tion during childhood.17 We found significantly more periods of coughing, short-
ness of breath and wheezing, at the corrected age of 2 years in the infants with 
BPD compared to the infants without BPD. These children also used more lung 
medication, especially more betamimethics. Vrijlandt et al.18 found no differences 
in reported pulmonary problems at the age of 3 – 5 years in premature infants 
with or without BPD, but a difference in lung function was described. Their 
definition of BPD however was different than in our study: supplemental oxygen 
at 28 days combined with radiographic pulmonary manifestations. Ehrenkranz et 
al. observed an increasing incidence of adverse pulmonary outcomes at 18 to 22 
months corrected age as the severity of BPD worsened from mild to severe. They 
also found a substantial rate of adverse pulmonary outcomes in the (preterm) 
infants without BPD.8 Many other studies however do not distinguish those 
children who developed BPD from others who were also premature but did not 
develop BPD. Furthermore, Greenough9 reminds us that most studies report the 
outcome of infants with “classical” BPD and that the long-term outcome of chil-
dren who have suffered “new” BPD is not known and that these infants require 
careful follow-up.
 In the present study we found an association between BPD and abnormal neu-
rodevelopmental outcome. Comparable results of the BSID at 2 years were found 
by Singer et al.19: they describe a mean MDI and PDI of 86 and 84 in preterm 
infants with BPD compared to a mean MDI and PDI of 99 and 102 in preterm 
infants without BPD. Although analyses of associations between outcome and 
BPD are complicated by the existence of coexisting morbidities, we still found 
an association between BPD and abnormal neurological outcome after correc-
tion for the use of dexamethasone. Vohr et al.14 already described BPD as well as 
the use of postnatal steroids to be a significant risk factor for neurodevelopmental 
impairment in very preterm survivors at 18 to 22 months. Van Baar et al.20 stud-
ied infants < 30 weeks GA at 5.5 years corrected age and they found multiple 
disabilities to be associated with birth weight and BPD. Moon et al.6 however 
found only an initial developmental lag in extremely preterm infants with BPD 
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compared to preterm peers at 1 and 2 years of age; at 4 years corrected age no 
differences between the groups were evident.  Katz-Salamon et al. reported that 
BPD had a deleterious effect on the control of hand and eye coordination and 
on perception and intelligence, when they compared 43 preterm infants with 
BPD but without severe IVH or PVL with preterm infants without BPD, IVH 
and PVL.21 
 The flaws of this study could be that we did not classify BPD according to the 
latest consensus4, but this definition was not known yet in the late nineteen-nine-
ties. Furthermore about one third of the children at 2 years could not be assessed 
according to the BSID. The lost-to-follow-up group had a lower socio-economic 
status and parents were less often of Caucasian race. However, socio-economic 
status and race were equally divided in the infants with and without BPD so it is 
not likely this will influence the outcome. Data about the outcome of very pre-
term infants with BPD from the Netherlands are scarce. This prospective, regional 
study of all live born preterm infants in three health regions in the Netherlands 
finds a comparable incidence of BPD with literature. Respiratory problems at 2 
years were analysed according to an international and reproducible questionnaire; 
the neurological examination was performed in a standardised way.  
 Despite antenatal steroid use, surfactant replacement therapy, gentle non-inva-
sive ventilation techniques BPD continues to be a major problem17, especially 
when people start using less postnatal corticosteroids22 and therefore follow-up 
of these infants remains necessary.
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Abstract
Objective: To determine the effect of prematurity (gestational age (GA) < 32 
weeks) on developmental outcome at the corrected age of 18 and 24 months in 
a regionally defined, prospective cohort study. 
Study design: The Leiden Follow-Up Project on Prematurity includes all live-
born infants of < 32 wks GA, born in 1996/1997 in 3 Dutch health regions 
(n=266). Mental and psychomotor developmental indices (MDI, PDI) were 
determined with the Bayley Scales of Infant Development I: > -1 SDS: normal, 
-2 to -1 SDS: moderate delay and < -2 SDS: severe delay. 
Results: At 18 months 168 (71%) and at 24 months 151 children (64%) of 235 
survivors were assessed. Moderate to severely delayed mental and/or psychomo-
tor development occurred in 40% of the children at both ages. Children lost to 
follow-up were of lower socio-economic status and more frequently of non-
Dutch origin. Since non-Dutch origin negatively affected outcome at both test 
ages, availability of the data of these children would probably have worsened 
the outcome. Postnatal treatment with dexamethasone was associated with an 
increased risk of delayed development. Other independent predictors of delayed 
development were bronchopulmonary dysplasia at 18 months and ethnicity, 
maternal age at birth, GA, birthweight and gender at 24 months. After adjust-
ment for these other predictors of delayed development, the mean PDI of dexa-
methasone-treated infants was 16.1 points lower than that of non-treated infants 
at 18 months (p=0.03) and 12.7 points lower at 24 months (p=0.04). 
Conclusions: At 18 and 24 months corrected age, 40 percent of the very pre-
maturely born children had both delayed mental and/or psychomotor devel-
opment. Treatment with dexamethasone postnatally was a major risk factor for 
delayed (psychomotor) development.
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Introduction
 Advances in neonatology have led to an increased survival of very preterm 
infants.1 To evaluate the effect of these ongoing changes in neonatal care 
on morbidity, the neurodevelopmental outcome of these infants is closely 
monitored. 
 Previous studies have shown that preterm infants, especially those with 
chronic lung disease or extensive intraventricular haemorrhage, are at greater risk 
of developmental disorders.2-4 Apart from these medical risk factors, social risk 
factors, such as low socioeconomic status of the parents, may also have negative 
effects on children’s development.3-5 
 In this paper we report on the developmental outcome at 18 and 24 months 
corrected age of a recent, regional, Dutch cohort of very preterm infants. We 
will compare the findings to the Dutch reference norms. Furthermore, the 
influence of both medical and social risk factors on developmental outcome will 
be examined. In view of recent findings suggesting that postnatal treatment with 
dexamethasone may have adverse effects on neurodevelopmental outcome6-8, 
close attention will be paid to the possible influence of this treatment on 
developmental outcome.
 Development was assessed at both 18 and 24 months to see if a developmental 




 The Leiden Follow-Up Project on Prematurity, a regional, prospective study, 
includes all liveborn infants less than 32 weeks gestational age (GA) from the 
Dutch health regions Leiden, The Hague and Delft, born in 1996 or 1997 
(n=266). All infants > 24 weeks GA were actively resuscitated at birth. 
 The three Dutch health regions used in the study are situated in the Dutch 
province Zuid-Holland. In the years 1996/1997 this province had 3.34 million 
inhabitants on a total of 15.53 million people living in the entire Netherlands. 
With 21% of the total Dutch population living in this province, it is a reasonably 
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densely populated region. The three studied health regions (The Hague, Delft 
and Leiden) together had 1.43 million inhabitants at that time, which is 43% of 
the total inhabitants of the province of Zuid-Holland and 9% of the entire Dutch 
population. The health region The Hague had the most inhabitants: 49% of the 
1.4 million, versus 33% in the health region Leiden and 19% in the health region 
Delft.
 The total number of live births in the Netherlands was 191.000 in the years 
1996/1997, 41.250 in the province Zuid-Holland (21% of the total) and 17.450 
(9% of total, 43% of live-births in Zuid-Holland) in the three studied health 
regions. Forty-five percent of the live-births in the studied health regions 
occurred in the region The Hague, 35% in Leiden and 20% in Delft. 
 Follow-up of the infants included physical examinations and assessment of 
neuromotor development by a paediatrician at term and at the corrected ages of 
12 and 24 months. Mental and psychomotor development was assessed at 18 and 
24 months corrected age by 6 developmental psychologists, who were ‘blind’ to 
the child’s medical history. 
 The study was approved by the Ethics Committee of the Leiden University 
Medical Center. Parental informed consent was obtained. 
In this work, all mentioned ages hereafter are corrected for prematurity. 
Instruments
 Mental and psychomotor development were assessed using the Dutch version 
of the Bayley Scales of Infant Development I.9;10 These scales have a population-
mean of 100 and a standard deviation of 16. The Mental and Psychomotor 
Developmental Index (MDI, PDI) range between 51 and 149. If raw test scores 
were either so low or so high that developmental indices could not be determined, 
index-scores of 50 and 150, respectively, were given. 
 An MDI or PDI > 84 (> -1 SD) was considered normal, an MDI or PDI 
between 68 and 84 (-2 to -1 SD) was considered as moderate delay and < 68 
(< -2 SD) as severe delay. 
 In accordance with the Bayley manual, a difference of 19 and 15 points at 18 
and 24 months respectively between MDI and PDI was considered to be signifi-
cant (p < 0.05). Such a difference was defined as dysharmonic. 
 For mental development a difference of 14 points between the MDI at 18 and 
24 months was considered significant, for psychomotor development a difference 
of 20 points.
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Medical factors
 Medical factors were collected on precoded forms. Data collected included: 
obstetric history, mode of delivery, GA, gender, birthweight, small for GA (birth-
weight < P10)11, complications during admission like hypotension (at least twice 
a mean blood pressure < 30 mmHg, measured oscillometrically [Dynamap] or 
intra-arterially), bronchopulmonary dysplasia (BPD, supplemental oxygen need 
at 36 weeks postmenstrual age)12, intraventricular haemorrhage (IVH)13, cystic 
periventricular leucomalacia (PVL)14 and treatment with dexamethasone in the 
postnatal period.
 Dexamethasone was given with an initial dose of 0.5 mg/kg and tapered over 
42 days to 0.1 mg/kg. However, duration of treatment depended on the clinical 
condition of the child and varied between 5 and 60 days (mean 31 days). 
 Neurological outcome at term (Prechtl)15 and at 2 years of age (Hempel)16 was 
defined as normal, mildly or definitely abnormal. Definitely abnormal means the 
presence of a full-blown neurological syndrome like asymmetry, general hyper/
hypotonia, hyper/hypokinesia; mildly abnormal the presence of only part of such 
a syndrome.
Social factors
 Socioeconomic status (SES) was determined by the level of education of 
each parent. A score of 1 was given if the parent’s educational level was low 
(elementary school, lower level secundary or professional education), a score 
of 2 for an average educational level (medium level secundary or professional 
education) and a score of 3 for higher levels of education (high level professional 
education, university).17
 Ethnicity was defined as Dutch or non-Dutch origin (mostly Turkish, Moroc-
can or Surinamese origin).
Statistical analysis
 The mean MDI and PDI scores of the study population were compared with 
the reference population using a one sample t-test. The observed percentages of 
children with normal, moderately or severely delayed mental and psychomotor 
development were compared with the expected values using the chi-square test. 
ANOVA and bivariate correlation (Pearson/Spearman) were used for univariate 
analyses. 
 Multiple linear regression analysis, with the continuous MDI and PDI scores 
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as dependent variables, was used to estimate the predictive value of medical and 
social factors on mental and psychomotor outcome. Ethnicity, SES, gender, use of 
glucocorticosteroids antenatally, maternal age at birth, GA, birthweight (percen-
tile according to GA), extra-uterine transportation, hypotension, IVH, PVL, BPD 
and treatment with dexamethasone in the postnatal period were the independent 
predictors. The goodness-of-fit of this model was evaluated by inspection of the 
histogram of the residuals and scatterplots of the residuals versus covariates. 
P-values < 0.05 were considered significant.
Results
 The study included 266 children, 92% of eligible infants born in 1996 and 
1997 (97% of eligible infants in 1996 and 88% of eligible infants in 1997). Thirty 
(11%) of the 266 children died, 28 in the neonatal period and 2 more before the 
age of one year. Treatment was withdrawn in 15 of these infants because it was 
considered to be medically futile. 
 In this study, a total of 163 (61%) children were born in hospitals with a neo-
natal intensive care unit ([NICU], tertiary referral centers), 103 (39%) in hospitals 
without a NICU. The patient characteristics of the entire cohort are presented 
in Table 1.
 One child was excluded from the analyses because of Down’s syndrome. Of 
the remaining 235 survivors, 168 children (71%) were assessed at 18 months and 
151 (64%) at 24 months. Three infants had such severe disabilities that scores of 
50 were given for both mental and motor development without actual testing. 
One child could not be tested due to blindness. 
Reasons for the loss-to-follow-up were families moving to other cities or countries 
and parental refusal to co-operate. Birth characteristics (GA, birthweight, gender) 
and incidences of respiratory distress syndrome, oxygen dependence at 28 days, 
BPD, hypotension, IVH, PVL and postnatal treatment with dexamethasone of 
the lost-to-follow-up-group did not differ from those of the study group. Parents 
of the children of the lost-to-follow-up-group were of lower SES and were more 
frequently of non-Dutch origin.
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Table 1. Characteristics of the LFUPP-cohort (n=266)
Antenatal steroids, % (n) 75 (182)
Male gender, % (n) 55 (147)
Gestational age:
 weeks, mean (SD) 29.2 (2.1)
 24-26 weeks, % (n) 17 (46)
 27-28 weeks, % (n) 23 (61)
 29-31 weeks, % (n) 60 (159)
Birthweight, mean (SD) 1250 (383)
Small for GA (birthweight <P10), % (n) 13 (33)
Apgar 5 min, mean (SD) 7.7 (1.8)
Extra-uterine transport, % (n) 35 (93)
Hypotension*, % (n) 34 (98)
O2 at 28 days, % (n) 26 (67)
Bronchopulmonary dysplasia**, % (n) 19 (49)
Mechanical ventilation, days, mean (SD) 7.2 (9.3) 
Dexamethasone postnatally, % (n) 17 (45)
Intraventricular haemorrhage, % (n)
 none 74 (190)
 grade 1-2 18 (48)
 grade 3-4 8 (20)
Periventricular leucomalacia (cystic), % (n) 3 (8)
In hospital mortality, % (n) 11 (29)
Dutch origin, % (n) 75 (167)
Level of education mother, % (n)
 high 29 (60)
 average 50 (105)
 low 21 (44)
Maternal age at birth, yrs, mean (SD) 30.5 (5.6)
LFUPP: Leiden Follow-Up Project on Prematurity; SD: standard deviation
GA: gestational age; * at least twice a mean blood pressure < 30 mmHg;
** O2 at 36 weeks postmenstrual age
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Developmental outcome
 The results of the assessments at 18 and 24 months of age are presented in 
Table 2 for MDI and PDI separately. 
 Mean MDI at 18 and 24 months and PDI at 24 months were significantly 
lower than 100. At both ages, the percentages of children with normal, moderately 
delayed and severely delayed development differed (p<0.001) from those in the 
reference population. Delayed development, especially more severely delayed 
development, occurred more often among the very preterm infants than in the 
reference population. 
 At 18 and 24 months of age, both mental and psychomotor development were 
normal in 60% of the children (98 and 85 children, respectively). Mental and 
psychomotor development were severely delayed in 11 children (7%) at 18 and 9 
children (6%) at 24 months. In the remaining 33-34% of children at least one of 
the parameters was abnormal.





















50-150 71 (116) 11 (18) 18 (29) 163**








50-150 70 (100) 22 (32) 8 (12) 144**
Reference population 100 (16) 84 13.5 2.5
SD: standard deviation, MDI: mental developmental index, PDI: psychomotor developmental index, 
Normal: > -1 SD, Moderate delay: -2 to -1 SD, Severe delay: < -2 SD.
 * significantly below the test mean of 100, p=0.003 for MDI and p=0.03 for PDI at 18 months, 
p=0.02 for PDI at 24 months.
**MDI and PDI could not be determined in respectively 2 and 5 children at 18 months and 5 and 
7 children at 24 months.
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Intra-individual differences
 Significant differences between MDI and PDI at 18 months were found in 
59 of 163 children (36%): 31 had better mental development and 28 had better 
psychomotor development. At 24 months, differences existed in 64 of 142 (45%) 
children: 33 had better mental development and 31 had better psychomotor 
development. These intra-individual differences exceeded the expected 5% of 
children with a dysharmonic profile in the reference population (p<0.001). 
Changes between the two test ages
 Although the mean MDI and PDI at 18 months did not differ from those at 24 
months, significant changes between MDI scores at 18 and 24 months were found 
in 67 of 136 tested infants (49%): 32 infants had a worse mental outcome and 35 
children had a better mental outcome at 24 months of age. Changes in PDI scores 
existed in 45 of 132 tested infants (34%): 23 infants had a worse psychomotor 
outcome and 22 children had a better psychomotor outcome at 24 months of 
age. These changes differed (p<0.001) from the expected 5% of children with a 
significant improvement or deterioration in the reference population. 
Association between medical factors and developmental outcome 
 Higher GA was associated with an increase in MDI scores at 18 and 24 months 
(correlation coefficient r = 0.29, p<0.001 and r = 0.19, p=0.02). PDI scores also 
increased with higher GA at 18 and 24 months (r = 0.25, p=0.001 and r = 0.26, 
p=0.001). 
 The association of other medical factors with developmental outcome is shown 
in Table 3 (18 months) and 4 (24 months). Male children had lower MDI scores 
at both ages and lower PDI scores at 24 months than female children, infants 
with hypotension in the neonatal period had lower PDI scores at 18 months 
than those without hypotension. Both MDI and PDI scores were lower at 18 and 
24 months in infants with PVL, oxygen dependence at 28 days, BPD, postnatal 
dexamethasone treatment and neurological abnormalities at term or at 2 years 
of age. 
 Better mental than psychomotor development or vice versa at 18 or 24 months 
of age was not associated with any of the medical factors listed in Tables 3 and 4. 
 No associations were found between the medical factors and the mental and 
psychomotor outcome of children whose outcome significantly improved or 


























































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Treatment with dexamethasone in the postnatal period
 Twenty-seven infants in the assessed group were treated with dexamethasone 
postnatally (16%). Treatment was started at a mean age of 19 days (range 5-42), 
the mean duration of treatment was 31 days (range 5-60). Treatment with dexa-
methasone was univariately associated with delayed mental and psychomotor 
development at 18 and at 24 months of age (Tables 3 and  4) and the duration 
of treatment was associated with delayed mental development at 18 months (r = 
-0.6, p=0.006; Fig. 1).
Figure 1. MDI-scores at 18 months in relation to duration of dexamethasone treatment 
postnatally   (MDI: Mental Developmental Index)
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Association between social factors and developmental outcome
 Both ethnicity and SES were divided into three groups. At 18 months of age 
the percentage of parents of Dutch origin was 80%, while 15% of the parents 
were of non-Dutch origin and 5% of the children had one parent of Dutch and 
one of non-Dutch origin. 
 Twenty-two percent of the mothers and 27% of the fathers had low levels of 
education, 56% and 39% average levels and 22% and 33% had high levels of edu-
cation. The percentages found at 24 months were comparable. 
Average maternal age at birth was 30.6 years (SD 4.7), which is comparable to 
the average age at birth of Dutch women of 30.4 years in those years.
Children of Dutch origin had higher MDIs at both 18 and 24 months than 
children of non-Dutch origin: mean MDI at 18 months was 97 vs. 88 for the 
non-Dutch children (p=0.04), at 24 months the corresponding numbers were 
101 and 84 (p=0.002). 
 Higher maternal age at birth was associated with better mental development at 
24 months (r = 0.19, p=0.03). Educational level of the parents was not associated 
with development at 18 or 24 months. 
 Higher educational levels of the mother and higher maternal age at birth were 
associated with improvement in mental development between 18 and 24 months 
(r = 0.18, p=0.004 and r = 0.26, p=0.003, respectively). 
Multivariate analysis
 Univariately, we found that lower maternal age at birth, non-Dutch origin, 
lower GA, male gender, hypotension, oxygen dependence at 28 days, BPD, 
postnatal treatment with dexamethasone, PVL and neurological abnormalities 
at term or 2 years were associated with delayed mental and/or psychomotor 
development at 18 and/or 24 months. In order to disentangle these univariate 
effects, a multiple regression analysis with stepwise selection was done. BPD was 
the only independent predictor for delayed mental development at 18 months. 
BPD and postnatal treatment with dexamethasone were the independent predic-
tors for delayed psychomotor development at this age. Birthweight and postnatal 
treatment with dexamethasone were the only independent predictors for delayed 
psychomotor development at 24 months; ethnicity, maternal age at birth and 
gender were predictive of delayed mental development as well. 
 Since postnatal dexamethasone treatment was associated with several of the 
covariates, we repeated the stepwise analysis without dexamethasone to identify 
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the confounders of the dexamethasone effect. These confounders were BPD at 
18 months and ethnicity, maternal age, birthweight and gender at 24 months for 
delayed mental development. For delayed psychomotor development these were 
BPD at 18 months and birthweight at 24 months. The effects of dexamethasone 
after correction for these significant confounders were a 10.9 (S.E. = 6.3) lower 
MDI score at 18 and a 9.3 (S.E. = 6.6) lower MDI score at 24 months, and 16.1 
(S.E. = 7.3) and 12.7 (S.E. = 6.1) lower PDI scores at 18 and 24 months, respec-
tively (Table 5). When correcting further for all other predictors, the dexametha-
sone effects were slightly less for mental development but remained approxi-
mately the same and significant for psychomotor development (Table 5).
Table 5. Results unstandardized coefficient (b) of dexamethasone + S.E. and p-value of 
multiple linear regression analysis
Mental Development Psychomotor Development





























(S.E. 7.0,  p=0.02)
The coefficient (b) represents the difference between the mean scores of infants treated and not-
treated with dexamethasone postnatally. The minus sign indicates that the mean score of treated 
infants was lower than that of untreated infants.  S.E.: standard error
* Mental development: 18 months: bronchopulmonary dysplasia (b =-12.3, p=0.03); 24 months: eth-
nicity (b =-11.4,p<0.001), maternal age (b =1.4, p=0.002), birthweight (b =0.19, p=0.001), gender 
(b =-10.1, p=0.02). Psychomotor development: 18 months: bronchopulmonary dysplasia (b =-14.2, 
p=0.03); 24 months: birthweight (b =0.12, p=0.03)
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Discussion
 In this study of the developmental outcome at 18 and 24 months corrected 
age of a cohort of very preterm infants (<32 wks GA) born in 1996/1997, we 
found that approximately 60% of the children had both normal mental and psy-
chomotor development at both ages. In the remaining 40% of infants, 6-7% had 
both severe mental and psychomotor delay, while 33-34% had either moderate 
to severe mental and/or psychomotor delay. 
 The use of different inclusion criteria makes it difficult to compare these 
results with previously reported outcome-studies. Most of these studies reported 
outcome according to birthweight and only included extremely preterm or 
extremely low birthweight infants. Since the introduction of surfactant, no stud-
ies matching our intake criteria were available for comparison. Furthermore, in 
our study the Bayley Scales of Infant Development I (BSID-1) were used, while 
most other recent reports on developmental outcome use the second edition 
of these scales. However, since the BSID-2 was not validated yet for the Dutch 
population in the study-period, we had to use the first edition. Since the BSID-2 
appears to give lower scores than the BSID-118, the results probably would have 
been worse if the BSID-2 could have been used.
 The loss-to-follow-up with regard to the Bayley-assessment was considerable 
in this study. The loss-to-follow-up group differed from the study group in 
both ethnic origin (more non-Dutch parents in the lost group) and SES (lower 
educational levels of the parents). Since ethnic origin affected outcome at both 
test ages, availability of the data of these children would probably have worsened 
the outcome. 
 Development was assessed at 18 and 24 months to investigate if a developmental 
profile could be detected and if so, which medical and/or social factors could 
explain this difference. Significant differences in mental development between 18 
and 24 months existed in 49% of the children. Except higher maternal education 
and age, which were associated with an improvement in mental outcome, no 
other social or medical factors were found which could explain this difference. 
As reported in previous studies, we also found that medical factors such as lower 
GA, BPD and neurological abnormalities were univariately associated with 
delayed mental and/or psychomotor outcome.2;4 Social factors did not play an 
important role at 18 months of age, but were associated with poorer outcome at 
24 months of age. At this age, delayed mental development occurred more often 
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in children of young mothers and in children of non-Dutch origin. 
 The fact that social factors become more important as children grow older 
has been reported before.4;19 The association between postnatal dexamethasone 
treatment and delayed mental and psychomotor outcome however, has been 
reported only recently. In a double blind randomized controlled trial O’ Shea 
et al.6 found a higher rate of cranial ultrasound abnormalities and cerebral palsy 
at 12 months corrected age in very low birthweight infants treated with a 42-
day course of dexamethasone, but they did not find differences in MDI or PDI 
scores. Yeh et al.8 reported a higher incidence of neuromotor dysfunction in 
dexamethasone-treated infants at 24 months corrected age. MDI and PDI scores 
in the dexamethasone treated infants did not differ from those of the control 
group. More recently, Shinwell et al.7 reported a higher incidence of cerebral 
palsy and developmental delay at a mean of 53 months of age in infants treated 
with dexamethasone before 12 hours of age compared to infants who received 
placebo. Development was however not assessed with a detailed developmental 
test and the age at follow-up ranged from 24 to 71 months.
 Although our study is not a randomized controlled trial studying the effects 
of dexamethasone treatment, we did find a strong association between postnatal 
treatment with dexamethasone and developmental delay. Treatment with 
dexamethasone was only given to infants with severe respiratory problems to 
wean them of the ventilator. The poor clinical condition of these infants may have 
negatively influenced their developmental outcome. Corrected for pulmonary 
and other perinatal and social risk factors for delayed development however, 
the association between dexamethasone treatment and delayed psychomotor 
development remained significant. These findings suggest that dexamethasone 
should be used with caution.
 In conclusion, we found that at 18 and 24 months of age, a considerable 
percentage (40%) of the very prematurely born children had moderate to 
severely delayed mental and/or psychomotor development. Early developmental 
assessment seems therefore useful, since intervention programs like physical and 
speech therapy can then be started at an early age. In this way the development 
of some of these children might be improved so that they will be able to follow 
main stream education later in life. 
 Postnatal treatment with dexamethasone appeared to be one of the major risk 
factors for delayed (psychomotor) development.
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Abstract
Objective: To determine changes in peri- and neonatal care concerning neonatal 
mortality and morbidity by comparing two cohorts of very prematurely born infants 
(gestational age [GA] <32 weeks), one from the 1980s and one from the 1990s. 
Methods: The Leiden Follow-Up Project on Prematurity (LFUPP-1996/97), a 
regional, prospective study includes all infants born alive after a gestational age (GA) 
<32 weeks in 1996 and 1997 in the Dutch health regions Leiden, The Hague and 
Delft. The Project On Preterm and Small for gestational age infants (POPS-1983), 
a national, prospective study from the pre-surfactant era, includes all liveborn infants 
<32 weeks’ GA and/or <1500 g from 1983 (n=1338). For comparison infants from 
the POPS-1983-cohort with a GA <32 weeks from the same Dutch health regions 
were selected (n=102). 
Results: The absolute number of preterm births in the study-region increased with 
30%: 102 in 1983 to on average of 133 in 1996-1997. Centralization of perinatal 
care improved: the percentage of extra-uterinely transported infants decreased from 
61% in 1983 to 35% in 1996-1997. A total of 182 (73%) of the LFUPP-1996/97 
infants were treated antenatally with glucocorticosteroids compared with 6 (6%) 
of the POPS-1983-infants. A total of 112 (42%) of the LFUPP-1996/97-infants 
received surfactant. In-hospital mortality decreased from 30% in the 1980s to 11% in 
the 1990s. Mortality of the extremely preterm infants (<27 weeks) decreased from 
76% to 33%. The incidence of respiratory distress syndrome remained the same: 
about 60% in both groups. Mortality from respiratory distress syndrome however 
decreased from 29% to 8%. The incidence of bronchopulmonary dysplasia increased 
from 6% to 19%. For the surviving infants, the average length of stay in the hospi-
tal and the mean number of NICU-days stayed approximately the same (about 67 
days total admission time and 44 NICU days in both groups); including the infants 
who died, the mean NICU-admission time increased from 27 days in the 1980s to 
41 days in the 1990s. Equal percentages of adverse outcome (dead or an abnormal 
general condition) at the moment of discharge from hospital were found (+ 40% in 
both groups). 
Conclusions: An increase in the absolute number of very preterm births in this 
study-region was found, leading to a greater burden on the regional neonatal inten-
sive care units. Improvements in peri- and neonatal care have led to an increased 
survival of especially extremely preterm infants. However, increased survival has 
resulted in more morbidity, mainly bronchopulmonary dysplasia, at the moment of 
discharge from the hospital.
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Introduction
 Perinatology has changed dramatically over the years. Advances in technology 
like high frequency oscillation and new ways of treatment like the administra-
tion of glucocorticosteroids antenatally and surfactant therapy have resulted in 
an increasing number of surviving infants. The limit of viability continues to be 
challenged. 
 Most studies comparing the outcome of infants born in the pre-surfactant 
era to that of infants born after the introduction of surfactant are hospital based. 
These hospitals are most often tertiary care-level centers, which leads to a selec-
tion bias as the older or more mature preterm infants who do not need this 
level of intensive care are not included. In this study we therefore compare a 
regional based follow-up study: the Leiden Follow-Up Project on Prematurity 
1996-1997 (LFUPP-1996/97) to a national follow-up study from the 1980s: the 
Project On Preterm and Small for gestational age infants 1983 (POPS-1983).1-3 
Changes in neonatal mortality and morbidity are described as well as changes in 
perinatal and neonatal management.
Patients and Methods
 The LFUPP was started in 1996. This regional, prospective study includes all 
infants born alive after a gestational age (GA) <32 weeks in 1996 and 1997 in the 
health regions Leiden, The Hague and Delft in the Netherlands. 
The three Dutch health regions used in the study are situated in the Dutch 
province Zuid-Holland. In the years 1996-1997 this province had 3.4 million 
inhabitants on a total of 15.5 million people living in the entire Netherlands. 
With 21% of the total Dutch population living in this province, it is a reasonably 
densely populated region. 
 Demographic data of the Netherlands and the studied region in 1983 and 
1996-1997 as well as socio-economic data are listed in Table 1.
 Inclusion was based on postal code; infants whose parents were residing in one 
of the three health regions but whose child for some reason was born outside the 
study-region, were included in the study, where as premature infants <32 weeks’ 
GA born in the study region but coming from another geographical area were 
not.
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The LFUPP-1996/1997 ultimately included 266 infants, constituting 92% of 
eligible infants born in 1996 and 1997 (97% of eligible infants from 1996 and 
88% of eligible infants from 1997). Of these 266 infants, 163 (62%) were born in 
tertiary-level centers (centers with a NICU), 122 of those (75%) were born in 
the Leiden University Medical Center. Seventy-one infants (27%) of 266 were 
born in regional hospitals in The Hague and immediately after birth transported 
to the NICU of the Juliana Children’s hospital in The Hague. This hospital did 
not have a maternity ward so all children born in The Hague with need for 
intensive care had to be transported to this hospital. 
 The Leiden University Medical Center and the Juliana Children’s hospital have 
the same clinical neonatal care, a total of 193 (73%) of the infants were admitted 
to either one of these hospitals. The other hospitals contributing to this study 
had the same clinical protocol for resuscitation, with the exception that other 
NICU-hospitals did not resuscitate infants <25 weeks’ GA. In the study-region, 
full resuscitation in the delivery room was started from a GA of 24+0 weeks.
 The POPS was started in 1983. This national, prospective study from the pre-
surfactant era includes all infants born alive after a GA <32 weeks and/or with 
a birthweight <1500 g in 1983 in the Netherlands. At that time, no data were 
routinely available on incidence of preterm or SGA birth and morbidity or 
mortality by GA or birth weight. Since collecting data on all high-risk newborns 




     The Netherlands 14.339.551 15.493.889
     Province Zuid-Holland 3.129.913 3.424.093
Live births
     The Netherlands 170.246 190.982
     Study-region 15.605 17.450
Ethnicity 
     Nonwhite* 607.216 1.171.113
Personal income, euro/ mo 1469 1656
*mostly Turkish, Moroccan and Surinamese (Creole, Hindu)
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in the Netherlands would have involved 10.000 or more infants per year, we 
decided to collect data on the smallest and least mature infants with the highest 
risk of mortality and morbidity. 
 The POPS-1983 included 1338 infants, constituting 94% of eligible infants 
born in 1983. A total of 102 of these infants had a GA <32 weeks and were 
born in the LFUPP-1996/97 health regions. Thirty-three of these infants (32%) 
were born in centers with a NICU; of those, 24 (73%) were born in the Leiden 
University Medical Center. Forty-one infants (33%) were born in regional 
hospitals in The Hague and immediately after birth transported to the NICU of 
the Juliana Children’s hospital in The Hague. As in the 1990s, this hospital did not 
have a maternity ward. In the 1980s, neonatal care in the LUMC and the Juliana 
Children’s hospital were equal; full resuscitation was also started from a GA of 
24+0 weeks. GA was generally well known in the Netherlands in the 1980s and 
certainly in the 1990s, because of good, standardized antenatal care with early 
(GA 12 weeks) ultrasound assessments. 
 For comparison of the 2 cohorts, only the infants of the POPS-1983 cohort 
<32 weeks GA and from the same health regions (selection by postal code) as 
the infants from the LFUPP cohort were included in the analyses. We choose not 
to include the SGA-infants >32 weeks GA, these infants are more mature and 
therefore not comparable to very preterm infants. 
 In both studies perinatal factors were collected on precoded forms. Data 
collected included preexisting diseases of the mother, obstetrical history, and 
neonatal data. 
 Causes of death were multiple in many infants (eg, both pulmonary and 
infectious problems). The main cause of death as judged by the pediatrician-
neonatologist was used to create Table 2 concerning causes of death.
Not all variables were encoded equally. RDS was divided in grades 1 to 4 in 
the LFUPP-1996/97. In the POPS-1983, RDS was defined as clinically or 
roentgenologically present.  A dichotomous variable was made for the comparison; 
both clinically and roentgenologically present RDS was encoded as RDS in the 
POPS-1983. 
 Bronchopulmonary dysplasia (BPD) was defined according to Shennan et al.4 
in the LFUPP-1996/97 and according to Bancalari et al.5 in the POPS-1983. 
According to Shennan, an infant suffers from BPD if it is still oxygen dependent 
at 36 weeks’ postmenstrual age. The Bancalari definition includes mechanical 
ventilation for at least 3 days in the first week after birth, clinical signs of chronic 
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respiratory disease, oxygen dependency and persistent radiographic changes at 
28 days post partum. 
 The variable ‘condition at discharge from hospital’ was dichotomous in 
the LFUPP-1996/97, if any abnormality existed this variable was encoded as 
abnormal. Abnormalities could include: neurological disorders (on clinical 
examination), pulmonary problems (BPD), cardiac disorders, feeding problems 
(eg, tube feeding), visual problems (retinopathy of prematurity) or hearing 
disorders. In the POPS-1983 this variable could also be encoded dubious; for the 
comparison dubious cases were considered abnormal.
 Both studies were approved by the Ethics Committee of The Leiden University 
Medical Center. Parental informed consent was obtained.
Statistical analysis
 SPSS 10.0 for Windows was used for statistical analyses. The chi-square test 
was used to compare categorical variables; Fisher’s exact test was applied where 
appropriate. Student’s t test was used for comparison of continuous variables. The 
Kaplan-Meier method was used for a survival analysis of the first 28 days post 
partum. P <.05 was considered significant.






Day of death, mean (SD) 5.9 (24.2) 12.7 (23.6) NS
RDS, % (n) 52 (16) 45 (13) NS
Cerebral, % (n)  6 (2) 24 (7) NS
Infectious, % (n)  6 (2)  7 (2) NS
NEC, % (n)  3 (1) 10 (3) NS
Congenital malformation, % (n) 10 (3)  7 (2) NS
Other, % (n) † 23 (7)  7 (2) NS
NS indicates non significant; NEC, necrotizing enterocolitis.
* Student’s t-test or Chi-square test.
† The 2 infants from the LFUPP group died of multi-organ failure and immaturity; other causes 
  of death were not specified in the POPS.
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Results
 In the LFUPP-1996/97 cohort, 266 infants were included over a 2-year 
period, on average 133 infants per year. In 1983, 102 infants were included. 
The absolute number of births <32 weeks GA therefore increased by 30%. The 
number of live births in the Netherlands increased from 170.246 in 1983 to on 
average 190.982 in 1996-1997. In the study region the number of live births 
increased from 15.605 in 1983 to 17.450 in 1996-1997 (these numbers were 
based on the known total number of live births and the number of inhabitants 
in the study region and the Netherlands). The number of live births in the study 
region increased over the years, the relative number of preterm births <32 weeks 
GA in the study region, however, still increased by 0.12% (0.65% of the number 
of live births in the region in 1983 vs. 0.76% in 1996-1997). 
Obstetric history
 Socioeconomic status and preexisting diseases of the mother, diseases, intoxi-
cations, and medication during pregnancy are shown in Table 3. 
 Socioeconomic status of the mother (as determined by level of education) was 
high in 29%, average in 50% and low in 21% of the mothers in the 1990s. The 
corresponding percentages in the 1980s are 33%, 30% and 37% (p = .005). In 
both groups, however, the number of missings for this variable was considerable: 
21% in the LFUPP-1996/97 group and 30% in the POPS-1983 group.
 No significant differences or any trends were found between the groups in 
incidences of diseases before and during pregnancy. The percentage of mothers 
who smoked during their pregnancy decreased from 24% in the POPS-1983 
group to 15% in the LFUPP-1996/97 group (p = .07). 
 Use of antibiotics increased almost 3-fold: 29% of the mothers in the LFUPP-
1996/97 group received antibiotics during their pregnancy as opposed to 10% in 
the POPS-1983 group (p < .001), Table 3. The percentage of mothers with pro-
longed rupture of membranes (PROM) who received antibiotics was higher in 
the LFUPP-1996/97 group: 48% (45 of 93) versus 9% (4 of 44, p < .001). Divid-
ing the PROM in <24 hours and >24 hours, the percentage of mothers treated 
with antibiotics was still significantly higher in the LFUPP-1996/97 cohort in 
both groups:  33% (6 of 18) versus 4% (1 of 23) when PROM was <24 hours 
(p = .01), and 52% (39 of 75) versus 14% (3 of 21, p < .001) when PROM was 
>24 hours. No significant difference was found in frequency of treatment with 
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antibiotics in women without PROM: 18% (29 of 165) in the LFUPP-1996/97 
group and 10% (6 of 58) in the POPS-1983 group, (p = .2).
 For the POPS-1983 group, no data about pregnancy induction (in casu hor-
mone treatment since in vitro fertilization [IVF] was just coming about in the 
early 1980s) were available. In the LFUPP-1996/97 group, pregnancy was induced 
in 21 mothers, leading to a total of 36 (14%) of 265 births: hormone treatment in 
6 mothers (12 infants [33%]), IVF in 13 (22 infants [61%]) and intracytoplasmatic 
sperm injection in 2 mothers (2 infants [6%]). 







Socioeconomic status, % (n)
   High 33 (24/71) 29 (61/210) .005
   Average 30 (21/71) 50 (105/210)
   Low 37 (26/71) 21 (44/210)
Pre-existing diseases, % (n)
   Cardiac disease 2 (2) 2 (4) NS
   Epilepsy - 0.8 (2) NS
   Diabetes mellitus 1 (1) 2 (5) NS
   Renal disease 2 (2) 2 (4) NS
   Hypertension 4 (4) 3 (7) NS
Diseases during pregnancy, % (n)
   Diabetes gravidarum 5 (5) 2 (6) NS
   Hypertension 10 (10)   9 (23) NS
   Preeclampsia 4 (4)   8 (20) NS
   Eclampsia 1 (1) 2 (4) NS
Intoxications during pregnancy, % (n)
   Smoking 24 (19) 15 (34) .07
Medication during pregnancy, % (n)
   Diuretics 1 (1) 3 (7) NS
   Antihypertensive medication 10 (10) 17 (44) NS
   Tranquilizers 10 (10)   6 (15) NS
   Anti-epileptics 1 (1) 1 (3) NS
   Antibiotics 10 (10) 29 (74) <.001
NS indicates non significant.
* Chi-square or Student’s t-test.
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Delivery
 Data concerning the delivery are listed in Table 4. Use of tocolytics and antenatal 
administration of corticosteroids occurred significantly more often in the 1990s 
cohort.  Mean maternal age at birth increased by almost 4 years, from 26.8 in 1983 
to 30.5 in 1996-1997. 
 The percentage of infants delivered vaginally or by caesarean section did not dif-
fer between the 2 groups. Although not significant, a greater percentage of 26 and 
27 weeks’ GA infants were delivered by cesarean section in the 1990s: 19% (4 of 
21) in the POPS-1983 and 31% (15 of 49) in the LFUPP-1996/97. In both groups, 
none of the 24- or 25-week-old infants were delivered by cesarean section. 







  Betamimetics > 24 h 39 (40) 51 (133) .04
  Indocid > 24 h 6 (6) 19 (49) .002
Antenatal glucocorticoids, % (n) 6 (6) 73 (182) <.001
Maternal age at birth, y, mean (SD) 26.8 (6.7) 30.5 (5.6) <.001
Mode of delivery, % (n)
  Head 46 (47) 46 (123) NS
  Other position 15 (15) 14 (37)
   Caesarean section 39 (40) 40 (106) NS
Duration of rupture of membranes at delivery, % (n)          
  No rupture 57 (58) 65 (170) <.001
  < 24 h 22 (23) 7 (19)
  1-7 days 11 (11) 20 (52)
  > 7 days 10 (10) 8 (22)
Gestational age
  Mean (SD) 29.0 (13.4) 29.2 (14.8) NS
  < 27 weeks, % (n) 17 (17) 17 (46) NS
Certainty of GA, % (n)
  Certain 70 (71) 95 (251) <.001
  Dubious 19 (19) 3 (8)
  Uncertain 11 (11) 2 (4)
NS indicates non significant.
* Chi-square or Student’s t-test .
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 The duration of rupture of membranes at delivery differed significantly 
between the groups. The majority of membrane ruptures was of short duration 
(<24 hours) in the POPS-1983 group (23 of 44 [52%]) and of longer duration 
(1-7 days) in the LFUPP-1996/97 group (74 of 93 [80%]).
 Mean GA (29 weeks) and the percentage of immature infants (< 27 weeks, 
17%) did not differ between the groups (Table 4). GA was certain in 251 (95%) 
of 263 LFUPP-1996/97 infants, dubious in 8 (3%), and uncertain in 4 (2%). In 
the POPS-1983 cohort, the corresponding numbers were certain in 71 (70%) of 
102, dubious in 19 (19%) and uncertain in 11 (11%, Table 4).
Birth characteristics
 A comparison of birth characteristics and neonatal morbidity of the infants 
from the POPS-1983 and LFUPP-1996/97 is presented in Table 5. 
 Mean GA; mean birth weight; and percentages of infants who were born SGA 
(birth weight < 10th percentile)6, were of male gender, had congenital malforma-
tions and were of white race did not differ between the 2 groups. 
 Although not significant, a 7% increase of infants from multiple births was 
found. In the LFUPP-1996/97 group, a significant association between multiple 
Table 5. Comparison of birth characteristics between 1983 and 1996-1997
 





GA, wk, mean 29.0 29.2 NS
Birth weight, g, mean (range) 1234 (540-2580) 1250 (420-2382) NS
SGA, % (n)† 18 (18) 12 (33) NS
Male gender, % (n) 50 (51) 55 (147) NS
Multiple birth (twin/ triplet), % (n) 25 (26) 32 (84) NS
Congenital malformations, % (n) 8 (8) 5 (14) NS
Inborn (NICU), % (n) 32 (33) 62 (163) <.001
Extrauterine transport, % (n) 61 (62) 35 (93) <.001
White, % (n)‡ 83 (84/102) 75 (167/209) NS
NS indicates non significant.
* Student’s t- or Chi-square test.
† Birth weight <10th percentile.
‡ Nonwhite = mostly Turkish, Moroccan, and Surinamese infants.
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birth and assisted reproduction was found: 30 (83%) of 36 infants from multiple 
births were born after induction of pregnancy versus 55 (17%) of 229 singletons 
(p < .001).  
 The percentage of infants born in hospitals with a NICU increased from 32% 
to 62%; the percentage of infants who were transported after birth to centers 
with a NICU decreased from 61% in the 1980s to 35% in the 1990s (p < .001). 
In both groups, the majority of transported infants were born in the region The 
Hague; almost all infants in this region had to be transported after birth to the 
Juliana Children’s Hospital. In the POPS-1983 group 41 (66%) of 62 transported 
infants were transported to this hospital, in the LFUPP-1996/97 group 71 (76%) 
of 93 transported infants. In the POPS-1983 group 7 (10%) infants of the 69 
who were born in a center without a NICU did not have to be transported after 
birth; the corresponding number in the LFUPP-1996/97 group was 10 (10%) 
of 103 infants.
In-hospital mortality
 In-hospital mortality was 11% (29 of 266) in the LFUPP-1996/97 and 30% 
(31 of 102) in the POPS-1983 (p < .001). For the immature infants (GA <27 
weeks) in-hospital mortality decreased from 76% (13 of 17) to 33% (15 of 46). 
In-hospital mortality is shown in Figure 1 according to GA. In the 1990s, mortal-
ity was lower in all GA-categories. A survival analysis (Kaplan Meier curve) for 
the first 28 days is shown in Figure 2 for both the immature and nonimmature 
infants. In the 1990s, the non-surviving infants died after on average 12.7 days, in 
the 1980s the corresponding number was 5.9 (p = .3, Table 2).
 Early neonatal death (within 7 days after birth) was 55% (16 of 29) in the 
LFUPP-1996/97 group; 34% (10 of 29) died within 24 hours. Twenty nine of 
the 31 deaths (93%) in the POPS-1983 cohort occurred in the first week after 
birth, 71% (22 of 31) within 24 hours. Thirty-three percent (5 of 15) of the 
immature LFUPP-1996/97 infants died within 24 hours compared with 85% 
(11 of 13) of the immature POPS-1983 infants (p = .009). In the older infants 
(>27 weeks GA) as well, the percentage of deaths within 24 hours was higher in 
the POPS-1983 group, although not significant: 61% (11of 18) versus 36% (5 of 
14; p = .2). Late neonatal death (between 7 and 28 days after birth) was 38% (11 
of 29) in the LFUPP-1996/97 group; none of the POPS-1983 infants died in 
this period. In both groups 2 infants died after 28 days post partum.  
 Treatment was withdrawn because it was considered to be medically futile in 























Figure 1. Mortality according to GA.
52% of the LFUPP-1996/97 deaths and in 45% of the POPS-1983 deaths (p = 
.6). Withdrawal of treatment occurred in equal percentages in the immature (<27 
weeks GA) and more mature infants and in infants who died within or after 24 
hours in both groups. 
 Pulmonary problems seemed to be the most important cause of death, in both 
groups about 50% of the infants who died in the neonatal period died mainly of 
RDS (13 of 29 LFUPP-1996/97 group; 16 of 31 POPS-1983 group; Table 2). 
Mortality from RDS as a function of the number of infants who had RDS, how-
ever, decreased significantly: 29% (16 of 55) of the infants with RDS from the 
POPS-1983 group died from RDS as opposed to 8% (13 of 156) of the infants 
from the LFUPP-1996/97 (p < .001). 
 There was a trend towards higher mortality from cerebral causes in the LFUPP-
1996/97 cohort: 24% versus 6% in the POPS-1983 cohort. This difference, how-
ever, did not reach significance (p = .06).
Neonatal morbidity
 A comparison of neonatal morbidity of the infants from the POPS-1983 and 
LFUPP-1996/97 is presented in Table 6. 
 The incidence of RDS remained the same, around 60% in both groups. In the 
LFUPP-1996/97 cohort 24% (29 of 121) of infants whose mothers were treated 
antenatally with a full course of corticosteroids (2 doses) developed severe RDS 
(grade 3 to 4) compared with 45 (35%) of 126 in the incompletely or non-
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treated infants (p = .04). Of the 6 infants in the POPS-1983 who received corti-
costeroids antenatally, 2 developed (roentgenologically proven) RDS (33%). 
 A total of 112 (42%) of the LFUPP-1996/97 cohort were treated with sur-
factant. Surfactant was given as rescue treatment, not prophylactically at birth. As 
expected, treatment with surfactant was associated with the severity of the RDS: 
95% of infants with RDS grade 3 to 4 received surfactant as opposed to 41% 
with grade 1 to 2 RDS and 3% of the infants without RDS (p < .001). 
 Pneumothorax was more frequently found in the POPS-1983 cohort, 15% 
of the infants had this complication as opposed to 6% in the LFUPP-1996/97 
Figure 2. Survival in the first 28 days post partum.
Gestational age ≥ 27 
weeks




































Pulmonary problems, % (n)
   RDS
   Pneumothorax
   BPD
   Mechanical ventilation
















Circulatory disorders, % (n)
   PDA 18 (18) 26 (70) NS
Sepsis (positive bloodculture), % (n) 16 (14) 28 (72) .03
Neurological disorders, % (n)
   IVH:  none
 Grade 1
 Grade 2 
 Grade 3
 Grade 4
   Seizures
   Hydrocephalus
   CNS abnormalities during 














  5 (12)
  4 (11)
3 (9)
  5 (13)








NEC, % (n) 4 (4) 9 (25/265) NS
Medication, % (n)
   Antibiotics
   Anticonvulsants
   Diuretics













Admission time, d, mean (range)
   NICU
 Survivors
 All (dead included)










NS indicates non significant; PDA, patent ductus arteriosus; CNS, central nervous system; NEC, 
necrotizing enterocolitis.
* Student’s t- or Chi-square test.
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cohort. The percentage of infants mechanically ventilated was significantly higher 
in the LFUPP-1996/97 cohort: 78% of the infants versus 63% in the POPS-
1983 group (p = .004). Infants from the LFUPP-1996/97 group were ventilated 
on average 3.8 days longer than the infants from the POPS-1983 group. 
 The incidence of BPD increased from 6% in the 1980s to 19% in the 1990s. 
No differences existed in incidences of patent ductus arteriosus, NEC and neu-
rological disorders like seizures, hydrocephalus, or central nervous system abnor-
malities during admission. 
 A trend towards less serious intraventricular hemorrhage (IVH) was found: 
the percentages of infants with grade 3 or 4 IVH remained about the same, but 
the percentage with grade 2 IVH decreased from 14% in the 1980s to 5% in the 
1990s while the percentage with IVH grade 1 increased from 7 to 13% (p = .02). 
In the LFUPP-1996/97 cohort IVH occurred less frequently in infants whose 
mothers were treated antenatally with a full course of glucocorticosteroids: 81% 
(97 of 120) of the fully treated infants did not develop IVH compared with 69% 
(84 of 122) of the nontreated or incompletely treated infants (p = .09).
 Sepsis (positive blood culture) occurred more frequently in the 1990s: 28% 
of the infants from the LFUPP-1996/97 versus 16% in the POPS-1983-cohort 
(p = .03). The percentage of infants who were treated with antibiotics increased 
from 77% to 93% (p < .01). 
 The average length of stay in the hospital stayed almost the same: 66.9 days 
(SD: 22.5; range: 23-127) in the 1980s and 67.2 days (SD: 28; range: 13-215) in 
the 1990s (p = .9). The number of NICU-days for survivors was almost equal 
as well: 41.2 days (SD: 27.3; range: 8-121) in the 1980s and 44.4 days (SD: 33.6; 
range: 1-215) in the 1990s (p = .8). However, including the infants who died, in 
determining NICU time, this increased from 26.7 days (SD 31.5) in the 1980s to 
40.7 days (SD 34) in the 1990s (p = .002).
 In conclusion, we found no difference in the incidence of RDS and severe 
IVH; a decrease in the incidence of pneumothorax and an increase in the inci-
dences of BPD and sepsis was found. The deceased infants included, the number 
of days spent in NICU increased. 
Condition at discharge
 Ten of the 102 patients of the POPS-1983 cohort were considered abnormal 
at discharge; 8 of these were encoded dubious, and 2 were abnormal. The dubi-
ous cases were considered abnormal for the comparison.
146 CHAPTER 9
 In the total group of infants, adverse outcome (dead or abnormal at discharge) 
was 41% (109 of 263) in the LFUPP-1996/97 group and 40% (41 of 102) in the 
POPS-1983 group (p = .8, Figure 3). 
 For the immature infants (GA <27 weeks), adverse outcome was 82% (37 of 
45) in the LFUPP-1996/97 group and 77% (13 of 17) in the POPS-1983 group 
(p = .7). Adverse outcome was found in 33% of the infants of > 27 weeks GA in 
both groups (Figure 3). 
 Of the surviving infants, condition at discharge was abnormal in 34% (80 of 
234) of the infants in the LFUPP-1996/97 group and in 14% (10 of 71) in the 
POPS-1983 group (p = .001). None of the 4 surviving immature POPS-1983 
infants were found to be abnormal, 73% (22 of 30) of the immature LFUPP-
1996/97 infants were (p = .01). Twenty-eight percent (58 of 204) of the surviv-
ing LFUPP-1996/97 infants of >27 weeks’ GA were abnormal, 15% (10 of 67) 
of the POPS-1983 infants were (p = .03).
Figure 3. Condition at discharge from the hospital
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Discussion
 In this study, we compared neonatal mortality and morbidity of 2 Dutch 
cohorts of very preterm infants (GA <32 weeks), one from the 1980s (POPS-
1983) and one from the 1990s (LFUPP-1996/97). The number of very preterm 
births in the studied health regions increased from 102 in 1983 to on average 133 
in 1996-1997, an increase in absolute numbers of 30%, which means a greater 
burden on the regional NICUs. 
Obstetrics
 Obstetrical management changed in respect to the percentage of mothers 
treated with corticosteroids antenatally, which increased significantly from 6% in 
1983 to 73% in 1996/1997. The 6% in the 1980s cohort may seem somewhat 
low. This percentage did not appear to be a good reflection of the 17% treated 
with steroids antenatally in the total POPS-1983-cohort <32 weeks’ GA. In 
1983, glucocorticoids were not given antenatally in the Leiden University 
Medical Center. At the time, administration of glucocorticoids antenatally 
for the acceleration of pulmonary maturation was still a matter of debate in 
the Netherlands, this therapy was restricted to 41 hospitals.7 Another possible 
explanation for the difference could be the percentage of mothers treated with 
the tocolytic ritodrine. Administration of this ß-agonist is an effective strategy to 
‘buy time’ for the administration of corticosteroids.8 The percentage of mothers 
treated with this drug was higher in the total POPS-1983 cohort (52%) compared 
with the regional cohort (39%). In the total cohort, 30% of the women treated 
with ß-agonists received corticosteroids as opposed to 4% of the women who 
were not treated with ß-agonists. 
 Mothers of the LFUPP-1996/97 cohort were more often treated with 
antibiotics than those of the POPS-1983 cohort. The percentage of prolonged 
rupture of membranes did not differ between the two groups; the percentage 
of mothers with ruptured membranes who received antibiotics however was 
significantly higher in the LFUPP-1996/97 group. The percentage of membrane 
ruptures of longer duration (>24 hours) was indeed higher in the LFUPP-
1996/97 group, but treatment with antibiotics occurred more often in the 
group with ruptures of short duration (<24 hours) as well. Evidence that in 
women with preterm rupture of membranes, treatment with antibiotics led to 
a significant prolongation of the pregnancy and a reduction in the incidence of 
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chorioamnionitis and neonatal infection has probably resulted in an increased 
percentage of women receiving this treatment.9
 Fourteen percent of the infants from the LFUPP-1996/97 were born after 
assisted reproduction, mainly IVF (8%). Since most of these children were part of 
a twin or triplet, the 7% increase in the percentage of infants from multiple births 
we found is most likely caused by the increased use of IVF (the first IVF baby in 
the Netherlands was born in 1983). 
Delivery/Birth characteristics
 A trend towards a higher percentage of 26- to 27-week-old infants being 
delivered with a caesarean section was found, which is probably the consequence 
of the better chance of survival these infants now have, justifying the greater risk 
the mother is exposed to when undergoing surgery than at natural child birth. 
GA was certain in 95% in the 1990s and in 70% in the 1980s, the higher 
certainty-level in the 1990s is very likely due to more early ultrasounds being 
made nowadays then in the early 1980s. The relatively low certainty-level in the 
1980s occurred throughout the GA range of 24 to 32 weeks, therefore probably 
not resulting in an outcome bias. 
 Centralization of perinatal care in the study-region has increased: in 1983, 32% 
of the infants were born in centers with a NICU, in 1996-1997, this number 
increased to 62%. This increased centralization, not only in our study region 
but in the entire Netherlands, is mainly attributable to findings of the POPS-
1983-study which showed that infants born in NICU’s had lower mortality rates 
than infants transported extrauterinely.10-13 The still relatively large number of 
extrauterinely transported infants in the LFUPP-1996/97 group is caused by the 
fact that all infants treated in the Juliana Children’s Hospital in The Hague (27%) 
were extrauterinely transported to this center because this hospital does not have 
an obstetric department. 
Mortality
 As could be expected a significant decrease in overall mortality from 30% in 
the POPS-1983 group to 11% in the LFUPP-1996/97 group was found. For 
the extremely preterm infants (GA <27 weeks) mortality decreased from 76% to 
33%. In both cohorts the majority of infants died in the first week of life. In the 
POPS-1983 cohort 71% died within 24 hours, in the LFUPP-1996/97 group 
34%. This difference was not caused by a change in attitude towards treatment 
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withdrawal, since this occurred in 40% of the infants who died within 24 hours 
in both cohorts. Mortality at later points in time was also found by Meadow et 
al.14 in their recent study on changes in mortality for extremely low birth-weight 
infants. Pulmonary problems were the main cause of mortality in both cohorts. 
Morbidity
 Many studies have shown a decrease in the incidence of RDS in infants whose 
mothers received antenatal steroids. Crowley15, in his meta-analysis of random-
ized trials from 1972-1994, found that antenatal corticosteroid therapy results in 
an overall reduction of approximately 50% in the odds of contracting neonatal 
RDS. Regarding these findings and the increased use of antenatal steroids, we 
expected to find a decrease in the incidence of RDS. The incidence of RDS 
however, was approximately the same in the 1980s (57%) and 1990s (60%). While 
the incidence of RDS remained the same, mortality from RDS significantly 
decreased. This suggests that the severity of RDS is reduced by antenatal treat-
ment with corticosteroids. In the LFUPP-1996/97 cohort, we did indeed find 
a smaller percentage of infants with severe RDS within the group antenatally 
treated with a full course of corticosteroids than in the non-treated or incom-
pletely treated infants. Besides this, survival of infants with severe RDS is now 
better because of treatment with surfactant. 
 The increased survival of infants with RDS was associated with an increase in 
the percentage of infants with BPD. BPD was defined according to Shennan in 
the LFUPP-1996/97 and according to Bancalari in the POPS-1983. The per-
centage of infants with BPD in the POPS-1983-cohort would probably have 
been even lower if the Shennan-definition was used since it is not likely that all 
infants who were oxygen dependent at 28 days post partum would still be at 36 
weeks’ postmenstrual age. Unfortunately, chart review of POPS-cases to verify 
this did not yield the necessary data.
 A shift towards less serious IVH was found. Although not significant, in the 
LFUPP-1996/97 cohort, IVH occurred less frequently in infants whose moth-
ers were antenatally treated with a complete course of corticosteroids. A positive 
influence of antenatal corticosteroids on the incidence of IVH has been found 
in many studies. The previously mentioned meta-analysis by Crowley15 showed 
that corticosteroid therapy reduces the odds of periventricular hemorrhage (odds 
ratio [OR]: 0.38; 95% confidence interval: 0.23-0.94). Shankaran et al.16 found 
an odds ratio of 0.39 (95% confidence interval: 0.27-0.57) for the association of 
a complete course of steroids with grades 3 and 4 IVH. 
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 Sepsis, defined as a positive blood culture, occurred more frequently in the 
LFUPP-1996/97 group. This could not be explained by a more frequent use of 
lines, 65 % (163 of 249) of the LFUPP-1996/97 infants had a venous and/or arte-
rial line, and 70% (69 of 99) of the POPS-1983 infants had a venous line. In the 
LFUPP-1996/97 infants, however, the lines were probably longer in situ because 
of the increased survival and mortality at later points (Fig 2), which could be an 
explanation of the increase in the occurrence of sepsis. Unfortunately data about 
the exact number of days of line-usage are not known in both cohorts, so this is 
only speculation. Another reason could be that detection techniques are nowa-
days better than before, leading to a higher number of positive blood cultures. In 
the Leiden University Medical Center, in the 1980s ‘home made’ culture bottles 
were used, where as in the 1990s, these were replaced by industrial culture bottles 
(BATEC). Furthermore, Beganovic et al17,  in their article on the occurrence of 
sepsis in POPS-1983 infants receiving total parenteral nutrition, described that of 
the clinically septic infants, only 29% had a positive blood culture. 
 Time spent in NICU stayed the same for surviving infants. Including the 
deceased, however, time spent in NICU increased with 14 days, reflecting mor-
tality at later points in time in the 1990s.
 The percentage of infants with an adverse outcome (dead or abnormal) at dis-
charge was comparable in both groups. Since mortality decreased considerably, 
this means that, in this study, increased survival resulted in more morbidity, at 
this age mainly BPD. The short-term outcome would be even more unfavorable 
for the LFUPP-1996/97 cohort if the dubious cases in the POPS-1983 cohort 
would have been considered normal.
 We realize that in this comparison of many obstetrical and neonatal data the 
possibility exists that significant findings are chance findings. However, the sig-
nificant differences found were mostly highly significant (p < .001), and most of 
them were based on clinical hypotheses, expected and in line with other publica-
tions, like for example considerably less mortality and improvement of centraliza-
tion of perinatal care. 
 In conclusion, we found in the studied Dutch health regions an increase in the 
absolute number of very preterm births between 1983 and 1996/1997. Mortality 
decreased considerably, but the increased number of surviving infants has resulted 
in more morbidity at the time of discharge from the hospital. 
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 The subject of this thesis is follow-up at 2 years of age of extremely preterm (< 
27 weeks GA) and very preterm infants (< 32 weeks GA). It is well documented 
that preterm birth may have adverse effects on a child’s development. Given the 
high risk for residual disability, the monitoring of long term morbidity is a criti-
cal function of neonatal care.1 It is important to register the influence of new 
techniques in perinatology on the infants born in one’s own region or country. 
Extremely preterm infants
 Based upon the high percentage of adverse outcome at 2 years of age of the 
infants born at 24 weeks gestational age (chapter 2) and the comparable results 
of other studies, the decision was made in the Leiden University Medical Cen-
ter, not to resuscitate infants of a gestational age (GA) below 25 weeks anymore 
(January 2002). Hereafter, the discussion about the limit of viability originated 
again in the Netherlands, and the Dutch Paediatric Association developed guide-
lines about the resuscitation of extremely preterm infants (appendix 1).2;3 Pur-
pose was that every neonatal centre could get along with these new guidelines. 
At this moment a complete agreement of the Dutch Association of Obstetrics 
and Gynaecology with these guidelines is lacking. The only issue no consensus 
is reached yet, concerns the timing of the precise moment of transfer of the 
mother in case of imminent preterm birth from 24+0 – 24+6 weeks gestational 
age to a level 3 centre. The Dutch Paediatric Association prefers a transfer in this 
period and the Dutch Association of Obstetrics and Gynaecology proposes to 
discuss the transfer of the mother in each individual case.4 So nowadays in the 
Netherlands, infants born at 24 and 25 weeks are not routinely resuscitated and 
intensive care will be withdrawn if treatment is clearly futile. If birth weight is less 
than 500 grams, comfort care is given. This policy is also based on reports from 
the Dutch Paediatric Association, which argue that withholding or withdrawing 
life-sustaining treatment in newborn infants with extremely poor prognoses is 
justifiable medical practice and that decisions should be taken by the medical and 
nursing team, together with well-informed parents.5
 The last American Academy of Pediatrics (AAP) statement (2007) about non-
initiation or withdrawal of intensive care for high-risk newborns, proposes that 
these decisions should be based on four key-elements: 1. direct and open com-
munication between health care team and the parents; 2. parents should be active 
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participants; 3. comfort care should be given in case of non-initiating or with-
drawal of intensive care and 4. treatment decisions should be guided primarily by 
the best interest of the child.6 Previously (2002) the AAP7 stated that resuscitation 
was only inappropriate in infants with a birth weight below 400 grams and/or 
gestational age below 23 weeks. The last consensus from Australia (2006)8 defines 
the “grey zone” between 23 and 25+6 weeks GA. It also says: “While there is an 
increasing obligation to treat with increasing length of gestation, it is acceptable 
medical practice not to initiate intensive care during this period if parents so 
wish, after appropriate counselling”. In the United Kingdom guidelines advise 
intensive care in some cases from a GA > 24 weeks, but in any case from 25 
weeks GA and upwards.9
 Previous papers about mortality and outcome of these extremely preterm 
infants are summarised in chapter 3. It seems that people all over the world are 
increasingly concerned about the long term outcome of these extremely preterm 
infants, especially after the publications of the EPICure study group (GA < 26 
weeks): at 30 months 49% of the survivors were disabled including 23% of the 
survivors who were severely disabled.10;11 At 6 years of age, 78% of the surviving 
children underwent standardised cognitive and neurological assessments. When 
the results were compared with their classmates, 41% of the assessed children 
showed cognitive impairment. Rates of severe, moderate and mild disability were 
22%, 24%, and 34% respectively.12
Why follow-up at the corrected age of 2 years?
 It has been argued that follow-up at 2 years of age is optimal to assess develop-
mental outcome, and although there has been a debate about the use of corrected 
age in assessing the development of preterm infants, nowadays it is recommended 
that correction is applied up to at least 2 years of age.1;13;14 Follow-up at this age 
provides information at a point where environmental bias (for instance socio-
economic status) and loss to follow-up is minimal, but disability and specific 
serious impairments can be assessed with sufficient reliability.15 A number of 
conditions commonly associated with preterm birth are not evident or resolved 
until approximately 2 years of age (e.g. cerebral palsy, transient dystonia).1;16 On 
the other hand Hack et al.17 showed that the Bayley Scales of Infant Development 
have a poor predictive validity for cognitive function of extremely low birth 
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weight children at school age: rates of cognitive impairment < 70 dropped from 
39% at 20 months corrected age to 16% at 8 years of age. Prediction was better 
for ELBW-infants with neurosensory impairments. Marlow et al.12 found the 
outcome at 30 months of age highly predictable of the outcome at 6 years of age. 
Doyle et al.18 found the assessment at 2 years of age to be predictive for outcome 
at later ages (5, 8 and 14 years) too, but mainly in case of severe developmental 
delay, and the prediction was less accurate for mild or moderate delay. 
 Of course, later follow-up is also important because preterm born children 
who appear to be “normal” at 3 years of age are often seen to have problems 
in motor or visual motor function or deficits at school age.15 Despite a normal 
intelligence or being neurologically intact, preterm infants perform less well than 
their peers on tests of language, visual perceptual organisation and memory.19;20 
O’Brien21 found in a cohort of preterm infants born < 33 weeks a decrease in 
Intelligence Quotient from 104 at 8 years to 95 at 15 years. During the same 
period, the percentage of impairments with disability increased from 11 to 22% 
and the percentage of impairments without disability from 16 to 26%. It is not 
clear whether this apparent deterioration in developmental outcome represents 
genuine deterioration in neurocognitive function or whether this presents the 
expression of pre-existing cerebral pathology in an increasingly complex envi-
ronment.21 In the POPS-cohort, at 9 years of age about one third of the survivors 
in mainstream education (so they seemed to have a rather normal development 
at an earlier age) were below the level for their age, compared with 10% of the 
9-year-old children in the general population.22 In contrast, Ment23 found an 
improvement in cognitive function (verbal and IQ-scores) over time in VLBW-
infants: mean IQ of a cohort infants with birth weight between 600 and 1250 
grams, increased from 90 at 36 months corrected age, to 95 at 96 months cor-
rected age. So some studies report an improvement in general development, some 
a deterioration. However, studies are difficult to compare because of differences 
in definitions and methods of assessment used in the various follow-up studies.
In conclusion, while follow-up at later ages is also very important and useful, we 
argue that every very preterm infant should at least be assessed at a follow-up 



















(Chapter 10 - Figure 1.)
LFUPP compared to POPS at the corrected age of 2 years
 In chapter 9 the LFUPP-cohort is compared to the POPS-cohort but only 
mortality and neonatal morbidity is described. Because we were also interested 
in differences in outcome at 2 years of age, we performed some additional analy-
ses. For this purpose only the infants from the POPS-cohort born < 32 weeks 
and from the same health regions as the LFUPP were included. Seventy (68.6%) 
of the 102 infants from the POPS-cohort survived until the corrected age of 2 
years. Fifty-three children (76%) were classified as having a normal development 
(developmental quotient > 90 and no motor, visual or hearing disabilities), 16 
(23%) had a mild handicap (defined as a DQ between 80 and 90, and/or at least 
one of the following: a mild neurological disorder such as a slight hemiparesis 
or quadriparesis, mild visual or hearing defects, or moderate psychosocial prob-
lems) and 1 (1%) was severely handicapped (defined as presence of retardation 
(DQ < 80) and/or at least one of the following: a severe neurological disor-
der, sever visual or hearing defects or serious psychosocial problems).24;25 In the 
LFUPP-cohort, 236 children (89%) survived until the corrected age of 2 years. 
One infant was excluded because of Down’s syndrome. Of the remaining 235 
children, 106 children (46%) had a normal outcome (defined as a normal neuro-
Figure 1. Comparison of outcome at 2 years of age in live born infants of the POPS(1983) 






logical examination according to Hempel26 and a normal MDI or PDI according 
to the BSID I), 51 children (22%) a mildly abnormal outcome (mild abnormal 
neurological examination or moderate delay in MDI or PDI) and 36 children 
(15%) a definitely abnormal outcome (defined as an definitely abnormal neuro-
logical examination or a severe delay in MDI or PDI). Forty infants (17%) were 
not assessed. 
 Figure 1 shows the outcome of live born infants of the POPS-cohort and 
the LFUPP-cohort. Adverse outcome, defined as dead or severely disabled, was 
32% (33/102) in the POPS-cohort compared to 29% (66/225) in the LFUPP-
cohort. Considering that the outcome in the missing children is perhaps not 
adverse, the percentage could also be 25% (66/265). In the survivors a normal 
development was seen in 76% (53/70) in the POPS-cohort compared tot 47% 
(108/235) in the LFUPP-cohort, the percentage of infants with a severely (or 
definitely) abnormal outcome increased from 1% (1/70) in the POPS-cohort 
to 15% (36/235) in the LFUPP-cohort (Fig. 2). After correction for gestational 
age, differences in outcome remained significant between the two cohorts. So 
mortality was higher in the nineteen eighties (POPS) compared to the nineteen 
nineties (LFUPP), but in the survivors more children were severely disabled in 
the LFUPP compared to the POPS, not only at term age (chapter 9) but also at 
Figure 2. Comparison of outcome at 2 years of age in survivors in the POPS(1983) and 
LFUPP(1996/1997) cohort 
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two years of age (Figures 1 and 2). Because the lost-to-follow-up group in the 
LFUPP had lower socioeconomic status and parents were more often non-Cau-
casian, the results of the LFUPP are possibly worse, because ethnicity was a risk 
factor for delayed development (chapter 8) and from literature we know that low 
socioeconomic status also is associated with abnormal outcome. On the other 
hand it is difficult to compare the two cohorts in detail because different defini-
tions for outcome were used. 
Study design
 This study lacks a control group, but this was logistically and financially not 
possible. The percentage lost-to-follow-up for the neurological and mental or 
psychomotor developmental assessment was 17% of the survivors. The lost-to-
follow-up group differed only in socioeconomic status and ethnicity from the 
study group. We found a high adverse outcome in the extremely preterm infants, 
especially in infants born with GA 24 or 25 weeks. Although we realise that the 
total number of infants with GA < 27 weeks was small, results point into the 
same direction as found in literature. Furthermore, throughout many chapters 
in this thesis dexamethasone is associated with abnormal neurodevelopmental 
outcome or sub-optimal growth. 
 We realise that the relationships in this descriptive cohort study are not more 
than associations, and not necessarily causal connections. On the other hand this 
was a prospective study which included all live born infants from three health 
regions. Neurological, psychomotor and mental outcome were precisely defined. 
Furthermore, international data of follow-up studies are important to be aware 
of, but results of one’s own country are also important to know, e.g. for providing 
quality control for perinatal care in the Netherlands.
 The comparison of the LFUPP-cohort with (a part of) the POPS-cohort was 
in one way accurate because geographically the same infants were included by 
using postal codes. On the other hand used definitions for the outcome at 2 years 
of age were not similar. Furthermore many more paediatricians assessed the chil-
dren at 2 years in the POPS (200 for the whole of the Netherlands) compared to 
only a few in the LFUPP.
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Results of this study in perspective of ongoing changes in 
perinatology
 In this study, several perinatal risk factors like bronchopulmonary dysplasia 
(chapters 7 and 8), hypotension (chapters 6 and 8), cystic periventricular leuco-
malacia (chapters 6 and 8) and the postnatal use of dexamethasone (chapters 2, 6 
and 8) are associated with adverse neurodevelopmental outcome in very preterm 
infants. Bronchopulmonary dysplasia, cystic periventricular leucomalacia and the 
use of dexamethasone were also associated with suboptimal later growth (chapter 
4), just like intrauterine growth restriction (resulting in being born small-for-ges-
tational-age) or extra-uterine growth restriction (PGR) in the neonatal period 
(chapter 5). 
 The Leiden Follow-Up Project on Prematurity was started more than 10 years 
ago. The disadvantage of follow-up studies is that during a follow-up period new 
techniques and interventions have developed, which could have an influence 
on perinatal care. Nowadays in the 21st century for example we use much lower 
doses and shorter courses of dexamethasone compared to 1996/1997. Techniques 
for the cerebral ultrasound scanning have been refined and the use of Magnetic 
Resonance Imaging (MRI) for detecting cerebral damage has increased. Because 
of the association of intracerebral abnormalities (especially periventricular leuco-
malacia) and the use of dexamethasone with abnormal long-term outcome, these 
risk factors will be discussed in relation to new insights. 
Periventricular leucomalacia 
 Although cystic periventricular leucomalacia (PVL) results in an increased risk 
of adverse outcome, many of the extremely preterm infants without cystic PVL 
survive with some degree of disability.27 Nowadays, not only the cystic PVL but 
also diffuse PVL is considered the principal form of brain injury, and prognosti-
cally important.19 Already in 1992, de Vries et al.28 described the whole spectrum 
of leucomalacia using cranial ultrasound. Van Wezel-Meijler et al.29 described in 
a follow-up study the degree of echogenicity on cranial ultrasound to carry the 
highest predictive value for abnormal neurodevelopment at 12 months corrected 
age, compared to duration of flaring on ultrasound and degree of periventricular 
signal intensity change on magnetic resonance imaging (MRI). Olsen et al.27 
found, as expected, significant differences between infants with PVL and normal 
controls, regarding psychological outcomes. Interestingly, preterm infants with-
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out PVL also scored significantly lower than normal controls. So they conclude, 
like others, that there must be subtle brain changes that cannot be identified by 
non-functional MRI. 
 In 1999, Maalouf et al.30 published results of a study in preterm infants with 
GA < 30 weeks, where they concluded that abnormalities on MRI are com-
monly seen in the brain of preterm infants in the first 48 hours and that further 
abnormalities develop between birth and term age. A characteristic appearance 
on MRI of Diffuse and Excessive High Signal Intensity (DEHSI) in the white 
matter was associated with the development of cerebral atrophy and might be a 
sign of white matter disease. The major risk factors for this white matter abnor-
mality are related to perinatal infection and hypotension associated with use of 
inotropics.31 Neonatal cranial ultrasound of the very preterm infant demonstrates 
high reliability in the detection of cystic PVL, but has significant limitations in 
the detection of the noncystic white matter injury. This restriction of neonatal 
cranial ultrasound is important, because non-cystic PVL is considerably more 
common than cystic PVL.32 For detection of DEHSI (and to help to predict the 
prognosis), it would be preferable to perform an MRI at term age in preterm 
infants at risk. 
Dexamethasone
 After Mammel et al.33 reported in 1983 a significant respiratory benefit from 
dexamethasone in preterm infants, a widespread use of high doses of dexameth-
asone for periods as long as 6 weeks or more arose. In the late 1990s, more 
than 25% of all very low birth weight infants were exposed to postnatal ste-
roid therapy.34 The first convincing reports of adverse effects of high-dose dexa-
methasone therapy on subsequent growth and neurodevelopment appeared in 
1998/1999.35;36 This resulted in a decrease in prescription of dexamethasone, 
demonstrated in a study by Shinwell: use of dexamethasone fell from 22% in 
1993/1994 to 6% in 2001, in preterm ventilator-dependent infants.37 However, 
in the DART study (Dexamethasone: A Randomized Trial), including infants 
with GA < 28 weeks or birth weight < 1000 grams, low-dose (0.15 mg/kg/day) 
dexamethasone treatment after the first week of life, clearly facilitated extubation 
and shortened the duration of intubation among ventilator-dependent infants, 
without any obvious short-term complications.38 Although this trial was stopped 
because of recruitment difficulties, rates of disabilities or CP at 2 years of age 
were not substantially different between the groups.39 Recently another positive 
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outcome was published by Nixon et al.40 who reported improved respiratory 
outcome at 8 years of age in preterm born infants treated with dexamethasone, 
compared to those treated with a placebo, partly as a result from fewer days of 
mechanical ventilation. 
 Because dexamethasone facilitates extubation in these infants, the benefits of 
a brief course of therapy in such infants could outweigh the risks.41 Grier and 
Halliday42 wrote in their guidelines for corticosteroid use in 2005, that there is no 
role for use of corticosteroids in the first 4 days of life; the use of this drug should 
be limited to exceptional clinical circumstances, such as ventilator-dependent 
infants after the second week of life who cannot be weaned from ventilation and 
whose condition is worsening. If used, corticosteroids should be prescribed at the 
lowest effective dose for the shortest possible time. 
 But, dexamethasone is not the only glucocorticosteroid. In 2003 van der 
Heide-Jalving et al.43 reported fewer short- and long-term adverse effects in 
infants treated with hydrocortisone compared to dexamethasone in the neonatal 
period. Recently, Rademaker et al.44 reported MRI-outcomes at school age (7-8 
years old) in a large cohort of preterm infants, comparing infants treated with 
hydrocortisone for BPD with infants who were not treated with postnatal glu-
cocorticosteroids. Infants receiving hydrocortisone had no functional disadvan-
tage or structural impairment with MRI. They also published that cerebral gray 
matter volume was reduced among preterm children compared with children 
born at term, but volumes were similar in children treated with hydrocortisone 
compared to children not treated with hydrocortisone.45 In another publication 
of this group, neuromotor development at school age was found to be poorer in 
preterm infants treated in the neonatal period with dexamethasone for chronic 
lung disease, compared to infants treated with hydrocortisone or a reference 
group.46 These findings are consistent with information from a multicenter ran-
domised trial, in which infants treated with early low-dose hydrocortisone (1 
mg/kg/day) showed no evidence of neurodevelopmental compromise at 18 to 
22 months corrected age, compared with infants who were treated with a  pla-
cebo.47 Kristi Watterberg41 however remarked that we hopefully have learned 
from the dexamethasone experience and apply a more scientific approach in 
case of hydrocortisone. So further randomised trials of low-dose corticosteroids 




 In the Leiden Follow-Up Project on Prematurity, a prospective regional study 
of live born infants with gestational age < 32 weeks, mortality was 35% in infants 
< 27 weeks gestational age (GA) and 6% in infants with GA 27–32 weeks. We 
found a high adverse outcome in the extremely preterm infants, especially in 
infants born with GA 24 or 25 weeks. These results are in line with data from 
international research. Therefore, infants born with a GA of 24 weeks are not 
actively resuscitated anymore in the Leiden University Medical Center and 
infants born at 25 weeks GA are resuscitated depending on the opinion of the 
parents, the viability at birth and the reaction of the infant to stimuli or intuba-
tion. Besides these characteristics at birth, we need a reliable parameter that could 
be obtained by examining an infant of 24 or 25 weeks’ gestation, which is critical 
in making a decision to resuscitate or not. Maybe in these immature infants the 
well known Apgar Score is a good predictor for outcome. Recently Forsblad et 
al.48 reported that the Apgar Score predicted short-term outcome in extremely 
preterm infants at 25 weeks GA, which is in line with an earlier publication of 
Shankaran et al.49 who found more neurological impairment at 18-22 months in 
extremely preterm infants with a low Apgar Score. 
 Next to the high adverse outcome in the extremely preterm infants, we found 
that 40% of  the children with GA < 32 weeks, had moderate or severe delayed 
mental and/or psychomotor development at 18 and 24 months of age accord-
ing to the BSID I. Furthermore 20% of the very preterm infants suffered from 
bronchopulmonary dysplasia (BPD), which was associated with more respiratory 
problems and abnormal developmental outcome at 2 years of age compared to 
infants without BPD. 
 Concerning growth, we found length and weight at 1 and 2 years of age to be 
lower compared to the Dutch reference group, but head circumference was com-
parable with the reference group. In addition, we noted that infants who suffered 
from preterm growth restraint (PGR), displayed similar sub-optimal growth at 
2 years of age compared to preterm infants with intra-uterine growth restric-
tion, especially concerning length and head circumference. Reassuringly, preterm 
infants who did not suffer from PGR, showed growth at 1 and 2 years of age 
comparable to the Dutch reference group. 
 Comparison of the results of the 2 cohorts, POPS (1983) and LFUPP 
(1996/1997) at time of hospital discharge and at 2 years of age, showed that, 
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unfortunately, despite a decrease in mortality (from 30% to 11%) during the last 
decade, the number of children with an abnormal outcome has increased. There-
fore, future follow-up of the LFUPP-cohort and comparison of these results 
with the POPS study is recommended.
 After being able to increase survival rates of very preterm infants, the most 
important challenge at present should be, to increase the rate of handicap- or 
disability-free survival. Further studies are needed to show, if refined ventilation 
and neuroimaging techniques, and other ways of handling glucocorticosteroids, 
have already contributed to that end.
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 In chapter 1, increased survival in very preterm infants, related to some new 
interventions in perinatology is reported. Long-term outcome of the infants is 
summarised and discussed. The objective and methods of the Leiden Follow-Up 
Project on Prematurity (LFUPP), subject of the thesis, are described.
 The purpose of chapter 2 was to analyse mortality and outcome at 2 years 
of age in extremely preterm infants (with a gestational age (GA) < 27 weeks). 
An extensive neurological examination according to Hempel was performed; 
mental and psychomotor development were assessed by using the Bayley Scales 
of Infant Development I. Mortality was 35% (16/46) in infants < 27 weeks GA, 
compared to 6% (14/220) in infants with GA 27–32 weeks. In infants with GA < 
27 weeks, mortality was higher after extra-uterine transport or pregnancy induc-
tion. Postnatal use of dexamethasone and still being hospitalised at term age, were 
associated with an abnormal neurological outcome at 2 years of age. Adverse 
outcome, defined as dead or an abnormal neurological, psychomotor or mental 
development was 92% (11/12) in infants of 23–24 weeks GA, 64% (7/11) in 
infants born at 25 weeks and 35% (8/23) in infants born at 26 weeks, compared 
to 18% (40/220) in infants born between 27–32 weeks GA. 
 Chapter 3 reviews survival rates and outcome of infants under 26 weeks of 
gestation, born in most European Countries along with some examples from the 
United States of America and Australia and discusses the role of parents and the 
influence of condition at birth, gender and birth weight in ethical decision-mak-
ing on behalf of these infants. Survival at 22 weeks of gestation has not improved 
over the last decades and surviving infants born at 23–24 weeks of gestation show 
high rates of disabilities. Most European guidelines propose an active approach at 
25 and 26 weeks, and a flexible approach at 23 and 24 weeks, depending on the 
opinion of the parents and the condition of the infant at birth. In the Netherlands 
an active approach is taken from 26 weeks and onwards and a flexible approach 
at GA 25 weeks. A table in this chapter illustrates the guidelines according to the 
Dutch Paediatric Association.
 Chapter 4 presents growth of 160 of the 192 (82%) surviving infants of the 
LFUPP until the corrected age of 2 years. Infants from one of the three health 
regions (Delft) were excluded because a high percentage of missing growth 
data. The relationship between perinatal risk factors and growth was also stud-
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ied. Furthermore, we analysed the relation between growth and neurodevel-
opmental outcome at 2 years of age. Length, weight and head circumference 
were measured. Standard Deviation Scores (SDS) were calculated and based on 
Dutch growth references. Besides, length SDS was corrected for target height 
SDS. Birth weight (BW)-SDS for GA was calculated according to Swedish refer-
ences. Length, weight and weight-for-length were equally impaired in males and 
females at 2 years of age, compared to the Dutch reference group. Head circum-
ference at 1 and 2 years of age was comparable with the reference group. The 
use of postnatal dexamethasone was associated with shorter length, lower weight, 
lower weight-for-length and smaller head circumference; this effect remained 
after adjusting for GA. Growth retardation in length and weight was associated 
with an abnormal neurological examination; smaller head circumference also 
with mental and psychomotor delay.
 The purpose of chapter 5 was to examine if preterm growth restraint (PGR), 
meaning extra-uterine growth restriction of preterm infants who suffered from 
medical complications in the neonatal period, had a similar effect on growth at 
the corrected age of 2 years, compared to intrauterine growth restriction in pre-
term born infants. PGR was defined as length or weight at term age below -1.3 
SDS. We compared various growth parameters (the same as in chapter 4) until 
2 years of age in three LFUPP-subgroups: preterm infants born small-for-gesta-
tional-age (SGA, defined as birth weight for GA < -1.3 SDS according to Swed-
ish reference curves), preterm infants born appropriate-for-gestational-age with 
PGR (AGA-PGR) and preterm AGA-infants without PGR (AGA-nonPGR). 
Of the 158 included infants, 23 (14%) were SGA, 61 (39%) AGA-PGR and 74 
(47%) AGA-nonPGR. From term age till 2 years of age, SGA-infants had the 
lowest growth parameters. At 2 years of age, length and head circumference were 
comparable in SGA- and AGA-PGR-infants; weight and weight-for-length were 
smaller in the SGA-infants. The AGA-nonPGR-infants displayed growth com-
parable to the Dutch reference group. After correction for confounders, PGR 
remained the most important predictor for length at 2 years.
 In chapter 6 we investigated the influence of perinatal risk factors, especially 
hypotension, on neurological outcome at term age according to Prechtl in the 
LFUPP-infants. Hypotension was defined as a mean arterial blood pressure < 
30 mmHg on at least 2 occasions. Fifty percent of the infants (106/211) were 
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classified as neurologically normal, 44% (92/211) as mildly abnormal and 6% 
(13/211) as definitely abnormal. The odds ratio of hypotension for neurological 
morbidity was 1.90 (95% CI 1.06 – 3.40); after adjustment for gestational age, 
birth weight, SGA and gender, it was 1.96 (95% CI 1.02 – 3.77). Other risk fac-
tors for major neurological morbidity at term age were gestational age, cystic 
periventricular leucomalacia and bronchopulmonary dysplasia.
 The aim of chapter 7 was to describe the incidence of bronchopulmonary 
dysplasia (BPD) in the LFUPP-cohort. Data about the incidence of BPD in the 
Netherlands are scarce. Besides, we wanted to analyse associations between BPD 
and respiratory problems and developmental outcome at 2 years of age. At 36 
weeks postmenstrual age, 49 infants (21% of the survivors at that time, 18.5% of 
all live born infants) suffered from BPD. Respiratory problems were the cause of 
death in 50% within this group. At 2 years of age, BPD-children had more respi-
ratory problems and used more lung medication than children without BPD. 
Mean MDI and PDI were lower in BPD-children compared to children without 
BPD (88 an 87 compared to 101 and 99). Only 38% of the children with BPD 
had a normal neurological examination compared to 80% of the children with-
out BPD.
 Chapter 8 presents the mental and psychomotor developmental outcome in 
the LFUPP-cohort at 18 and 24 months corrected age, according to the Bayley 
Scales of Infant Development I. Developmental Indices were defined as normal 
(> -1 SD), moderate delay (-2 to -1 SD) and severe delay (< -2 SD).  At 18 months 
168 children (71%) and at 24 months 151 children (64%) of 235 survivors were 
assessed. Moderately to severely delayed mental and/or psychomotor develop-
ment occurred in 40% of the children at both ages. Postnatal treatment with 
dexamethasone was associated with an increased risk of delayed development. 
Other independent predictors of delayed development were BPD at 18 months 
and ethnicity, maternal age at birth, birth weight and gender at 24 months.
 
 Finally, in chapter 9 we compared mortality and neonatal morbidity as well 
as changes in perinatal and neonatal management in two cohorts of very preterm 
infants: the Leiden Follow-Up Project on Prematurity (LFUPP) and the Project 
On Preterm and Small for gestational age (POPS) infants. The absolute number 
of preterm births in the study-region increased from 102 in 1983 to on average 
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133 in 1996/1997. In-hospital mortality decreased from 30% in the nineteen 
eighties to 11% in the nineteen nineties. Mortality of the extremely preterm 
infants with gestational age < 27 weeks decreased form 76% to 33%. Equal per-
centages (40%) of adverse outcome (dead or an abnormal condition at discharge) 
were found. The incidence of BPD increased from 6 to 19%. Improvements in 
peri- and neonatal care resulted in an increased survival but also in more morbid-





 In hoofdstuk 1 wordt een toegenomen overleving gerapporteerd van zeer 
vroeggeboren kinderen, gerelateerd aan enkele nieuwe interventies in de perina-
tologie. Uitkomsten op de lange termijn van de kinderen worden samengevat en 
bediscussieerd. Het doel en de methoden van het Leidse Follow-Up Project van 
Prematuren (LFUPP), onderwerp van dit proefschrift, worden beschreven.
 Hoofdstuk 2 beschrijft de mortaliteit en de uitkomsten op 2 jaar in extreem 
vroeggeboren kinderen (met een zwangerschapsduur van < 27 weken). Een uitge-
breid neurologisch onderzoek volgens de methode van Hempel werd uitgevoerd; 
de mentale en psychomotorische ontwikkeling werd beoordeeld door middel 
van de Bayley ontwikkelingsschalen I. De mortaliteit bedroeg 35% (16/46) in 
kinderen < 27 weken zwangerschapsduur, vergeleken met 6% (14/220) in kin-
deren met een zwangerschapsduur tussen 27 – 32 weken. In kinderen met een 
zwangerschapsduur < 27 weken was de mortaliteit hoger na extra-uterien trans-
port en na zwangerschapsinductie. Postnataal gebruik van dexamethason en het 
nog steeds opgenomen zijn op de à terme leeftijd, was geassocieerd met een 
abnormale neurologische uitkomst op 2 jaar. Een zeer slechte uitkomst, gedefi-
nieerd als overleden of een afwijkende neurologische, psychomotorische of men-
tale ontwikkeling, kwam voor in 92% (11/12) van de kinderen geboren na 23-24 
weken, in 64% (7/11) van de kinderen geboren na 25 weken en in 35% (8/23) 
van de kinderen geboren na 26 weken, vergeleken met 18% (40/220) van de 
kinderen geboren tussen 27 – 32 weken zwangerschapsduur.
Hoofdstuk 3 geeft een overzicht van overlevingspercentages en uitkomsten 
van kinderen geboren vóór 26 weken zwangerschapsduur, geboren in de meeste 
Europese landen samen met enkele voorbeelden uit de Verenigde Staten en 
Australië. De rol van de ouders en de invloed van de conditie bij de geboorte, het 
geslacht en het geboortegewicht in relatie tot het maken van ethische beslissin-
gen rondom de geboorte, worden besproken. De overleving bij 22 weken zwan-
gerschapsduur is niet verbeterd gedurende de laatste decaden en overlevende 
kinderen geboren na 23 – 24 weken zwangerschapsduur laten hoge percentages 
beperkingen (in het functioneren) zien. De meeste Europese richtlijnen stellen 
een actieve benadering voor bij 25 en 26 weken en een flexibele benadering bij 
23 en 24 weken, afhankelijk van de mening van de ouders en de conditie van 
het kind bij de geboorte. In Nederland wordt een actieve benadering gehan-
teerd vanaf 26 weken en een flexibele benadering bij 25 weken. Een tabel in 
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dit hoofdstuk illustreert de richtlijnen volgens de Nederlandse Vereniging voor 
Kindergeneeskunde. 
 In hoofdstuk 4 wordt de groei van 160 van de 192 (82%) overlevende kin-
deren van de LFUPP tot de gecorrigeerde leeftijd van 2 jaar gepresenteerd. Kin-
deren van één van de drie gezondheidsregio’s (Delft) werden geëxcludeerd van-
wege een hoog percentage ontbrekende groei data. De relatie tussen perinatale 
risicofactoren en groei werd ook bestudeerd. Tevens analyseerden wij de relatie 
tussen de groei en de ontwikkeling op 2 jaar. Lengte, gewicht en schedelom-
vang werden gemeten. Standaard Deviatie Scores (SDS) werden berekend en de 
gemiddelden werden vergeleken met de Nederlandse groei referenties. Daarnaast 
werd de gemiddelde SDS voor lengte gecorrigeerd voor de gemiddelde SDS 
voor target height (eindlengte in relatie tot lengte ouders). Geboortegewicht-
SDS naar zwangerschapsduur werd berekend volgens Zweedse referentiecur-
ven. Lengte, gewicht en gewicht naar lengte waren lager (evenveel in jongens 
als meisjes) op 2-jarige leeftijd, vergeleken met de Nederlandse referentiegroep. 
Schedelomvang op 1 en 2 jaar was vergelijkbaar met de referentiegroep. Het 
gebruik van postnataal dexamethason was geassocieerd met kortere lengte, lager 
gewicht, lager gewicht naar lengte en een kleinere hoofdomvang; dit verschil 
bleef bestaan na correctie voor zwangerschapsduur. Groeiretardatie wat betreft 
lengte en gewicht was geassocieerd met een afwijkend neurologisch onderzoek; 
een kleinere hoofdomvang ook met een mentale en psychomotorische ontwik-
kelingsachterstand.
 Het doel van de in hoofdstuk 5 beschreven studie was om te onderzoeken 
of “preterm growth restraint (PGR)”, hiermee bedoelende extra-uteriene groei 
vertraging, van te vroeggeboren kinderen die te lijden hebben gehad van medi-
sche complicaties in de neonatale periode, een vergelijkbaar effect op de groei 
had als intra-uteriene groeivertraging bij te vroeggeboren kinderen. PGR was 
gedefinieerd als lengte of gewicht op de à terme leeftijd kleiner dan -1.3 SD. 
We vergeleken verschillende groei parameters (dezelfde als in hoofdstuk 4) tot 
de leeftijd van 2 jaar in 3 LFUPP-subgroepen: te vroeggeboren kinderen die 
ook small-for-gestational-age geboren zijn (“SGA”, gedefinieerd als geboorte-
gewicht voor zwangerschapsduur < -1.3 SD volgens Zweedse referentiecurven), 
te vroeggeboren kinderen die appropriate-for-gestational-age geboren zijn mét 
PGR (“AGA-PGR”) en te vroeggeboren AGA-kinderen zónder PGR (“AGA-
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nonPGR”). Van de 158 geïncludeerde kinderen waren er 23 (14%) SGA, 61 
(39%) AGA-PGR en 74 (47%) AGA-nonPGR. De SGA-kinderen hadden op 
alle leeftijden de laagste groeiparameters. Op 2 jarige leeftijd waren lengte en 
schedelomvang vergelijkbaar in de SGA- en AGA-PGR-kinderen; gewicht en 
gewicht naar lengte waren kleiner in de SGA-kinderen. De AGA-nonPGR-
kinderen lieten vergelijkbare groei zien vergeleken met de Nederlandse referen-
tiegroep. Na correctie voor confounders bleef PGR de belangrijkste voorspeller 
voor lengte op de leeftijd van 2 jaar.
 In hoofdstuk 6 onderzochten we de invloed van perinatale risicofactoren, 
in het bijzonder hypotensie, op de neurologische uitkomst volgens Prechtl op 
de à terme leeftijd in de LFUPP-kinderen. Hypotensie was gedefinieerd als een 
gemiddelde arteriële bloeddruk < 30 mm Hg op minimaal 2 momenten. Vijftig 
procent van de kinderen (106/211) werd geclassificeerd als neurologisch nor-
maal, 44% (92/211) als mild abnormaal en 6% (13/211) als definitief abnormaal. 
De odds ratio voor neurologische morbiditeit was 1.90 (95% CI 1.06 – 3.40). Na 
correctie voor zwangerschapsduur, geboortegewicht, SGA en geslacht bedroeg 
deze 1.96 (95% CI 1.02 – 3.77). Andere risicofactoren voor ernstige neurolo-
gische morbiditeit op de à terme leeftijd waren zwangerschapsduur, cysteuze 
periventriculaire leucomalacie en bronchopulmonale dysplasie. 
 In hoofdstuk 7 wordt de incidentie van bronchopulmonale dysplasie (BPD) 
in het LFUPP-cohort beschreven. Data betreffende de incidentie van BPD in 
Nederland zijn schaars. Bovendien wilden we analyseren of er associaties waren 
tussen BPD en respiratoire problemen en ontwikkelingsproblemen op de leeftijd 
van 2 jaar. Op 36 weken postmenstruele leeftijd hadden 49 kinderen (21% van 
de overlevenden op dat moment, 18.5% van alle levendgeborenen) BPD. Van de 
overleden kinderen was in 50% respiratoire problematiek de doodsoorzaak. Op 2 
jarige leeftijd hadden BPD-kinderen meer respiratoire problemen en gebruikten 
ze meer medicatie voor de longen dan kinderen zonder BPD. De gemiddelde 
mentale en psychomotorische ontwikkelingsindex was lager in de BPD-kin-
deren vergeleken met de kinderen zonder BPD (88 en 87 vergeleken met 101 
en 99). Slechts 38% van de kinderen met BPD had een normaal neurologisch 
onderzoek vergeleken met 80% van de kinderen zonder BPD.
180 CHAPTER 12
 Hoofdstuk 8 presenteert de mentale en psychomotorische ontwikkelings-
uitkomsten van het LFUPP-cohort op 18 en 24 maanden gecorrigeerde leef-
tijd, volgens de Bayley Ontwikkelings-Schalen I. Ontwikkelingsindexen werden 
gedefinieerd als normaal (> -1 SD), matige achterstand (-2 tot -1 SD) of ernstige 
achterstand (< -2 SD). Van de 235 overlevende kinderen werden op de leeftijd 
van 18 maanden 168 kinderen (71%) onderzocht en op 24 maanden 151 kin-
deren (64%). Matige tot ernstige mentale of psychomotorische ontwikkelings-
achterstand werd gevonden in 40% van de kinderen op beide leeftijden. Postna-
tale behandeling met dexamethason was geassocieerd met een verhoogd risico 
op een vertraagde ontwikkeling. Een andere onafhankelijke voorspeller van een 
ontwikkelingsachterstand op de leeftijd van 18 maanden was BPD; etniciteit, 
leeftijd van de moeder bij de geboorte, geboortegewicht en geslacht waren op 
de leeftijd van 24 maanden andere onafhankelijke prediktoren voor een ontwik-
kelingsachterstand.
 Tot slot vergeleken we in hoofdstuk 9 zowel de mortaliteit en neonatale 
morbiditeit als ook veranderingen in perinataal en neonataal handelen, in twee 
cohorten van zeer vroeggeboren kinderen: het Leidse Follow-Up Project van 
Prematuren (LFUPP; 1996/1997) en het Project On Preterm en Small for 
gestational age infants (POPS; 1983). Het absolute aantal premature geboorten 
(< 32 weken) in de studieregio nam toe van 102 in 1983 tot gemiddeld 133 in 
1996/1997. De mortaliteit gedurende de eerste ziekenhuisopname daalde van 
30% in de 80er jaren tot 11% in de 90er jaren. Sterfte van de extreem vroegge-
boren kinderen met een zwangerschapsduur onder de 27 weken daalde van 76% 
naar 33%. Gelijke percentages (40%) van een zeer ernstige uitkomst (overleden 
of een abnormale conditie bij ontslag) werden gevonden. De incidentie van BPD 
nam toe van 6% naar 19%. Verbeteringen in peri- en neonatale zorg hebben 
geresulteerd in een toegenomen overleving, maar ook in meer morbiditeit, voor-
namelijk BPD, op het moment van ontslag uit het ziekenhuis.
181
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Consensus on treatment of extremely premature infants at birth in the 
Netherlands (Dutch Paediatric Association, November 2005)
Appendix 2.
Registration forms up to and including 2 years corrected age

Gestational 
age in weeks 
& days
Intrauterine 





in the delivery room




 24+0 – 24+6 Indicated Can be 
considered
Only on maternal 
indication
Family-centred 
comfort care, unless 
an active approach 
seems justified
 25+0 – 25+6 Indicated Yes Rarely on foetal 
indication
Active approach, 
unless comfort care 
seems more justified
 ≥ 26+0 Indicated Yes Yes, unless an active 
approach does not 
seem justified
Active approach, 
unless this does not 
seem justified
If a child weighs less than 500 grams at birth, neonatal treatment will be withheld, except for family-
centred comfort care.
Appendix 1. Consensus on treatment of extremely premature infants at birth in the 
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